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SUMMARY 
Biomaterial implants are a critical component to successful treatment of many types 
of orthopaedic injuries. In 2004, over 2.6 million orthopaedic devices were placed with 4% 
developing infections, resulting in an economic burden of nearly $2 billion. In the United 
States, nearly 112,000 orthopaedic device infections occur annually with Staphylococcus 
aureus being the most common pathogen accounting for roughly 33% of all infections. 
Bacterial infection of orthopaedic implants frequently results in complete removal of the 
implant despite aggressive antibiotic therapy. Lysostaphin is an antimicrobial enzyme 
specific to staphylococcal species. It is composed of a cell wall targeting domain, 
responsible for its specificity, and a lytic domain that catalytically degrades the 
peptidoglycan cell wall of bacteria, causing cell lysis. We have previously engineered a 
poly (ethylene glycol) (PEG)-based hydrogel system for controlled delivery of therapeutic 
proteins. We have shown that BMP-2 delivery facilitates bone repair in a murine radial 
segmental defect model. Contamination of these BMP-2 loaded hydrogels with bacteria 
leads to complete inhibition of bone healing, persistence of bacteria, and bone resorption. 
The objective of this project was to engineer PEG-based hydrogels that prevent and treat 
orthopaedic infections while simultaneously repairing orthopaedic injuries. The central 
hypothesis was that delivery of lysostaphin using a PEG-hydrogel will reduce infection 
and promote bone repair using mouse models of orthopaedic device infections.  
 We engineered injectable hydrogels for the delivery of lysostaphin to infected 
mouse femoral fractures. Encapsulation of lysostaphin within a PEG hydrogel carrier 
provided an in situ polymerizable delivery platform that maintained enzyme activity and 
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stability while conforming and adhering to the injured tissue. Lysostaphin-delivering 
hydrogels were effective at eliminating infection, and provided enhanced anti-biofilm 
activity compared to soluble lysostaphin in vitro. Lysostaphin-delivering hydrogels 
eradicated mouse femoral fracture infections and out-performed soluble lysostaphin 
delivery as well as prophylactic antibiotic administration. Infected fractures treated with 
lysostaphin-delivering hydrogels healed equally well as uninfected fractures, as measured 
by µCT analysis and mechanical testing. The local cytokine milieu of infections treated 
with lysostaphin-delivering hydrogels was no different than uninfected fractures, 
demonstrating restoration of a normal healing microenvironment. Additionally, 
lysostaphin-delivering hydrogels were effective at eliminating methicillin resistant S. 
aureus (MRSA) infections. Taken together these results show that lysostaphin delivery via 
a hydrogel carrier is effective at treating biomaterial-stabilized femoral fracture infections. 
 Segmental bone defect injuries have infection rates reported as high as 30% and 
successful treatment often requires bone grafting, multiple surgeries, and unacceptably 
high therapeutic failure rates. To address this unmet clinical need, we extended our 
lysostaphin-delivering hydrogel to co-deliver both lysostaphin and BMP-2 in order to 
investigate simultaneous elimination of infection, and induction of growth factor-mediated 
bone repair of non-healing segmental defects. Lysostaphin and BMP-2 co-delivery 
effectively eliminated bacterial infection and promoted bone regeneration in our mouse 
radial segmental defect infection model. We characterized the local inflammatory response 
to infections treated with lysostaphin-delivering hydrogels and showed that the local 
cytokine profile is no different than uninfected defects at both 1 and 4 weeks post-
operation. In addition, no differences between the inflammatory cell profiles were observed 
 xx 
for infections treated with lysostaphin-delivering hydrogels one week after implantation. 
These results demonstrate that lysostaphin and BMP-2 co-delivery can eliminate infection 
and facilitate segmental bone defect regeneration. 
 We also investigated the activity of lysostaphin-delivering hydrogels to reduce 
established S. aureus infections in vivo. We developed a novel model of established S. 
aureus infection by modification to the mouse radial segmental bone defect model. 
Infections were first initiated by placing infected hydrogel implants and bacteria were 
allowed to colonize the injury for one week. Once the infection was established, the 
infected implants were removed, the wound was debrided and washed, and a lysostaphin-
delivering hydrogel was injected at the injury site. Our results indicated that lysostaphin 
delivery alone reduced biofilm infection but significant bacteria numbers remained. 
However, a combined effect was seen when both lysostaphin hydrogels and systemic 
antibiotic therapy were delivered together. These results show that lysostaphin-delivering 
hydrogels effectively reduce established S. aureus orthopaedic infections. 
This research is innovative because it develops bi-functional materials that prevent 
and treat S. aureus infections while simultaneously repairing orthopaedic injuries. 
Additionally, lysostaphin provides specifically targeted bacteriolytic activity, acting as an 
alternative to traditional antibiotic therapy, which may help to reduce the spread of 
antibiotic-resistant bacteria. As outcomes of this research, we have engineered a 
lysostaphin delivery vehicle to eradicate long bone fracture infections, prevent infection of 
non-healing segmental defect injuries while simultaneously regenerating bone, and 
reduced bacteria using a segmental defect model of established biofilm infection. This 
 xxi 
research has established a strategy for preventing and treating orthopaedic biomaterials 
implants that could be extended to other biomedical device infection scenarios. 
 1 
INTRODUCTION AND SPECIFIC AIMS 
1.1 Introduction 
Biomaterial-associated infections account for over one million nosocomial 
infections per year (1). Infection prevention and treatment is a critical component to 
successful regenerative medicine strategies, as infection leads to significant patient 
morbidity and even mortality, frequently resulting in complete removal of the implant 
despite aggressive antibiotic therapy (1). Staphylococcus aureus is the most clinically 
significant gram-positive pathogen associated with implanted orthopaedic device failure 
(2). Lysostaphin is a bacteriolytic enzyme with specific activity against staphylococcal 
species. The lysostaphin enzyme is composed of two domains, a cell wall targeting domain, 
that provides specificity to staphylococcal species, and a lytic domain, which provides 
antimicrobial activity by catalytically degrading the bacterial cell wall, leading to lysis (3, 
4). Additionally, lysostaphin is effective at reducing bacteria growing in biofilm, and 
provides an enhanced effect when administered with antibiotics (5, 6). Lysostaphin is 
effective against methicillin resistant S. aureus (MRSA) and vancomycin resistant S. 
aureus (VRSA) (7-9), and has been shown to be effective at treating staphylococcal 
infections in several animal models (7, 9-13). Taken together, these characteristics make 
lysostaphin an ideal candidate for treating infections primarily limited to staphylococcal 
species. However, lysostaphin therapy has been significantly limited by a lack of effective 
delivery vehicles.   
The objective of this project is to engineer novel lysostaphin-delivering hydrogels 
to reduce infection and enhance bone repair in murine models of implant-associated 
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orthopaedic infection. The central hypothesis is that controlled delivery of lysostaphin 
from our osseo-repartive hydrogels will reduce infection, allowing for bone repair to occur. 
The proposed work is innovative and significant because it establishes a local strategy to 
effectively reduce bacterial infections during bone healing using an antimicrobial 
bacteriospecific enzyme. This proposed work could have implications for other biomedical 
implants that are associated with morbidity and mortality due to bacterial infection. By 
engineering PEG-based hydrogels to release lysostaphin, we will reduce infection and 
improve bone repair without the need for antibiotics. This will be achieved through the 
following specific aims. 
1.2 Specific Aim 1 
Engineer injectable hydrogels for the delivery lysostaphin to infected bone fractures 
We hypothesize that controlled local delivery of lysostaphin to infected bone fractures will 
eliminate S. aureus infection in a murine femur fracture model. We engineered 
poly(ethylene glycol) PEG hydrogels that release active lysostaphin in response to local 
environmental cues. We evaluated the ability of lysostaphin-delivering hydrogels to 
eliminate S. aureus infections and support fracture healing using a pin-stabilized femur 
fracture model. We measured bacterial counts and bone repair by µCT imaging, performed 
histology and mechanical testing, and characterized the host inflammatory response to 
lysostaphin therapy using cytokine array profiling. Lysostaphin-delivering hydrogels were 
benchmarked against systemic antibiotic therapy and soluble lysostaphin delivery. We also 




1.3 Specific Aim 2 
Engineer PEG hydrogels co-delivering lysostaphin and BMP-2 to eliminate S. aureus 
infection and repair non-healing segmental bone defects. 
We hypothesize that in vivo co-delivery of lysostaphin and BMP-2 will eliminate bacterial 
infection and promote bone repair in an infected mouse radial segmental defect model. 
Lysostaphin-delivering hydrogels were investigated in vivo using a mouse radial segmental 
defect model. Hydrogels containing lysostaphin and BMP-2 were infected with S. aureus, 
implanted into the mouse model, and radial defect healing was monitored over time with 
µCT imaging. Infection clearance was analyzed by histology and bacterial counts, and 
functional healing was assessed with torsion to failure testing. Lastly, we characterized the 
inflammatory response to lysostaphin delivering hydrogels by performing cytokine 
profiling and flow cytometry of the local wound environment. 
1.4 Specific Aim 3 
Engineer injectable lysostaphin-delivering hydrogels to treat established S. aureus 
infections in non-healing segmental bone defects 
We hypothesize that lysostaphin-delivering hydrogels will reduce established S. aureus 
infections in vivo. We developed a murine model of an established S. aureus infection by 
implanting infected hydrogels and allowing for the infection to establish itself over the 
course of one week. One week after the infection was initiated, the implant was removed, 
the wound was washed and debrided, and a lysostaphin-delivering hydrogel was placed. 
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One week later, bacterial counts were assessed. Systemic antibiotic therapy with and 
without lysostaphin delivering hydrogels was also assessed. 
1.5 Significance and Innovation 
This research is innovative because it develops a biomaterial platform that reduces 
infection without the use of antibiotics, thereby mitigating the development of antibiotic 
resistant bacteria while minimizing orthopaedic device failure. As outcomes of this 
research, we established the feasibility of controlled lysostaphin release from hydrogels to 
reduce infection and promote bone repair. This research established a strategy for infection-




SCAFFOLD-BASED ANTI-INFECTION STRATEGIES IN BONE REPAIR1 
Implant-associated infection is a significant clinical problem (1). Bacterial 
colonization of implants is associated with surgical sites, central line access points, 
ventilators, surgical drains and shunts, urinary and central venous catheters, and others. 
Current strategies used to prevent such infections include, but are not limited to, antibiotic 
therapy, healthcare-provider hygiene, environmental controls such as isolation or negative 
pressure rooms, surface coatings and modifications, sterilization, and the use of sterile 
technique during procedures. Nearly all types of bacteria and fungi are capable of infecting 
implanted devices (1). Some of the most common pathogens include Staphylococcus 
aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Cutibacterium acnes, beta 
hemolytic Streptococcus, Proteus mirabilis, and Escherichia coli (14, 15). The 
development of biomaterials with antimicrobial properties to prevent device-associated 
infection is a rapidly expanding field. 
2.1 Device-associated Infections in Bone Reconstruction  
In the field of orthopedics alone, 2-5% of all procedures involving implants are 
complicated by infection (1). This number can be as high as 30% when open fractures are 
present (16). Significant morbidity and even death are associated with implant-related 
infections, with outcomes often leading to complete implant removal, surgical debridement 
                                                 
1 Adapted from: Johnson CT and García AJ. Scaffold-based Anti-infection Strategies in Bone Repair. Annals 
of Biomedical Engineering. 2015 Mar;43(3):515-28. DOI: 10.1007/s10439-014-1205-3 
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of the affected tissue, and long-term antibiotic therapy (17, 18). Device-associated 
infections not only occur from direct implantation of bacteria, but also develop post-
operatively following hematogenous bacteremia, or direct spreading from a nearby 
infection site (17, 18). Further complicating treatment is the emergence of antibiotic-
resistant bacteria (19). Choosing the correct antibiotic for initial treatment is directly 
correlated with successful infection management and becomes more difficult in the case of 
nosocomial infections, due to the inherent resistance that these organisms possess (20). The 
above circumstances motivate the development of implantable materials with antibacterial 
properties to significantly improve surgical outcomes and reduced patient morbidity and 
mortality. Engineered scaffolds for regenerative medicine applications provide a 
framework for tissue repair as well as a substrate for the inclusion of antimicrobial 
properties. 
2.2 Biofilm and Nonunion Defects 
 Device-associated infection is characterized by bacterial adhesion, colonization, 
and biofilm development, which is outlined in Figure 1 (21, 22). The most common 
organisms associated with orthopedic implant infections include the gram positive strains 
Staphylococcus epidermidis, Staphylococcus aureus, and Propionibacterium acnes, as 
well as the gram negative Pseudomonas aeruginosa (22). Osteomyelitis is inflammation of 
the bone, which can be due to biofilm formation, causing increased bone resorption and 
reactive bone formation (17, 18). These biofilms are composed of secreted bacterial 
components, such as protein, lipid, lipopolysaccharide, and DNA (21), forming a matrix 
around the bacteria that provides protection from antibiotic therapy and immune defenses 
(23, 24). Bacteria in a biofilm have higher mutation rates (25), and can display increased 
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virulence (26) than if growing planktonically, and when exposed to antibiotics, mutation 
rates increase further, allowing for accelerated development of a drug-resistant phenotype 
(27). Moreover, incomplete resolution following therapy leads to highly resistant cells, or 
persistors, that then replenish the biofilm (28). These characteristics paired with availability 
of only semi-effective treatment options leave a significant, unmet need for the 
development of therapies to combat device-associated biofilm and infection (21, 29). 
 
Figure 1: Bacterial adhesion and biofilm development. Biofilm formation begins by 
bacteria adhering and growing on a surface. As the pathogen continues to replicate a 
extracellular polymeric substances, including polysaccharide, DNA, and protein is 
produced, leading to biofilm formation. This matrix protects the pathogen from the host 
immune system and increases the development of antibiotic resistance. 
 Non-union bone defects are fracture injuries that cannot heal without intervention. 
Currently, standard medical therapies include the use of bone auto- and allo-grafts, or 
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delivering high doses of therapeutic protein, such as bone morphogenetic protein 2 (BMP-
2), to facilitate healing. However, there are unacceptably high failure and complication 
rates associated with these interventions (30), which are significantly increased when an 
infection develops (31-33).  Advances in biomaterials and regenerative therapies have led 
to the development of engineered scaffolds capable of correcting non-union defects without 
the need for bone grafting procedures (34). These strategies for bone repair often rely on 
biomaterial-based scaffolds to bridge the defect. This provides a convenient framework to 
introduce antibacterial agents to prevent and treat infection after surgical intervention. 
 Engineering regenerative medicine implants to overcome bacterial contamination 
is a critical and emerging area of biomaterials research. These technologies require rigorous 
in vitro and in vivo evaluation, bringing together the fields of microbiology and 
biomaterials engineering. Significant progress has been made in the design of infection-
resistant surfaces, as recently reviewed by Campoccia et al. (35, 36). Therefore this review 
will focus on relevant animal models and techniques to assess antimicrobial tissue scaffolds 
in the context of bone repair, potential therapeutic additives to fight infection, and the 
current and future of scaffolds with infection resistant properties to promote bone repair. 
2.3 Animal Models to Assess Infection and Bone Repair 
 Successful evaluation of antimicrobial scaffolds for bone regeneration requires the 
development of reliable and robust infection models. This proves to be a very challenging 
task, as pathogenic bacteria are required to induce the infection without causing overly 
adverse harm to the host. Furthermore, the model should provide a sustained infection over 
a prolonged period of time to have increased relevance to human health. Several animal 
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models to assess fracture therapy exist, and appropriate model selection was discussed in 
depth by Mills and Simpson (37). Bone regeneration is most frequently evaluated using 
critical-sized, segmental defect models. Critical-sized segmental defects are bone injuries 
that do not spontaneously heal, allowing for assessment of bone regeneration due to the 
therapy, such as implantation of a scaffold.  
 Few validated models exist to evaluate bone regeneration in infected defects. These 
models introduce infection to bone repair models. Table 1 summarizes validated models 
developed to characterize the efficacy of antimicrobial bone repair scaffolds. The most 
common repair model extends the rat femoral segmental defect (38) to include pathogenic 
bacteria (39-43). Femoral segmental defects have been widely used in regenerative 
medicine studies, and allow for the evaluation of a long, weight-bearing bone that will not 
spontaneously heal. This procedure requires bone fixation hardware and effectively tests 
the reparative capacity of regenerative scaffolds. To introduce infection, two distinct 
inoculation techniques exist. In one, a segment of the femur is excised, the bone is 
stabilized, bacteria is introduced, and the surgical site is closed. Once enough time has 
elapsed for the infection to become established, reoperation occurs and the infected tissue 
is debrided and a sterile regenerative scaffold is placed (39-42). This method has been used 
to evaluate osteogenic protein-1 (39) as well as systemic antibiotic therapy paired with 
recombinant human BMP-2 (40) and recombinant human osteogenic protein-1 (41) in the 
presence of infection. This technique provides clinical relevance, as it mimics how implant 
infections are treated, but two surgical procedures may increase variability and add more 
stress to the animal. The second approach requires a single procedure, where the defect is 
created and stabilized and the implant is placed. Following implant placement, the 
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pathogen is injected into the implant (or the implant is inoculated prior to implantation), 
simulating intraoperative contamination (43). This technique is advantageous because it 
only requires a single procedure, which may reduce variability associated with surgery. 
This model was later adapted to realize a 50% overall infection rate in order to reduce the 
chances of observing false-negative (type II error) in vivo results (44). An infected femoral 
segmental defect model in the rabbit has also been reported where infection was induced 
48 hours after bone excision and defect stabilization by a percutaneous injection of a 
bacterial suspension (45). These models provide an economical way to assess bone-healing 
strategies, but are complicated by requiring defect fixation with plates and wires. 
Stabilization can pose a problem when assessing the antimicrobial abilities of regenerative 
scaffolds if the stabilization pins become infected and cause failure (39). 
Ref. Animal Procedure Advantages Disadvantages 
(39-
43) 
Rat Femoral segmental 
defect, debridement 
following 2 weeks 
later 
Evaluates long weight 
bearing bone, widely 
validated, not self-
healing 
Failure if infection 
extends to fixation 





Rat Femoral segmental 
defect, contaminated 
scaffold 
Evaluates long weight 
bearing bone, widely 
validated, not self-
healing, single operation 
Failure if infection 
extends to fixation 
pins, complicated 
procedure 
(45) Rabbit Femoral segmental 
defect 
Evaluates long weight 
bearing bone, not self-
healing 
Failure if infection 
extends to fixation 
pins 
(46) Rabbit Radial segmental 
defect 
No fixation device 
required, evaluates long 






Table 1: Infection-based segmental defect models. 
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 Self-stabilizing segmental defects could be a means to avoid complications 
associated with infected stabilization hardware. Self-stabilization is achieved by removing 
a segment of a non-weight bearing bone, such as the radius. This allows for the study of 
regenerative implants in critically sized defects of long bones that will not self-heal, but 
may not be as clinically relevant since many orthopedic procedures require fixation of long 
bones. Bi et al. developed a lapine radial segmental defect infection model to assess 
localized antibiotic release compared to systemic therapy (46). In this model, a defect was 
created and a bacterial suspension was placed in the wound. After 30 minutes, the area was 
washed, the implant was placed and the wound was closed. This model only requires a 
single procedure and also simulates intraoperative contamination.  
Although several different animal models have been developed to assess bone 
repair, to our knowledge a validated critical-sized segmental defect murine model has not 
yet been published, even though murine models have been used extensively throughout the 
osteomyelitis literature (47). A need exists for smaller animal models that may allow for 
more rapid screening of therapeutics to both treat infection and repair bone. Three 
important models have been described, covering a variety of orthopaedic infection 
scenarios. A common infection model is to simultaneously introduce an implant to an 
injury and the bacteria together. Prosthetic joint infection models do this by inserting a pin 
into the femoral canal, leaving 1 mm protruding into the joint space. An infection is then 
initiated by injecting bacteria over the protrusion (48-51). Bioluminescent bacteria have 
been used in conjunction with this model, allowing for in vivo monitoring of bacterial 
numbers. However, prevention models are limited by not allowing for the establishment of 
 12 
the bacteria infection before treatment, making this the easiest case to successfully 
eradicate bacteria.  
To address the clinical case of hematogenous seeding of a prosthetic joint, which 
can occur any time after implantation, Wang et al. implanted a titanium K-wire into a 
mouse femur, and then 21 days later, injected bioluminescent bacteria intravenously to 
initiate infection (52). This effectively models bacteremic seeding of a prosthetic joint. The 
authors report significantly higher rates of infection in the leg containing the implant. 
However, roughly 30% of animals infected did not develop an infection. This model serves 
as an important step towards being able to effectively evaluate a materials ability to resist 
infection long after implantation. The most rigorous models for evaluating a materials 
antimicrobial activity is to utilize a two-stage approach to first initiate an infection and then 
provide treatment at a later time point. Inzana et al. developed a novel murine mouse 
established femoral fracture infection model to screen therapies for fracture fixation 
hardware associated infections (53). In the first surgical procedure, the femur is 
mechanically fixated using a PEEK fixation plate and then a 0.7 mm osteotomy is 
performed to mimic a femoral fracture injury. The infection is initiated at the osteotomy 
site and allowed to develop for 7 days. The second stage involves expanding the osteotomy 
to 3 mm, debriding the surrounding tissue, and placing an antibiotic impregnated spacer, 
mimicking what would be done clinically to treat infected defects before bone grafting. 
This rigorous model allows for the rapid and economical screening of interventions to treat 
established orthopaedic hardware associated infections. 
 The advent of in vivo imaging systems has significantly improved the analysis of 
biomaterial-associated infections (54).  Genetic engineering of bioluminescence genes into 
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clinically relevant bacterial strains allows for in vivo monitoring of infection. 
Commercially available gram positive (Xen29 S. aureus) and gram negative (Xen5 P. 
aeruginosa) strains contain a stable luminescence reporter, and can be tracked over time in 
vivo, providing the assessment of infection progression (55), and treatment efficacy (56). 
However, limitations do exist. For example, the luminescence signal detected is not a direct 
marker of the number of bacteria, but of the metabolic activity of the colony (55-57). The 
population of bacteria making up a biofilm is composed of both rapidly dividing and 
quiescent cells.  This heterogeneity may be a possible explanation for the large variability 
between bacterial counts and bioluminescent signal. The use of bioluminescent bacteria 
has been successfully established in vivo in the context of osteomyelitis (58, 59), suggesting 
that this technology could be adaptable to monitoring scaffold-associated infections in bone 
repair. Nevertheless, genetic modification of bacteria through bioluminescent gene 
insertion could reduce the virulence of the clinically isolated strains, which could 
complicate the evaluation of infection resistant materials. 
 In addition to bioluminescent bacteria, several in vivo probes utilizing fluorescent, 
magnetic, and radioactive tracers have been developed. Near infrared (near-IR) imaging 
probes that specifically identify bacteria have received heightened interest as a viable 
alternative to luminescent bacteria. Discrimination between infection and inflammation is 
the key challenge associated with their development (60). Eggleston and Panizzi provide 
an extensive review on this topic (60). Our lab has recently developed near-IR probes that 
specifically discriminate between infection and inflammation through targeting the 
products produced by the inflammatory response (61). Reactive oxygen species (ROS) are 
characteristic of the body’s response to biomaterials implants, whereas large quantities of 
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nitric oxide (NO) are produced by macrophages and neutrophils in a direct response to 
bacteria. Dual administration of ROS- and NO-selective probes allows for the simultaneous 
in vivo observation of infection and inflammation with high specificity (61). Furthermore, 
we have shown these fluorescent probes exhibit increased sensitivity compared to 
bioluminescent strains. Fluorescent probes also have a dose dependent response to the 
number of bacteria regardless of metabolic activity, in a strain independent manner (62). 
Other strategies to achieve specificity include utilizing antimicrobial peptides that have 
been labeled with radioactive isotopes and paired with clinically available imaging 
systems, such as SPECT (single photon emission computed tomography) (63), and labeling 
the antibiotic vancomycin with a near-IR fluorophore to identify gram positive infections 
(64). The technologies described above provide real-time, in vivo means to monitor 
infection initiation, progression, and resolution, and could provide an indispensable tool in 
the development of infection-resistant scaffolds.  
 Although significant effort has been made to develop finely tuned animal models 
for the assessment of a materials antibacterial properties as described above, ethical 
concerns do exist surrounding these methods. This is especially relevant when evaluating 
infection resistant properties of scaffolds after a sterile implantation, which is the most 
clinically realistic scenario. These types of studies require large animal numbers to 
adequately power the analysis due to the relatively low rates of spontaneous infection 
developing (less than 7%) and that both the control and treatment groups will require large 
animal numbers to resolve a difference (65). Concerns also exist surrounding animal 
welfare. Many infection models are highly variable and it can be challenging defining a 
sub-lethal bacterial dose that does not cause animal suffering. This is particularly difficult, 
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as simply increasing the bacterial dose could result in sepsis and termination before the 
desired experimental end point. 
2.4 Antimicrobial Agents to Fight Infection 
 Several different strategies exist to combat bacterial infection. Table 2 provides a 
list of major antimicrobial strategies (66-70). Brief overviews of the major antibacterial 
classes, including the advantages and limitations of each follow. 
Ref. Antimicrobial Topics Covered 
(67) Antibiotics Mechanisms of action, and how resistance has emerged 
(70) Silver Antimicrobial properties of silver nanomaterials and 
effects on human health and the environment 
(66) Host Defense Peptides Host defense peptides as therapeutics for antibiotic 
resistant infections 
(69) Host Defense Peptides Immunomodulatory aspects of host defense peptides 




Bacteriophage endolysin structure, function, efficacy, 
antibiotic synergy, and resistance 
(72) Lysostaphin Lysostaphin activity, therapeutic applications, 
immunogenicity, and limitations 
Table 2: Review articles detailing various antimicrobial strategies 
 Clinically, antibiotics are the most common agent used to clear bacterial infections. 
They are widely used throughout clinical medicine as treatment and prophylaxis. However, 
over the past decades, the emergence of antibiotic-resistant bacteria, such as methicillin 
resistant Staphylococcus aureus (MRSA), have become more common (67). Sub-
inhibitory aminoglycoside antibiotic treatment can induce biofilm formation (73). The 
development of biofilm can potentiate the emergence of resistant cells, further 
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complicating the infection (74). Biofilm requires higher doses and longer trials of therapy 
to eradicate infection, thereby prolonging the patient’s exposure to drug side effects. 
Moreover, it has been shown that bactericidal antibiotics are toxic to mammalian cells, 
causing mitochondrial dysfunction (75). However, the benefits of treatment far outweigh 
the risks, and until viable alternatives are available, antibiotics will remain the standard of 
care. For a comprehensive review of antibiotic therapy including drug mechanisms, 
specificities, and the development of resistance, refer to Davies and Davies (67). 
 Silver is a broad-spectrum antimicrobial agent used in research and clinically. 
Silver exerts bactericidal activity on both gram positives and gram negatives through 
several mechanisms. Silver ions enter the bacterium and generate ROS capable of 
damaging DNA, they interact with membrane proteins affecting their function, and alter 
membrane permeability leading to cell death (70). It is believed that silver resistance is 
widespread, but not realized since it is not widely tested for. A Chicago hospital revealed 
that over 10% of enteric bacteria exhibit silver resistance (76), and overuse could potentiate 
the problem. Furthermore, the bactericidal mechanisms of silver ions are not specific to 
bacterial cells, and also disrupt mammalian cell function placing significant concern on 
toxicity (77, 78). However, it has been reported that silver can be effective against 
antibiotic-resistant bacterial strains, and even induce susceptibility towards antibiotics that 
were ineffective in the absence of silver (79). Silver can also be adapted to reduce bacterial 
adherence to orthopedic implants by killing adherent pathogens (80). For a more detailed 
discussion, the reader is referred to Marambio-Jones and Hoek (70). Clinically, silver has 
translated to several applications, including wound dressings, creams, urinary catheters and 
endotracheal tubes. However, little if any data has demonstrated efficacy. An analysis of 
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2066 patients enrolled in several clinical trials failed to show any benefits to silver-doped 
wound dressings (81). Silver-coated endotracheal tubes (82) have exhibited modest 
efficacy in preventing bacterial colonization, whereas silver-coated urinary catheters have 
shown mixed results (83). 
 Host defense peptides or antimicrobial peptides (AMPs) have activity against 
bacteria, viruses, and fungi (84). Defensins, cathelicidins and histatins are AMPs produced 
by many mammalian cells (85). AMPs are amphiphilic peptides characterized by a several 
cationic and hydrophobic residues and exhibit broad-spectrum activity against both gram 
positive and gram negative bacteria (69, 84, 85). The cationic residues associate with the 
negatively charged bacterial membrane. The hydrophobic and hydrophilic residues cause 
membrane penetration, leading to instability, pore formation, osmotic changes, and 
bacterial lysis (84). As with all antimicrobial strategies, the development of resistance is a 
concern. This could be especially problematic since AMPs are part of the natural host 
response to pathogens and resistance could make simple infections dangerous (66, 86). 
Another drawback is the observation that AMPs are not stable over long periods of time in 
an in vivo environment. However, AMPs are easily engineered, and several synthetic 
peptides have been developed in an attempt to overcome these shortcomings (87). It has 
been well documented that AMPs possess immunomodulatory activity in addition to being 
antipathogenic (69, 84, 85). AMPs modulate both the innate and adaptive immune 
responses to control infection and stimulate regenerative processes (69). These attributes 
make AMPs an enticing candidate for antimicrobial regenerative scaffolds. However, there 
are no reports of human safety or efficacy trials for AMPs. 
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 Bacteriophage therapy has gained renewed interest with the increased prevalence 
of antibiotic resistance (88). Bacteriophages are viruses that specifically infect bacteria. 
The phage binds to a membrane receptor, introducing phage DNA into the cell. This DNA 
is replicated and translated by the host bacterium, leading to phage replication, progeny 
assembly, bacterial lysis, release of progeny, and phage propagation to surviving bacteria. 
Following eradication of the infecting organism, phage replication ceases, allowing for 
resolution of the affected tissue. Bacteriophage DNA can also code for lysins, lytic 
enzymes that destroy the bacterial cell wall (89), as well as polysaccharide depolymerases, 
enzymes that break down the biofilm matrix created by bacteria (90, 91). This allows 
bacteriophages to disperse biofilm as well as eradicate infection. In addition, synergism 
between phage therapy and antibiotics has been demonstrated (92). Host bacterial strains 
can develop resistance to phage infection, which can be reduced using several different 
phages at once (93). There are also concerns surrounding the immunogenicity of in vivo 
phage administration, even though adverse events have not been reported in the literature 
(94, 95). Currently, the safety of bacteriophage therapy administered orally (96) and 
cutaneously (97) has been evaluated in humans in phase I clinical trials. Preliminary results 
of the first controlled trial to evaluate bacteriophage efficacy in chronic otitis to treat 
antibiotic-resistant P. aeruginosa have been positive, demonstrating therapeutic value in 
humans (98). 
 Bacteriolytic enzymes, such as bacteriophage lysins and lysostaphin, are enzymes 
that catalytically degrade the bacterial cell wall, leading to cell lysis (99). In general, these 
enzymes are specific to a particular bacterial species or genus; however, there have been 
reports of some with expanded target ranges (100). Structurally, the enzymes are usually 
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composed of a cell wall binding domain, responsible for the specificity, and a catalytic 
domain, that degrades pathogens cell wall (99).  Bacteriophage lysins are enzymes coded 
by bacteriophage DNA that are directly responsible for lysing the host cell allowing for 
phage propagation during the bacteriophage life cycle. Notably, resistance to lysins has 
never been reported, making them an ideal candidate for clinical translation to treat 
antibiotic resistant bacteria (101). Lysostaphin is a bacterial exolysin produced by the 
bacteria Staphylococcus simulans as a defense mechanism to kill S. aureus (4). Lysostaphin 
has similar structure and function to a bacteriophage lysin with a cell wall binding domain 
and an enzymatic domain (3). Bacteriolytic enzymes have several advantages over small 
molecule antibiotics. First, they carry high activity against bacteria growing in biofilm 
since they do not require target pathogens to be metabolically active (102, 103). Second, 
they are specific to only the target pathogen of interest. This can help to prevent many of 
the side effects associated with broad spectrum antimicrobial therapy such as perturbation 
of native flora and driving the development of antibiotic resistance (101). Third, they are 
often synergistic with small molecule antibiotics and have been shown to resensitize 
antibiotic resistant strains to the antibiotic they were resistant too (89, 103, 104). These 
characteristics have continued to push bacteriolytic enzyme translation to the clinic. 
2.5 Antimicrobial Scaffolds for Bone Repair 
 Recently, tissue engineered scaffolds for bone repair have started to include 
antimicrobial agents to prevent or fight infection. These scaffolds provide a substrate for 
sustained, localized drug release, tunable degradation properties to promote tissue 
integration, and support for cell delivery. Rigorous evaluation of the antimicrobial efficacy 
exhibited by these scaffolds has proven difficult, and requires expertise in both 
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microbiology techniques as well as biomaterials engineering. Antimicrobial scaffolds are 
required to be toxic to bacterial cells, while promoting local tissue regeneration and 
minimizing the adverse inflammatory events. Figure 2 is a schematic diagram illustrating 
how engineering antimicrobial properties into scaffolds for bone repair can improve 
outcomes associated with bacterial infection. Bacterial contamination is introduced into a 
model used to evaluate regenerative implants. If the contaminate is not cleared by the 
immune system or an infection-resistant scaffold, the infection becomes established, which 
may lead to the development of osteomyelitis. Infection fighting scaffolds can be implanted 
into defects with ongoing infection or osteomyelitis to remove the existing pathogen and 
facilitate repair. Further development of these technologies will allow for bone repair to 
occur in both sterile and contaminated conditions. 
 
Figure 2: Critically-sized non-union bone defects are used to assess the therapeutic 
efficacy of regenerative scaffolds. Contamination of these defects can be introduced 
before or after the scaffold is placed to establish the infection. Absence of antimicrobial 
agents will lead to the development of osteomyelitis, which is characterized by bone 
resorption and reactive bone formation. Infection resistant scaffolds are designed to 
prevent initial bacterial colonization whereas infection fighting scaffolds can be used to 
resolve an established biofilm and promote defect repair. 
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2.5.1 Antibiotic-releasing scaffolds 
 Antibiotic delivery scaffolds are the most well developed area in the literature. In 
orthopedics, antibiotic-loaded fillers and bone cements have been used clinically for a 
number of years. Zilberman and Elsner published an extensive review on antibiotic-
releasing materials (105). We will focus on advances in tissue engineering scaffolds that 
incorporate antibiotics. 
 Scaffolds provide an ideal substrate to deliver long-term bactericidal doses of 
antibiotics to the injury site. This is accomplished by modifying drug release characteristics 
through encapsulation within degradable matrices. Antibiotic releasing matrices have been 
used as coatings for orthopedic implants prone to infection. Sol-gel thin films have been 
engineered to provide sustained release of vancomycin and protect against implant 
associated infection of titanium rods. The addition of the thin film minimized bacterial 
adherence to the implant, and protected against the development of osteomyelitis in vivo 
(106). A similar has also been applied to stainless steel K-wires (107).  
Antimicrobial activity can also be engineered into scaffolds for tissue regeneration. 
Poly (L-lactic acid) (PLLA) nanofiber scaffolds were synthesized with poly (lactic-co-
glycolic acid) (PLGA) nanospheres to provide extended release of the antibiotic 
doxycycline (108). These scaffolds provided sustained antimicrobial activity against S. 
aureus and E. coli over 42 days in bacterial culture, demonstrating an approach to provide 
extended, localized antibiotic release, which would reduce the systemic side effects 
associated with antibiotic therapy. This is especially important when treating osteomyelitis, 
which typically involves extended courses of high dose antibiotics. Poly(caprolactone) 
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(PCL) scaffolds were synthesized by electrospinning PCL using 10% and 20% (w/w) 
rifampin (109). These scaffolds exhibited extended rifampin release over eight hours and 
were bactericidal towards S. epidermidis and P. aeruginosa in vitro. Shi et al. demonstrated 
the addition of lecithin can increase the encapsulation efficiency of gentamicin and protein 
into PLGA microsphere-based scaffolds (110). After an initial burst release, gentamicin 
release occurred for 60 days, and protein was released for 18 days. The material was active 
against E. coli while still supporting mesenchymal stem cell (MSC) viability, proliferation, 
and mineralization. These observations suggest that this scaffold is a viable candidate for 
delivering protein therapeutics as well as antibiotics, and supporting bone formation for the 
treatment of infected bone defects. The encapsulation of growth factors has also been 
paired with antibiotic encapsulation. Calcium sulfate scaffolds with chitosan microspheres 
containing vancomycin, recombinant human BMP-2 (rhBMP-2), or both were developed 
and assessed in vitro for bactericidal activity and regenerative properties (111). It was 
shown that these scaffolds are bactericidal against S. aureus for 18 days and release 
rhBMP-2 over 6 weeks, causing increased alkaline phosphatase (a marker of osteoblast 
differentiation) expression. These investigators found that an optimal balance between 
antibiotic and growth factor release is required for optimal osteoblastic differentiation, as 
high antibiotic concentrations can lead to inhibition of osteoblastic differentiation. 
However, these techniques have not yet been extended to in vivo models. 
As mentioned above, the current standard of care for critically sized bone defects 
is bone grafting. Infection is one of the most significant side effects associated with grafting 
procedures. Bi et al. engineered bone xenografts (grafts from a different animal species) 
composed of antigen-free calf cancellous bone combined with calf cortical bone extract 
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and bovine BMP impregnated with clindamycin to treat critically sized defects 
contaminated with S. aureus (46). This scaffold was evaluated in vivo within a rabbit radial 
segmental defect. After the graft was implanted, 1x106 colony forming units (CFU) of S. 
aureus were administered to the injury. All animals in the clindamycin-impregnated graft 
group healed completely. Defect repair was observed in the clindamycin-graft group 
including recanalization of the medullary cavity. Systemic clindamycin therapy resulted in 
either non-union, or delayed union after the 16 week period, whereas the non-treatment 
control developed osteomyelitis characterized by reactive bone formation and resorption. 
This study shows that local, sustained delivery of antibiotics can overcome an infection, 
while still providing regenerative properties. 
 The bone graft substitute calcium sulfate has also been combined with antibiotics 
and assessed in vivo. The antibiotic moxifloxacin has been evaluated with commercially 
available Stimulan®, a synthetic semihydrate form of calcium sulfate (112). In this study, 
osteomyelitis was induced in a rabbit tibia by injection of 2x107 CFU of a clinical 
osteomyelitis isolate of MRSA into the intramedullary cavity. After the infection was 
allowed to develop for three weeks, the rabbits underwent surgical debridement of all 
necrotic bone tissue and implant placement. The results showed a significant reduction in 
viable bacteria throughout the six week observation period. In vitro assessment of the 
delivery system showed sustained moxifloxacin release over 35 days. However, this study 
did not evaluate whether the regenerative properties of the moxifoxacin doped Stimulan® 
are still intact in the presence of sustained antibiotic release. Xie et al. compared bioactive 
borate glass to the clinically used calcium sulfate as a carrier for vacomycin to treat MRSA-
induced osteomyelitis in rabbits (113).  Bioactive borate glass provided sustained 
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vancomycin release over 28 days in vitro and improved mechanical properties compared 
to calcium sulfate. The scaffold was assessed in vivo using a rabbit model for osteomyelitis. 
After three weeks of infection, surgical debridement was performed and scaffolds were 
placed within the defect. Both the vancomycin-loaded calcium sulfate and vancomycin-
loaded borate glass significantly reduced the number of bacteria, improved the 
radiographic score and improved the histopathologic score at the end of the eight-week 
observation period. This study further illustrates that scaffolds serve as an effective 
mechanism to provide sustained antibiotic therapy to eradicate osteomyelitis.  
Polyurethane scaffolds have also received interest as a substrate to deliver 
antibiotics and growth factors for bone repair. Polyurethane scaffolds designed for 
prolonged release of vancomycin were compared to the clinically used vancomycin-loaded 
PMMA- beads (114). Extended vancomycin release from polyurethane scaffolds could be 
controlled by changing the solubility of vancomycin. In vivo evaluation of the vancomycin-
loaded polyurethane scaffolds in a contaminated rat femoral segmental defect reduced 
viable bacterial counts as well as the clinical standard of vancomycin-loaded PMMA beads. 
Importantly, nearly 10 times less antibiotic was loaded to the polyurethane scaffolds. Dual 
delivery of vancomycin and the growth factor BMP-2 to a S. aureus infected rat femoral 
segmental defect using a biodegradable polyurethane scaffold demonstrated increased 
bone formation as determined by microCT and histological analysis (115). The addition of 
vancomycin to the scaffold reduced the clinical signs of infection while not affecting bone 
regeneration. Together, these studies illustrate that extended release of vancomycin can 
eradicate infection and the addition of BMP-2 can enhance regeneration in contaminated 
defects. 
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 Clearly there has been significant progress in towards the development of antibiotic 
releasing materials for bone repair. However, as mentioned before, biofilm can offer 
protection to the microorganisms against antibiotic therapy, leading to the development of 
resistance. In a study evaluating the efficacy of gentamicin-loaded bone cement against the 
well-known biofilm former S. epidermidis in rats, it was shown that even though the 
number of bacteria was reduced, there was a significant increase in the number of 
gentamicin-resistant bacteria (116). In another study evaluating vancomycin-releasing 
polyurethane scaffolds in an infected rat segmental defect, significantly fewer bacteria 
were recovered at two weeks (98). Nonetheless, this was only a roughly three-fold 
reduction, leaving over 1x105 CFU/gram of bone tissue, demonstrating a significant 
limitation in effectively treating infections.  
Administration of multiple antibiotics simultaneously reduces the chances for 
antibiotic resistance to develop compared to monotherapy (117). Ashbaugh et al. 
engineered an antibiotic releasing electrospun coating to prevent prosthetic joint infections 
capable or releasing multiple antibiotics from different drug classes simultaneously (51). 
This is in contrast to current local delivery strategies that are limited to heat stable 
antibiotics, such as those used in antibiotic eluting bone cement (118). The electrospun 
costing was capable of releasing multiple antibiotics, both individually and in combination, 
above the minimum inhibitory concentration over the course of days to weeks. Release 
profiles could be controlled through modulation of the material properties. Importantly, 
combination therapy prevented infection and subsequent bone remodeling using a mouse 
model of prosthetic joint infection.  
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2.5.2 Silver-presenting scaffolds 
 Silver can be easily incorporated into materials through various manufacturing 
techniques such as reduction or the addition of silver nanoparticles. This ease of 
incorporation combined with silver’s broad spectrum antimicrobial activity has led to the 
development of several silver-containing antimicrobial scaffolds. Several designs have 
demonstrated in vitro efficacy, but success in vivo has been limited.  
 Naturally derived tissue engineered scaffolds have been used for a multitude of 
applications, include bone repair. These materials can be modified to present silver and 
exhibit infection resistance. Collagen scaffolds were fabricated to include silver 
nanoparticles coated with poly(ethylene glycol) (PEG) and Triton X-100 (119). The 
scaffolds had increased elasticity and antimicrobial effects against both gram positives (B. 
cereus and S. aureus) and gram negatives (E. coli and P. mirabilis). Silver nanoparticles 
have also been incorporated into type I collagen scaffolds synthesized using UV initiation 
of a non-toxic, water-soluble benzoin to facilitate polymerization (120). The collagen 
scaffolds served to stabilize the nanoparticles and supported fibroblast and keratinocyte 
viability at silver concentrations less than or equal to 100 μM. Bactericidal activity (E. coli, 
B. megaterium and S. epidermidis) was determined using a modified minimum inhibitory 
concentration assay. These studies show that collagen-based scaffolds that include silver 
nanoparticles can prevent bacterial growth in vitro, while also supporting mammalian cell 
viability. Further development of these technologies and evaluation in in vivo models is 
necessary to establish the feasibility of silver nanoparticle-containing collagen scaffolds 
for infection prevention and bone repair. Bioactive glass containing silver has been 
incorporated into extracellular matrix-derived hydrogels to exhibit sustained antimicrobial 
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effects and bone regenerative properties (121). These materials show sustained silver ion 
release over 25 days and is bactericidal against E. coli and E. faecalis. The composite 
hydrogels support dental pulp cell viability, making them a plausible candidate for tooth or 
bone regeneration. Silver ions have been added to composite chitosan/nano-hydroxyapatite 
scaffolds to add antimicrobial properties (122). The chitosan/nano-hydroxyapatite 
scaffolds were immersed in silver nitrate, allowing for an ion-exchange and reduction to 
occur between the scaffold and silver. The scaffolds support osteoprogenitor and 
osteosarcoma cell viability and demonstrate antimicrobial effects against both gram 
positive and gram negative bacteria (S. aureus and E. coli).  
 PLGA has been of particular interest for bone repair due to its biocompatibility, 
degradable properties, and being used in FDA-approved devices. Silver was incorporated 
into tricalcium phosphate (TCP) nanocomposite, mixed with PLGA and then electrospun 
to form a fibrous scaffold. These scaffolds provided sustained silver release at bactericidal 
levels in vitro against E. coli, a frequent contaminator of dental implants. The scaffolds 
were equally as effective as the clinical standard of tetracycline-soaked cotton swabs. 
However, upon media exchange in the assay, the silver scaffolds maintained antimicrobial 
ability due to sustained release characteristics. This study demonstrates the importance of 
sustained antimicrobial release, and that scaffolds for tissue engineering provide a 
convenient avenue to accomplish this. Zheng et al. reported a promising antimicrobial 
regenerative scaffold (43). In this study, microporous PLGA scaffolds were fabricated to 
contain silver nanoparticles. Interestingly, 1.0% silver containing grafts supported 
increased osteoblastic differentiation and increased alkaline phosphatase activity compared 
to the 2.0% silver grafts in vitro. These scaffolds were evaluated using a rat femoral 
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segmental defect. After implantation, 1x108 CFUs of vancomycin-resistant MRSA was 
injected into the implant. Radiographic and histological analysis showed that the 2.0% 
silver implants completely eliminated infection and supported defect bridging, whereas the 
1.0% silver implants only reduced the number of bacteria present, but supported some bone 
regeneration. Control scaffolds that did not contain silver were grossly infected, 
demonstrating bone resorption and reactive bone formation, indicative of osteomyelitis. 
The in vitro analysis paired with the in vivo data show that although high concentrations of 
silver can inhibit osteoblast differentiation, it is more important to eliminate the 
contaminating bacteria to facilitate bone formation. This is a clear demonstration that 
developing implants capable of resisting infection while providing functional cues to 
facilitate bone repair is possible. 
As an alternative to silver, copper ions loaded into microporous bioactive glass 
scaffolds reduce bacterial growth and support MSC viability and differentiation (123). 
These scaffolds significantly reduced E. coli growth, and promoted human MSC 
differentiation towards osteoblasts in a dose dependent manner. Vascular endothelial 
growth factor levels were also elevated, suggesting the scaffold could promote 
vascularization.  
2.5.3 Antimicrobial Peptides, Bacteriophage, and Other Antimicrobial Strategies 
 Interest has been building surrounding technologies that take advantage of 
alternative antimicrobial therapies. These alternatives to silver and antibiotics could 
expand the arsenal against infection, while also reducing the chances of bacteria developing 
resistance to our most efficacious treatments. Scaffolds provide a means to extend the 
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activity of these agents by providing sustained release characteristics. Antimicrobial 
peptides have been introduced into scaffolds designed for orthopedic regeneration. 
Poly(caprolactone) (PCL)-chitosan nanofiber scaffolds were synthesized and PEG-
microgels containing the cationic antimicrobial peptide L5 were electrostatically 
associated with the nanofibers(124). These novel scaffolds demonstrated antimicrobial 
activity against S. epidermidis, and maintained L5 stability and activity. The scaffolds 
supported osteoblast adhesion, spreading, and proliferation.  
Stainless steel K wires used in orthopedic procedures coated with a 
hydroxypropylmethlycellulose (HPMC) hydrogel containing bacteriophage, the antibiotic 
linezolid, or both were developed to prevent MRSA infection (125). The coated wires 
showed sustained phage and linezolid release over several days, as well as inhibiting 
MRSA adherence in a dose dependent manner. The bacteriophage and linezolid group 
exhibited the greatest efficacy toward inhibiting MRSA attachment and growth, suggesting 
synergism exists between the co-delivery of antibiotics and bacteriophage. This claim was 
further supported by analysis of recovered MRSA after treatment showing reduced 
mutation rates in the dual treatment group suggesting lower drug resistance. This in vitro 
evaluation of scaffolds presenting bacteriophage and antibiotics suggests the treatment 
could be extended to an in vivo environment to prevent infection associated with stainless 
steel implants. Bacteriophage has also been evaluated in a regenerative context. In one 
study, the E. coli bacteriophage λ was loaded into microporous hydroxyapatite or beta-
tricalcium phosphate scaffolds with various porosities by passive adsorption (126). 
Bactericidal activity against E. coli K12 was observed in vitro, demonstrating the 
prophylactic potential bacteriophage loaded materials could provide. 
 30 
 Polyelectrolyte scaffolds assembled by electrostatic interactions of chitosan 
gamma-polyglutamic acid and carboxy-methylcellulose were developed for treating dental 
bone defects. These scaffolds supported pre-osteoblast cell adhesion and viability in vitro, 
and antimicrobial activity against S. aureus and E. coli. Scaffold biocompatibility was 
assessed by extracting the second pre-molars of beagle dogs and replacing them with the 
material. The scaffolds were explanted after 10 weeks and histology revealed no adverse 
foreign body reaction. 
 Neutrophils and macrophages produce peroxide and other free radicals to kill 
invading pathogens. This mechanism was extended to electrospun polycaprolactone (PCL) 
scaffolds with different concentrations of calcium peroxide to exhibit antimicrobial activity 
by releasing a significant initial burst of peroxide (127). This short-term antimicrobial 
response was effective in controlling E. coli and S. epidermidis in vitro, illustrating broad 
applicability. The nanowires supported osteoblast viability for four days of culture despite 
the cells being exposed to toxic peroxide levels for the first 24 hours. This novel method 
of direct peroxide generation from a PLC scaffold shows that burst release from materials 
can be toxic to bacteria but still provide a means to promote bone growth. 
Berberine is a natural antimicrobial agent that exhibits activity against several 
different organisms and is non-toxic to mammalian cells. For these reasons, Huang et al. 
incorporated it into a chitosan coating on a nano-hydroxyapatite/polyamide66 scaffold 
developed for bone regeneration (128). These scaffolds provided a continuous release of 
berberine over 150 hours and were bactericidal to S. aureus. Furthermore, the scaffolds 
supported MG63 cell adhesion, proliferation, and spreading, supporting that berberine is 
nontoxic. However, this material has not been evaluated in vivo. These data provided 
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preliminary evidence that berberine may be suitable for in vivo evaluation to provide 
antimicrobial and regenerative properties in a bone repair setting.  
Preventing biofilm formation may be another way to protect against chronic 
osteomyelitis. Sanchez et al. demonstrated biofilm dispersal agents reduce infection in vivo 
(129). A polyurethane scaffold containing D-amino acids was contaminated with S. aureus 
and implanted into a rat femoral segmental defect. The treated scaffolds significantly 
reduced the number of contaminating bacteria, showing that preventing biofilm formation 
can improve post-operative outcomes, by preventing the biofilm from shielding the 
bacteria from endogenous antimicrobial defenses. 
2.6 Conclusions and Outlook 
 Preventing infection in the presence of biomaterials implants is a major unmet need 
and will significantly improve patient outcomes. Currently, implant infection leads to 
removal, and significant medical costs from reoperations and extended antibiotic therapy. 
Moreover, after an initial infection, patients are at a much higher risk for relapse, further 
complicating management and causing increased patient morbidity. As medicine advances, 
we have become more and more reliant on implantable devices to more effectively correct 
patient problems, which increase the risk of implant-associated infections (1). Demand 
exists for the prevention of orthopedic implant infections due to the frequency of their 
occurrence, as well the challenges associated with combating osteomyelitis. Despite 
improvements in intraoperative techniques and the invention of antibiotic-doped cements 
and fillers, infection continues to be a significant issue associated with non-union defects. 
Furthermore, the increased prevalence of antibiotic resistant bacteria raises concern over 
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widespread use of antibiotic presenting materials. This suggests alternative antimicrobials 
such as silver, antimicrobial peptides or bacteriophage could help to preserve the efficacy 
of our most potent weapons against infection. These alternative strategies to fight infection 
offer exciting opportunities to introduce new properties into scaffolds. For example, the 
rapid expansion, but self-limiting characteristics of a bacteriophage infection provide a way 
to engineer materials that respond only when a pathogen is present. Scaffolds can shield 
the phage from the host response, while providing activity only in the presence of offending 
bacteria. Antimicrobial peptides can enhance the body’s defenses against pathogens, and 
even promote wound healing. Scaffolds can serve a means to extend the stability of these 
peptides and enhance their utility.  
 In addition to extending the stability of antimicrobial agents, scaffolds provide a 
highly controlled means to release therapeutics. Modulation of scaffold degradation 
typically correlates with therapeutic drug release. Traditionally, bone repair is driven by a 
scaffold degradation leading to therapeutic release. The drug release recruits cells and 
further promotes scaffold degradation, leading to tissue healing. This process is outlined in 
Figure 3. Degradable scaffolds are also advantageous from an in vivo infection resolution 
point of view. Implanted biomaterials are prone to infection after implantation by transient 
bacteremia causing colonization and direct bacterial spreading from infection sites (17, 18). 
Degradable scaffolds provide the benefit of controlled therapeutic release while facilitating 
integration into the native tissue.  
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Figure 3: Scaffold based drug delivery for tissue repair. Current regenerative 
medicine strategies focus on delivering therapeutics to drive cell recruitment and tissue 
repair. As cells are recruited the scaffold degrades, releasing therapeutics, and promoting 
integration. Next generation biomaterials will include abilities to prevent or eliminate 
pathogens and provide regenerative cues. 
Degradable scaffolds to treat infection and regenerate bone have been primarily 
investigated in the bioactive glass literature (130). These studies are mostly centered on 
extending the release of antibiotics to provide continuous antimicrobial activity (113, 131, 
132). However, a significant gap exists in understanding how the degradation properties of 
scaffolds influence antimicrobial efficacy in vivo. Future studies could focus on optimizing 
scaffold degradation properties to efficiently eliminate pathogens and guide the bone repair 
process. These studies can then be extended to characterize and understand how 
engineering extended release of antimicrobial therapies affects drug activity though drug 
scaffold interactions. Modifications of scaffolds to provide continuous release may 
negatively impact the efficacy of the loaded therapeutic. 
 The next generation of antimicrobial scaffolds for bone repair will optimally 
balance antimicrobial delivery with regenerative therapeutics. This could be achieved by 
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tuning material properties such as porosity, charge, degradation speed, density, 
antimicrobial agent, growth factors, and the bulk material. Understanding how material 
design choices prevent bacterial contamination, biofilm development, eradication of 
existing osteomyelitis, while simultaneously regenerating bone, will lead to optimized 
scaffold designs. 
 In order for these new technologies to translate into the clinic, several challenges 
need to be overcome. The development of robust, controlled, and reproducible animal 
models of infected scaffolds is a critical need for the success of this fast emerging field. 
Animal models that utilize bioluminescent bacteria allow for real time monitoring of 
infection progression without animal sacrifice, which addresses some of the ethical 
concerns of biomaterial infection research. Reproducible, controlled infections that 
accurately simulate clinical scenarios are required to effectively evaluate experimental 
materials to prevent infection and facilitate bone regeneration. 
 Scaffolds provide an ideal substrate for designing regenerative therapies due to the 
exquisite engineering control we have over them. They provide a platform for controlled 
drug release, a substrate for therapeutic cell delivery, tunable degradation characteristics 
that facilitate replacement by regenerating tissue, reduced immunogenicity, and response 
to the surrounding environment. It is clear that progress is being made towards the 
development of infection-resistant bone repair implants. However, the in vivo validation of 
these technologies is still in its infancy. The advancement of in vivo imaging techniques, 
paired with robust bone repair models will facilitate the translation from the bench to the 
bedside.  
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HYDROGEL DELIVERY OF LYSOSTAPHIN ELIMINATES 
ORTHOPAEDIC HARDWARE INFECTION BY STAPHYLOCOCCUS 
AUREUS AND SUPPORTS FRACTURE HEALING2 
3.1   Abstract  
Orthopaedic hardware infections are a significant clinical problem with current 
therapies limited to surgical debridement and systemic antibiotic regimens. Lysostaphin is 
a bacteriolytic enzyme with high anti-staphylococcal activity. We engineered a 
lysostaphin-delivering injectable poly(ethylene glycol) hydrogel to treat Staphylococcus 
aureus infections in bone fractures. The injectable hydrogel formulation conforms and 
adheres to the fracture and surrounding tissue, ensuring efficient, local delivery of 
lysostaphin. Lysostaphin encapsulation within this synthetic hydrogel maintained enzyme 
stability and activity. Lysostaphin-delivering hydrogels exhibited enhanced anti-biofilm 
activity compared to soluble lysostaphin. Lysostaphin-delivering hydrogels eradicated S. 
aureus infection and out-performed prophylactic antibiotic and soluble lysostaphin therapy 
after 7 days in a murine model of femur fracture. Analysis of the local inflammatory 
response to infections treated with lysostaphin-delivering hydrogels revealed 
indistinguishable differences in cytokine secretion profiles compared to uninfected 
fractures, demonstrating clearance of bacteria and associated inflammation. Importantly, 
infected fractures treated with lysostaphin-delivering hydrogels fully healed by 5 weeks 
                                                 
2 Submitted: Johnson CT, Wroe JA, Agarwal A, Martin KE, Guldberg RE, Donlan RM, Westblade LF, and 
García AJ. Hydrogel Delivery of Lysostaphin Eliminates Orthopaedic Hardware Infection by Staphylococcus 
aureus and Supports Fracture Healing.  
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with equivalent bone formation and mechanical properties to uninfected fractures, whereas 
fractures treated without the hydrogel carrier were equivalent to untreated infections. 
Finally, lysostaphin-delivering hydrogels eliminate methicillin-resistant S. aureus 
infections, supporting this therapy as an alternative to antibiotics. These results indicate 
that lysostaphin-delivering hydrogels effectively eliminate orthopaedic S. aureus 
infections while simultaneously supporting fracture repair. 
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3.2 Introduction 
Orthopaedic disease and injuries often require biomaterial hardware and devices for 
successful clinical treatment. In 2011, 1.2 million prosthetic joint arthroplasty procedures 
were performed in the United States (US), and this number is projected to increase to 3.8 
million procedures by 2030 (133). However, infection of these devices is a major limitation 
with ineffective treatment options (134). For example, over 1,000,000 joint prostheses 
(135) and 6,000,000 fracture-fixation devices (136) are deployed each year,  with 2% and 
5% of these procedures, respectively, developing infection at an economic cost of over $2 
billion (1). In the US, 112,000 orthopaedic device-related infections occur annually with 
approximately 66% of these bacterial infections involving Staphylococcus species (2). 
Fracture fixation devices have infection rates ranging from 1-2% for closed fractures and 
rates as high as 30% for open fractures (137-139). Current treatment of these infections is 
limited to a combination of aggressive surgical debridement, device removal, and long-
term systemic antibiotic regimens. Antibiotic treatment can lead to the development of 
opportunistic infections through perturbations to the gut microbiota (140) and the 
development of antibiotic resistance (141). Further complicating the scenario is the 
formation of bacterial biofilms, populations of sessile and slowly dividing bacteria 
encapsulated within extracellular polymeric substances (142, 143). The biofilm matrix 
provides significant protection from the host immune system and acts as a diffusion barrier 
for antibiotics. The biofilm induces antibiotic tolerance through sequestration of 
antimicrobial agents, modulating nutrient gradients, and driving the development of 
persistor cells, together, allowing for bacteria to be resistant to antibiotic concentrations 
1,000 times higher than that required to kill the same planktonic strain (144). Bacteria in 
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biofilms can be exposed to sub-inhibitory antibiotic concentrations, further driving the 
development of antibiotic resistance (141). As such, current treatment strategies for device-
related infections are significantly limited, often requiring 1-2 revision surgeries, and 
causing significant patient morbidity, at a high economic cost of over $50,000 per case (2). 
The widespread emergence of antibiotic-resistant bacteria is a growing public health 
threat, leading to a post-antibiotic era, where current therapies are no long effective (145).  
This threat has prompted the investigation of alternative strategies to traditional systemic 
antibiotic therapy. Lysostaphin is a 27 kDa antimicrobial enzyme with activity specific to 
Staphylococcus species (4). The enzyme has two domains, a cell wall targeting domain, 
responsible for its specificity, and a lytic domain, that cleaves the pentaglycine cross-
bridges present in the bacterial cell wall (i.e., peptidoglycan) (3). Lysostaphin exhibits 
activity against antibiotic-resistant Staphylococcus aureus strains, including methicillin-
resistant S. aureus (MRSA), vancomycin-intermediate S. aureus, and vancomycin-resistant 
S. aureus (7-9), and Staphylococcus epidermidis (103). Importantly, lysostaphin kills 
planktonic and quiescent bacteria as well as cells growing in a biofilm (6), in contrast to 
most antibiotics that require active cellular metabolism to be effective (72). Widespread 
resistance to lysostaphin has not been reported from clinical samples (146), although 
several isolates have been generated in laboratory settings (5, 147). Additionally, the 
specificity of lysostaphin allows for only offending staphylococcal species being 
eliminated, thus preventing adverse effects of gut microbiota perturbation, which is 
associated with systemic antibiotic therapy. These characteristics make lysostaphin an 
ideal candidate to treat infections primarily limited to Staphylococcus species and where 
biofilm formation is often implicated in the disease process (148). Lysostaphin has been 
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delivered topically, systemically, or as material coatings in several small animal models to 
target S. aureus infections (9, 11, 149, 150). In humans,  topical application of lysostaphin 
reduces S. aureus nasal carriage five days after treatment with no reported toxicity (151). 
Additionally, parental administration in a human patient has been reported without major 
side effects (152).  
Despite these attributes, lysostaphin therapy has been severely limited by the lack of 
effective delivery vehicles. Conjugation of poly(ethylene glycol) (PEG) to lysostaphin 
increases the in vivo half-life of systemically administered enzyme from less than one hour 
to up to 24 hours, but at the expense of reduced enzymatic activity (153). Biomaterial 
carriers have focused on surface conjugation of lysostaphin to a material to prevent 
bacterial colonization (150, 154-156), as opposed to developing enzyme delivery vehicles. 
Localized delivery of antimicrobial therapeutics allows for higher drug concentrations to 
be achieved at the infection site over a longer period of time, with a lower risk of toxicity 
compared to systemic delivery (157, 158). Hydrogels are water-swollen polymer networks 
that exhibit significant therapeutic versatility for localized protein delivery (159). We 
previously engineered injectable PEG-based hydrogels for controlled delivery of protein- 
and cell-based therapeutics (160-165). In this platform, four-arm PEG macromers 
functionalized with terminal maleimide groups (PEG-4MAL) that react specifically with 
thiols are functionalized with cell adhesive peptides and cross-linked into a network using 
thiolated molecules such as protease-degradable peptides with terminal cysteines. These 
synthetic hydrogels exhibit significant advantages to other delivery vehicles including 
well-defined composition and structure, minimal toxicity, stoichiometric incorporation of 
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biomolecules, controlled polymerization kinetics, and non-toxic degradation products that 
are excreted in the urine (162, 163). 
Here, we engineered lysostaphin-delivering injectable hydrogels to treat S. aureus 
orthopaedic hardware infections and support fracture repair. We characterized the activity, 
stability, and release of hydrogel encapsulated lysostaphin, as well as antimicrobial and 
anti-biofilm performance. The efficacy of lysostaphin-delivering hydrogels was tested in 
vivo using a murine femur fracture infection model. Bacterial reduction, cytokine profiling, 
and functional healing was measured to assess the therapeutic potential of lysostaphin-
delivering hydrogel therapy. Finally, the antimicrobial efficacy of lysostaphin-delivering 
hydrogels against antibiotic-resistant bacteria was tested. 
3.3 Results  
3.3.1 Encapsulation of lysostaphin within injectable PEG hydrogels maintains activity 
Orthopaedic fractures range from simple closed fracture patterns with minimal soft 
tissue injury to complex open compound fractures with significant muscle injury, making 
delivery by injection and in situ polymerization desirable features in an antimicrobial 
delivery system. This property allows for the material to conform to the injury by 
integrating into the tissue. We synthesized PEG hydrogels in a one-step reaction by mixing 
PEG-4MAL macromers with the protease-degradable peptide cross-linker 
GCRDVPMSMRGGDRCG (VPM) (166) and cell adhesive peptides (e.g., RGD, 
GFOGER), which were covalently incorporated into the network by terminal cysteine 
groups that react specifically with maleimides on the PEG-4MAL macromer (Fig. 1A).  
Lysostaphin enzyme was physically entrapped within the hydrogel without covalent 
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incorporation onto the polymer network due to the lack of free thiol groups in the protein 
(167). This injectable format allows for lysostaphin to maintain its activity throughout the 
hydrogel synthesis process. Sustained release of lysostaphin, both via passive diffusion 
through the hydrogel network and protease-dependent degradation of the hydrogel, results 
in lysis of target bacteria and supports bone formation and subsequent fracture repair 
(Figure 4A). To assess the effect of hydrogel mesh size on diffusion-dependent of release 
of lysostaphin, we labeled lysostaphin with a fluorescent dye (Figure 5) and measured its 
diffusion out of the hydrogel. We synthesized hydrogels using different sized PEG-4MAL 
macromers (10 kDa, 20 kDa) at 8.0% and 4.0% w/vol to generate hydrogels with different 
mesh sizes. Exponential one-phase association curves were then fit to these data. The 20 
kDa hydrogels with a relatively larger mesh size exhibit more rapid lysostaphin release 
compared to the 10 kDa hydrogels with a tighter mesh structure (Figure 4B). This shows 
that as the mesh size is reduced the rate of diffusion-mediated release of lysostaphin is 
decreased. To evaluate lysostaphin activity following encapsulation and release, hydrogels 
were synthesized and placed in a bacterial suspension of S. aureus UAMS-1, a clinical 
isolate from a pediatric case of osteomyelitis (168), and reduction of bacteria was 
monitored overtime by optical density measurements. In this experiment, no protease was 
included so lysostaphin is released from the hydrogel only by diffusion. Lysostaphin-
containing hydrogels rapidly and completely reduced bacteria levels in suspension (Figure 
4C). Importantly, the rate of bacterial clearance was dependent on the dose of encapsulated 
lysostaphin. Retention of enzyme activity after hydrogel polymerization is a critical design 
criterion. We assessed the long-term activity of lysostaphin encapsulated within the 
hydrogel carrier and compared it to enzyme maintained in solution and fresh, reference 
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lysostaphin. Hydrogels were synthesized with lysostaphin and not swollen to prevent loss 
of enzyme to directly assess the hydrogel’s capacity to maintain enzyme stability. Enzyme 
activity was determined by calculating the rate of bacterial killing, as defined by the time 
required to kill 50% of a UAMS-1 bacterial suspension. The rate of bacterial killing was 
determined by fully degrading the hydrogels in protease and incubating this product with 
bacteria, then monitoring the reduction in optical density over the course of 1 hour (Figure 
6A-D). A one-phase decay curve was then fit to these data to obtain the half-life metric. 
Remarkably, hydrogel encapsulation preserved lysostaphin activity over 14 days when 
kept at 25ºC compared to soluble unencapsulated lysostaphin, which rapidly degraded 
(Figure 4D). There was no difference in lysostaphin activity between hydrogel-
encapsulated enzyme throughout 14 days and fresh enzyme. 
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Figure 4: Lysostaphin-delivering hydrogel synthesis and characterization. (A) 
Schematic diagram of lysostaphin encapsulation within protease degradable PEG-MAL 
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hydrogel and subsequent application to infected femurs, which leads to fracture callus 
formation and healing. (B)  Passive lysostaphin release with one-phase association fit 
with extra sum of squares F test to compare K values are different. (C) Optical density 
curves of lysostaphin-laden hydrogels placed in S. aureus UAMS-1 suspensions as a 
function of incubation time. (D) Lysostaphin activity as measured by the average half-life 
of the kinetic bacteria reduction assay (Figure 6A-D) at 1, 3, 7, and 14 days after 
hydrogel polymerization. (E) Protease-triggered release of lysostaphin with one-phase 
association fit using extra sum of squares F test to compare all K values are different. 
Means ± SD. N=3-5. 
 
 
Figure 5: Fluorescent lysostaphin labeling and purification. Lysostaphin was labeled 
with an AlexaFluor 488 fluorescent dye conjugated to a 2000 Da PEG chain 
functionalized with an NHS-ester to label free-amines and purified with size exclusion 
chromatography. During the elution phase, 280 nm light was used to monitor protein 
content (blue) and 488 nm light monitored dye fluorescence (red). The peak with both 
280 nm and 488 nm components was collected and used for the release studies. 
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Figure 6: Kinetic optical density plots of UAMS-1 reduction from degraded 
hydrogels. Hydrogels and soluble lysostaphin were degraded in protease and the sample 
was added to a bacterial suspension of UAMS-1. The optical density of the suspension 
was monitored for one hour after (A) one day, (B), three days, (C) seven days, and (D) 
fourteen days at 25ºC. Solid line represents one-phase decay line of best fit. Means ± SD. 
N=3-5. 
Bacterial infection often triggers an inflammatory response, including locally 
elevated protease levels (169).  The inclusion of protease-degradable peptide cross-links in 
lysostaphin-delivering hydrogels allows for lysostaphin to be released on-demand in 
response to infection and local protease activity. Protease-dependent release of lysostaphin 
was characterized by monitoring the release of fluorescently labeled lysostaphin from 
lysostaphin-laden hydrogels (20 kDa, 4.0% w/vol) exposed to different levels of protease 
(Figure 4E). The results show that higher levels of protease cause faster lysostaphin release, 
indicating protease-responsive release. Importantly, nearly all of the loaded enzyme was 
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released in these assays. Measurement of the mechanical properties of lysostaphin-
delivering hydrogels reveals that the addition of lysostaphin does not affect the elastic or 
viscous properties of the hydrogel, as determined by measuring the storage and loss moduli 
of the gels respectively (Figure 7A-D).  
 
Figure 7: Mechanical properties of lysostaphin-delivering hydrogels. Angular 
frequency sweep of (A) empty and (B) lysostaphin-delivering hydrogels at a constant 
strain of 2%. Average (C) storage and (D) loss modulus of empty and lysostaphin-
delivering hydrogels of eight data points within the linear region of the angular frequency 
sweep of each sample. Student t test. Means ± SD. N=7. 
3.3.2 Encapsulated lysostaphin kills bacteria, including in biofilms 
Lysostaphin is highly active against both S. aureus and S. epidermidis (6). We 
examined the bactericidal activity of the enzyme encapsulated in the hydrogel delivery 
system. Hydrogels were synthesized with different strains of S. aureus (Xen29, UAMS-1, 
46106) or S. epidermidis (IDRL-8883, a clinical strain isolated from a prosthetic joint 
infection), trapped within the hydrogel matrix with or without lysostaphin (Table 3). The 
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gels were then cultured overnight in bacterial growth media and after 24 hours were 
assayed for viable bacteria. Encapsulated lysostaphin reduced viable bacteria to 
undetectable levels for all bacterial strains tested (Figure 8A-D). After confirming that 
lysostaphin-laden hydrogels are effective against various strains of bacteria, we tested the 
in vitro cytocompatibility of lysostaphin using human mesenchymal stem cells.  We 
induced human mesenchymal stem cells to differentiate towards an osteogenic lineage and 
added lysostaphin to the culture media. Lysostaphin had no effects on the osteogenic 
differentiation of human mesenchymal stem cells as assessed by alkaline phosphatase 
activity (Figure 9A) and calcium deposition (Figure 9B-C), demonstrating that lysostaphin 
effectively kills staphylococcal species but does not interfere with osteogenic 
differentiation by mammalian cells. 
Strain Source Characteristics Ref. 
S. aureus Xen29 Perkin Elmer - derived 
from ATCC 12600 
Methicillin sensitive, pleural fluid 
isolate 
(50) 
S. aureus UAMS-1 ATCC 49230 Methicillin sensitive, pediatric 
osteomyelitis isolate, strong 
biofilm former 
(168) 
S. aureus 46106 Centers for Disease 





Methicillin sensitive, abdominal 
wound isolate 
 
S. aureus USA300 ATCC BAA-1556 Methicillin resistant, wrist abscess 




Mayo Clinic Methicillin resistant, prosthetic 
joint infection 
(171) 




Figure 8: Lysostaphin-laden hydrogels effectively kill bacteria in vitro. Bacterial 
counts reported as CFU/gel after 24 hours of culture for (A) S. aureus Xen29, (B) S. 
aureus UAMS-1, (C) S. aureus 46106, and (D) S. epidermidis IDRL-8883. (E, F) 
Biofilms were generated by culturing UAMS-1 for 24 hours statically and were then 
treated overnight with a hydrogel or soluble enzyme. (E) Images and (F) quantification of 
average image intensity of live bacteria after treatment. Scale bar is 500µm. Means ± SD. 
N=3-4 per group. *P < 0.05, ***P < 0.001, ****P < 0.0001, one-way ANOVA with 
Tukey’s post-hoc test. 
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Figure 9: Lysostaphin supports hMSC differentiation. (A) Alkaline phosphatase 
production of hMSC exposed to lysostaphin after 9 days in culture. (B) Quantification of 
calcium deposition by Alizarin Red extraction from hMSC after 21 days in culture. (C) 
Representative images of Alizarin Red staining of hMSC cultures. One-way ANOVA 
with Tukey’s post-hoc test. Means ± SD.  N=3-4. All comparisons not significant. 
Orthopaedic hardware infections typically involve formation of a bacterial biofilm. 
The biofilm protects the bacteria from the host immune response and acts as a diffusion 
barrier for antibiotics, making them particularly difficult to eliminate. We evaluated the 
anti-biofilm activity of lysostaphin-delivering hydrogels. We hypothesized that delivery 
via the hydrogel carrier would improve the anti-biofilm activity of the enzyme compared 
to soluble enzyme alone based on our observation that encapsulation within the hydrogel 
prolonged enzyme stability (Figure 4C). S. aureus strain UAMS-1 is a known prolific 
biofilm former (172). We grew UAMS-1 biofilms for 24 hours and then treated them with 
lysostaphin-laden hydrogels or soluble enzyme. After 18 hours of treatment, bacterial 
reduction was assessed by staining for live bacteria and subsequently imaging the biofilm. 
Figure 8E shows representative images of biofilms after treatment. There is a clear 
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lysostaphin dose-dependent reduction in live bacteria for the hydrogel-treated group, which 
is confirmed by image quantification (Figure 8F). Soluble delivery of the enzyme had little 
effect at the lower concentration tested with a reduction in live bacteria only at the higher 
concentration (Figure 8F).  
3.3.3 Lysostaphin-laden hydrogels effectively reduce S. aureus infection of bone 
fractures 
 Treatment of long bone fractures, such as the femur, often requires fixation devices 
to stabilize the injury, enable healing, and promote return to mobility. However, bacterial 
infection of devices used to stabilize orthopaedic injuries leads to the inability of fractures 
to heal, characterized by bone resorption, reactive bone formation, implant loosening, and 
ultimately device failure (134). To model this situation in vivo, we developed a mouse 
model of orthopaedic hardware infection. In this model, the femur is fractured using a 
custom three-point bending device, the fracture is then stabilized with a 25G needle placed 
in the femoral shaft (173), and then a hydrogel is polymerized in situ over the fracture 
(Figure 10A). Importantly, the injectable hydrogel formulation conforms and adheres to 
the fracture and surrounding tissue, ensuring efficient, local delivery. For mice receiving 
an infection, bacteria is mixed with the hydrogel components and polymerized in situ over 
the fracture. We then measure bacterial counts one week after fracture or assess fracture 




Figure 10: Lysostaphin-delivering hydrogels eliminate bacteria in infected fractures. 
(A) Schematic diagram of mouse femur infection model. Quantification of S. aureus 
UAMS-1 recovered from the (B) tissue surrounding the femur, (C) femur bone, and (D) 
stabilization needle 7 days post-fracture. Dashed line indicates detection limit. (E) 
Histological sections of femurs 7 days post fracture stained for hematoxylin and eosin, 
safranin-O and fast green, and Gram. Black arrows indicate Gram-positive bacteria. 
Kruskal-Wallis test with Dunn’s multiple comparisons test. Means ± SD. N=4-8, 
compilation of four independent experiments. *P < 0.05, **P < 0.01.  
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Lysostaphin-delivering hydrogels should support fracture repair in the absence of 
infection to be an acceptable therapy for preventing staphylococcal infections. We 
hypothesized that the application of a lysostaphin-laden hydrogel would not impair normal 
(sterile) fracture healing. To test this, femoral fractures were treated with a sterile, 
lysostaphin-delivering hydrogel or left untreated. No bacteria were delivered in this 
experiment. After 5 weeks, femora were explanted and analyzed by microcomputed 
tomography (µCT), mechanical testing, and histology to evaluate fracture repair. µCT 
reconstructions revealed no gross morphologic differences in the fracture callus (Figure 
11A). Similarly, no differences in fracture callus volume (P=0.26, Figure 11B) or 
mechanical strength (P=0.94, Figure 11C) of the repaired femora were detected between 
untreated and lysostaphin-delivering hydrogel-treated mice. Histological staining with 
hematoxylin and eosin (H&E) for tissue morphology and safranin-O and fast green (Saf-
O/FG) for cartilage also showed no gross differences in healing between sterile control 




Figure 11: Lysostaphin-delivering hydrogels support fracture healing. (A) µCT 
reconstructions of the fracture callus 5-weeks post-operation. Quantification of (B) 
fracture callus volume and at 5 weeks. (C) Mechanical integrity of femurs as assessed by 
ex vivo torsion to failure testing. (D) Hematoxylin and eosin and safranin-O and fast 
green staining of femurs. N=6 per group. *P < 0.05, Student’s t test. 
 We next evaluated the ability of lysostaphin-delivering hydrogels to prevent S. 
aureus infection in vivo using the murine infected femur fracture model. Mouse femora 
were fractured and hydrogels containing methicillin-sensitive S. aureus UAMS-1 were 
polymerized in situ over the fracture to induce infection with or without lysostaphin. We 
included a group treated with soluble lysostaphin (no hydrogel) as well as an antibiotic 
prophylaxis group that received a single injection of oxacillin (100 mg/kg) pre-operatively 
to directly compare the lysostaphin-delivering hydrogel to antibiotic-based therapy. Seven 
days post-operation, animals were sacrificed, tissue was separated, and viable bacteria were 
enumerated in the tissue surrounding the femur (Figure 10B), the femur (Figure 10C), and 
the stabilization needle (Figure 10D). Untreated infected controls had high numbers of 
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recovered bacteria, indicating a persistent infection. Mice receiving prophylactic oxacillin 
therapy before the operation also had elevated bacteria counts, demonstrating that 
prophylactic antibiotic treatment did not prevent bacterial infection in this model. This 
result is consistent with clinical experience with systemic antibiotic regimens that do not 
consistently eliminate S. aureus infections. Treatment with lysostaphin-laden hydrogels 
significantly reduced the amount of recovered bacteria compared to the infection-only 
control and infections receiving systemic oxacillin. Importantly, the lysostaphin-laden 
hydrogels reduced bacteria counts to the same level as sterile controls. For the soluble 
lysostaphin-treated group, variable levels of bacteria were recovered and there was no 
difference in bacteria counts between this group and the infection-only control or the 
oxacillin-treated group, demonstrating that the hydrogel delivery vehicle is necessary to 
effectively treat these infections. The variability of infection clearance within the soluble 
lysostaphin group could be due to inadequate delivery of lysostaphin to the infection site 
since the soluble enzyme is not localized within a delivery carrier. Further, our in vitro data 
suggests the stability of the enzyme is reduced compared to lysostaphin delivered within 
the hydrogel. Histologic analysis demonstrated significant leukocyte infiltration for 
infection-only and oxacillin-treated fractures compared to sterile fractures and fractures 
treated with lysostaphin-laden hydrogels (Figure 10E). Safranin-O/fast green staining 
indicated poor collagen staining at the fracture site, characteristic of inhibited fracture 
repair, for the infection-only and oxacillin-treated fractures. In contrast, the lysostaphin-
laden hydrogel treated samples showed collagen deposition at the fracture site, consistent 
with the sterile control. Gram-positive bacteria were detected in the infection-only control 
and oxacillin-treated groups showing that the infection persisted over the course of the 
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experiment. No Gram-positive bacteria were detected in the lysostaphin-treated and sterile 
groups. Taken together, these results demonstrate that lysostaphin-delivering hydrogels 
eliminate S. aureus infections of bone fractures and outperform systemic antibiotic and 
direct delivery of soluble lysostaphin. 
3.3.4 Lysostaphin delivery to infections restores a sterile inflammatory environment 
A major concern of bactericidal therapy is an elevated and sustained inflammatory 
response to bacterial degradation products that negatively impacts healing responses (142). 
Lysostaphin catalytically degrades the bacterial cell wall, leading to cell lysis and 
subsequent release of bacterial debris; the release of these bacterial products could cause a 
significant inflammatory response. To analyze this inflammatory response and assess the 
safety profile of lysostaphin therapy, we treated infected fractures with hydrogels 
containing lysostaphin or empty hydrogels. Sterile hydrogels containing lysostaphin were 
included as the healing control. One week post-infection, we performed a multiplexed 
cytokine array assay on explanted tissue. Hierarchal cluster analysis using the Ward 
Method revealed clear separation between the infected scaffolds and the sterile and 
lysostaphin-hydrogel treated gels (Figure 12A). Looking at the second tier of the cluster 
analysis shows two clusters containing a mix of sterile and lysostaphin-delivering hydrogel 
treated mice in the bottom right of the array. Closer analysis of these samples reveals that 
the individual cytokine levels measured are at or near the detection level of the assay and 
normalization by the protein content of the sample affects the values. Individual analysis 
of these cytokines using two-way ANOVA with Fisher’s LSD test reveals no statistical 
differences between experimental groups. Multivariate ANOVA with a sum combination 
across all cytokines demonstrated significant differences (P<0.001) between the infection-
 56 
only group and the sterile and lysostaphin-gel treated fractures (Figure 12B). Importantly, 
significant overlap was observed between the sterile and lysostaphin-laden hydrogel 
groups, suggesting that the lysostaphin-delivering hydrogels restored the local 
inflammatory environment to a sterile state. Elevated levels of G-CSF, IL-1a, IL-1b, IL-6, 
KC, IP-10, MIP-1a, MIP-1b, and MIP-2 (Figure 12C-K), important cytokines in the 
inflammatory response to infection, were present in the infection-only group compared to 
the sterile control and lysostaphin-hydrogel treated infections. No differences were 
detected between the sterile and lysostaphin hydrogel-treated groups for any of the 
cytokines. These results provide further evidence that lysostaphin-delivering hydrogels 





Figure 12: Lysostaphin-laden hydrogel therapy restores a sterile inflammatory 
environment. Femora were fractured and infected with UAMS-1 and treated with 
hydrogels with or without lysostaphin and the inflammatory milieu of tissue at the 
fracture site 7 days post-infection was assessed using multiplexed cytokine analysis. (A) 
Hierarchical cluster analysis of cytokine profiles using the Ward Method. (B) 
Multivariate-ANOVA plot using a sum combination across cytokines, P<0.001. (C-K) 
Cytokines with statistically different tissue levels as determined using two-way ANOVA 
with a Bonferonni Correction for multiple comparisons. Means ± SD. N=6-8 per group. 
*P < 0.05, ***P < 0.001, ****P < 0.0001, ns is not significant. 
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3.3.5 Lysostaphin-delivering hydrogels result in healing of infected femoral fractures 
 To determine whether treatment of infections with lysostaphin-delivering 
hydrogels effectively reduces the bacterial infection and promotes fracture repair, we 
assessed functional fracture healing at 5 weeks post-infection. Mouse femora were 
fractured and hydrogels containing S. aureus UAMS-1 were placed at the fracture site to 
induce infection. These hydrogels contained lysostaphin or were left naïve as controls. The 
lysostaphin-delivering hydrogels were benchmarked against soluble lysostaphin delivery. 
Sterile, lysostaphin-delivering hydrogels were included as the positive healing control. The 
fractures were allowed to heal for five weeks, and then fracture repair was analyzed using 
µCT imaging, torsion to failure testing was used to assess the mechanical integrity of the 
femora, and histologic evaluation. Reconstructions of µCT scans (Figure 13A) show no 
callus formation in the UAMS-1-infected control group and the presence of bone resorption 
and reactive bone formation around the fracture site, which is characteristic of 
osteomyelitis caused by bacterial infection. The sterile controls developed a robust fracture 
callus with evidence of bone remodeling, demonstrating fracture healing. All mice in the 
lysostaphin-laden hydrogel treated group showed significant fracture healing. A fracture 
callus was formed and the volume of the callus (Figure 13B, P>0.99) and bone deposition 
within the callus (Figure 13C, P>0.99) were equal to the sterile controls. Callus volume 
and bone volume were higher for infected fractures treated with lysostaphin-laden 
hydrogels compared to infection-only fractures (Figure 13B-C, P<0.05). Fracture repair 
was highly variable in the soluble lysostaphin treated group, 2/6 samples did not form a 
fracture callus and displayed features of osteomyelitis, including bone resorption and 
reaction bone formation (Figure 14A). The remaining 4/6 samples treated with soluble 
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lysostaphin formed a fracture callus and progressed towards fracture healing (Figure 
14B).Importantly, the torsional strength of infected fractures treated with lysostaphin-laden 
hydrogels was significantly higher than that for the infection-only control (P<0.001), and 
these high torque values were equivalent to those for the sterile control group (Figure 13D).  
This result demonstrates that lysostaphin-delivering hydrogels clear the bacterial infection 
and support effective and complete fracture repair. No differences were observed between 
infected fractures treated with soluble lysostaphin and infection-only controls, again 
showing poor outcomes for lysostaphin therapy without the hydrogel carrier. Histologic 
sections of infected fractures treated with lysostaphin-delivering hydrogels and sterile 
fractures show no notable morphological differences (Figure 13E), providing further 
support of successful fracture repair. The infection-only group shows significant leukocytic 
infiltrate on H&E staining and the presence of Gram-positive bacteria (black arrows). This 
result clearly demonstrates persistent infection and inflammation for infected fractures that 
were not treated with lysostaphin-laden hydrogel. 
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Figure 13: Lysostaphin-delivering hydrogels enable fracture healing. (A) µCT 
reconstructions of the fracture callus 5 weeks post-operation (scale bar 1mm). 
Quantification of µCT reconstructions showing the (B) fracture callus volume and (C) 
bone volume within the fracture callus at 5 weeks. (D) Mechanical strength of femurs as 
assessed by ex vivo torsion to failure testing. (E) Hematoxylin and eosin, safranin-O and 
fast green, and Gram staining of femurs. Black arrows indicate Gram-positive bacteria. 
Kruskal-Wallis test with Dunn’s multiple comparisons test. Means ± SD. N=6-8, 
compilation of two individual experiments. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 14: µCT reconstructions of non-healing and healing soluble lysostaphin 
treated fractures. Mice treated with soluble lysostaphin exhibited a non-healing (A) and 
healing (B) response. 
3.3.6 Lysostaphin-delivering hydrogels clear MRSA bone infections 
To test the efficacy of lysostaphin-delivery hydrogels to combat antibiotic-resistant 
bacteria, we measured bacterial numbers of the persistent infection 7 days post-operation 
with the MRSA strain USA300. Mouse femora were fractured and hydrogels containing 
MRSA were placed at the fracture sites to induce infection. These hydrogels contained 
lysostaphin or were left empty as controls.  Sterile lysostaphin-delivering hydrogels were 
used as controls. Consistent with the results obtained with UAMS-1, lysostaphin-delivering 
hydrogels significantly reduced MRSA bacteria counts compared to the infection-only 
control for the tissue surrounding the femur (Figure 15A), the femur (Figure 15B), and the 
stabilization needle (Figure 15C). Notably, all of the lysostaphin hydrogel treated mice had 
undetectable levels of bacteria. This shows that lysostaphin-delivering hydrogels eradicate 
antibiotic-resistant bacteria.  
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Figure 15: Lysostaphin-laden hydrogels clear MRSA infections. Quantification of 
MRSA USA300 recovered from the (A) tissue surrounding the femur, (B) femur, and (C) 
stabilization needle at 7 days post-fracture. Dashed line indicates detection limit. 
ANOVA with Tukey post-hoc test for (A) and (B). Kruskal-Wallis test with Dunn’s 
multiple comparisons test for (C) Means ± SD. N=3-4. *P < 0.05, ****P < 0.0001. 
3.4 Discussion  
 Orthopaedic hardware infections are a significant clinical problem and lack 
effective therapies. Current interventions are limited to long term systemic antibiotics, 
surgical debridement, and implant removal. Alternative therapy with antimicrobial 
enzymes such as lysostaphin provides for effective killing of specific bacterial species, 
however these approaches are limited by the lack of suitable delivery vehicles. Here, we 
engineered synthetic hydrogels to deliver active lysostaphin to infected bone fractures to 
clear the infection and promote fracture healing. The synthetic hydrogel delivery vehicle 
maintained lysostaphin activity over 14 days and controlled the release of active enzyme 
via passive and protease-triggered mechanisms. These hydrogels displayed high activity 
against various strains of S. aureus, as well as a methicillin-resistant S. epidermidis clinical 
isolate from a prosthetic joint infection in vitro. Importantly, lysostaphin delivery via the 
hydrogel carrier outperformed soluble enzyme when treating biofilms, most likely due to 
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the sustained release of active lysostaphin. In a murine model of fracture infection, 
lysostaphin-delivering hydrogels cleared the infections and supported fracture repair, with 
bone formation and mechanical properties equivalent to that of uninfected fractures. 
Lysostaphin-delivering hydrogels restored the local inflammatory environment to that of 
sterile fractures at 7 days. In contrast, infected fractures treated with either prophylactic 
antibiotics or soluble lysostaphin showed no differences in bacterial levels and impaired 
healing compared to the infection controls. Notably, delivery of lysostaphin with this 
hydrogel carrier significantly reduced MRSA infections in this fracture model. Taken 
together, these results show that hydrogel-mediated delivery of lysostaphin eliminates 
fracture infections, including antibiotic-resistant strains, allowing for the endogenous 
fracture repair mechanisms to progress and healing to occur. 
Biomaterial strategies to deliver active lysostaphin have primarily focused on 
surface functionalization, either by passive adsorption (11, 13), covalent tethering (155, 
174), or impregnation within a coating (150, 175). This is an effective way to reduce 
bacteria at the material surface, but may not be practical for settings where infection is 
already established, or not localized to a material surface (e.g., surrounding tissue). Our 
injectable formulation allows for in situ polymerization of the hydrogel at the fracture site, 
adhering and conforming to the injured tissue, which is an important feature for treating 
complex fractures. We demonstrate that lysostaphin-delivering hydrogels have greater 
anti-biofilm activity compared to soluble lysostaphin. This effect may be attributed to the 
enhanced enzyme stability and higher concentrations of lysostaphin localized to the biofilm 
achieved using the hydrogel carrier. Together, these material properties could allow for a 
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broader application of lysostaphin-delivering hydrogels to treat other types of 
staphylococcal infections. 
We demonstrate that lysostaphin-delivering hydrogels are effective at reducing 
infection for both clinical osteomyelitis and MRSA isolates in vivo. As with any 
antimicrobial therapy, the development of resistance to the treatment is a potential concern. 
Interestingly, lysostaphin exhibits synergism with β-lactam antibiotics, and lysostaphin 
exposure can sensitize strains to the antibiotic they have resistance against (5, 103). 
Therefore, lysostaphin delivery together with antibiotics could broaden the activity of the 
enzyme, while also reducing the chance of resistance developing. A lysostaphin-based 
approach offers several advantages over traditional small molecule antibiotics. The 
bacteriospecific nature of lysostaphin provides specific targeting of the infecting organism, 
which may reduce complications associated with disrupting commensal bacteria (140). 
Small molecule antibiotics primarily function through disruption of bacterial metabolic 
processes, leading to growth inhibition and death. This reliance limits drug activity against 
biofilm bacteria. The enzymatic nature of lysostaphin sidesteps this requirement, as the 
enzyme directly disrupts and kills bacteria. This feature contributes to the low 
concentrations (ng/mL range) required to kill bacteria compared to antibiotics (µg/mL 
range) (6), thereby reducing the amount of enzyme needed to provide bactericidal activity 
to the infection site. 
 Lysostaphin-delivering hydrogel treatment assists in restoring a pro-healing 
inflammatory environment, supported by the absence of differences in cytokine secretion 
profiles compared to the sterile control. We attribute this effect to the kinetics of bacterial 
debris clearance by inflammatory cells, which is complete by 7 days after treatment. This 
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result also supports the translation of lysostaphin therapy, as rapid bacterial killing and 
clearance are critical features for materials designed to treat infections. Importantly, 
lysostaphin administration with the hydrogel carrier eradicates the infection while 
supporting fracture healing as assessed by both µCT imaging and mechanical testing. The 
protease degradable nature of the hydrogel carrier, in addition to protease-triggered release 
of lysostaphin, allows for host cells to degrade the hydrogel during repair, resulting in 
replacement of the gel with repair tissue. This is in contrast to non-degradable scaffolds 
that are either never removed, or only removed at revision surgery once the infection is 
cleared. A concern with lysostaphin use is the development of neutralizing antibodies. 
Indeed, several studies have reported antibody development (151, 153, 176), but 
bacteriolytic activity was preserved in rabbits immunized to lysostaphin before therapy 
(176). Additionally, de-immunization of lysostaphin by removing protein recognized by 
T-cell epitopes reduces the likelihood of antibody generation (177, 178), which could 
eliminate concerns of systemic immune response to therapeutic delivery. We found that 
1/5 mice treated with lysostaphin-delivering hydrogels tested positive for anti-lysostaphin 
IgG antibodies five weeks after treatment, with none of the sterile or infected lysostaphin-
free mice testing positive. However, pre-exposure serum was not tested for existing IgG 
titers, making it difficult to definitively conclude that the lysostaphin-delivering hydrogel 
generated an immune response. Furthermore, concerns over the development of 
neutralizing antibodies against lysostaphin are minimal for the bone repair application 
presented here as it would be exceedingly rare for a patient to have multiple independent 
infected or open fractures requiring lysostaphin therapy in a lifetime. 
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The present application focused on a biomaterial to specifically reduce S. aureus 
infections using lysostaphin. This technology could be further enhanced by broadening the 
antimicrobial spectrum to target other relevant pathogens in osteomyelitis cases, such as 
other coagulase-negative Staphylococcus species, Pseudomonas, and Enterococcus (2). 
Broadening the bacterial targets of the material will increase its utility as an effective 
prophylactic (179, 180). It will also be important to evaluate the ability to treat established 
biofilms in vivo (53). Species-specific antimicrobial therapies with activity towards 
bacteria growing in biofilm will help to successfully treat these complicated infections with 
reduced side effects to patients, such as disruption of the gut microbiota. Finally, this 
strategy will need to be evaluated in larger animal models for safety and efficacy to further 
assess its clinical potential. 
3.5 Materials and Methods 
Study Design 
This study was designed to test whether lysostaphin-delivering hydrogels reduce S. aureus 
infection and allow for femoral fracture repair to occur. We hypothesized that a hydrogel 
carrier would improve the efficacy of lysostaphin’s ability to kill bacteria, while allowing 
for the endogenous fracture healing mechanisms to occur. Lysostaphin-delivering 
hydrogels were first characterized and the antimicrobial activity was assessed in vitro. We 
examined the antimicrobial activity of lysostaphin in vivo using a mouse femur fracture 
infection model. The study groups included untreated UAMS-1 infections, lysostaphin-
delivering gels, soluble lysostaphin (no hydrogel), pre-operative oxacillin injection, and 
uninfected lysostaphin-delivering gels. Male C57/B6 mice were used for all studies with 
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4-8 biological replicates per group with the experiment performed at least in two 
independent runs. Sample sizes were selected based on statistical power calculations and 
estimates from previous studies. The time point of one week was selected for the 
microbiologic assessment because it allowed for the development of a persistent infection. 
Colony forming units were assessed in the surrounding tissue, femur, and fixation needle. 
Inflammatory profiling was performed at one week to allow for a persistent infection to 
develop. We hypothesized that lysostaphin-delivering hydrogels would allow for infected 
fractures to undergo repair. Five weeks was selected based on previous studies as the 
endpoint for analyzing fracture repair to allow for adequate bone remodeling and mineral 
deposition to occur. Ex vivo µCT imaging and torsion to failure testing were used to 
evaluate fracture healing. To assess the activity of lysostaphin-delivering hydrogels to 
reduce antibiotic resistant infections, mice were infected with the MRSA strain USA300 
and assessed for viable bacteria at seven days. Animals were randomly selected for 
histological examination. The experimental groups were not blinded except for the analysis 
µCT imaging. Excluded data was limited to animals that did not reach the pre-specified 
end point due to post-operative surgical complications, such as significant weight loss or 
destabilization of the fixation needle.  
Bacteria strains and culture 
The bacteria strains used in these studies were UAMS-1 (ATCC 49230 (168)), USA-300 
(ATCC BAA-1556 (170)), Xen29 (Perkin-Elmer (50)), 49230 (CDC Clinical and 
Environmental Microbiology Branch Culture Collection), IDRL-8883 (Clinical isolate 
(171)) and are compiled in Table S1. All strains were cultured on trypic soy agar (TSA) 
plates (BD Diagnostics) at 37ºC unless otherwise specified. 
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Preparation of lysostaphin-delivering hydrogels 
20 kDa PEG-4MAL macromer (Lysan Bio) was mixed with recombinant lysostaphin 
protein (AMBI Products LLC) in 100 mM MES buffer pH 5.5-6.0. Hydrogels were then 
cross-linked in a one-step reaction by combining PEG-lysostaphin with either the 
GFOGER peptide, GGYGGP(GPP)5GFOGER(GPP)5GPC (New England Peptide), or the 
RGD peptide, GRDGSPC (AAPPTEC), VPM cross-linker, GCRDVPMSMRGGDRCG 
(Genscript), and the bacterial suspension. Bacterial suspensions were prepared by picking 
individual colonies of bacteria grown on a TSA plate overnight and suspending them in 
Dulbecco’s Phosphate Buffered Saline supplemented with calcium and magnesium  (PBS) 
to an optical density of 0.20 at 600 nm (MicroScan Turbidity Meter, Seimens) and then 
diluting this suspension 100-fold. The viable count for all bacterial inocula was determined 
by plate count on TSA medium. Unless otherwise noted the hydrogels were 4.0% w/v 20 
kDa PEG-4MAL, 1 mM GFOGER, and 424 U/mL lysostaphin.  The amount of VPM cross-
linker added was determined stoichiometrically by matching the remaining maleimide 
groups after accounting for GFOGER or RGD incorporation. After mixing, the hydrogels 
were allowed to gel for 15 minutes in a humidified incubator at 37ºC and 5.0% CO2 for in 
vitro studies or polymerized over the fracture for in vivo studies. 
Lysostaphin activity and stability assays 
Lysostaphin was encapsulated within 25 µL sterile hydrogels (4.0% w/v 20 kDa PEG-
MAL, 1 mM RGD, VPM, 424 U/mL lysostaphin). The soluble lysostaphin group was 424 
U/mL lysostaphin in an equivalent buffer to the hydrogel formulation in 25 uL aliquots. 
The reference lysostaphin group was prepared fresh from frozen at each time point. At 1, 
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3, 7 and 14 days, samples were incubated in 50 µL of 730 U/mL collagenase for 1 hour at 
37ºC and then 50 µL of each sample was assessed for activity by incubating with 150 µL 
UAMS-1 inoculum. The inoculum was prepared by culturing UAMS-1 overnight in brain 
heart infusion (BHI) broth with shaking at 37ºC, washing three times in 200 mM Tris-HCl 
pH 8.0 by centrifugation, and adjusting the optical density to 0.25 at 600 nm (MicroScan 
Turbidity Meter, Seimens). Changes in optical density at 590 nm were measured using a 
HTS 7000 Plus plate reader (Perkin Elmer) every minute for 1hr at 35ºC.  
Lysostaphin release from PEG hydrogels 
Amine groups on lysostaphin were fluorescently tagged using an AlexaFluor 488 dye 
conjugated to a 2 kDa PEG linker functionalized with an NHS ester (Nanocs). The reaction 
was performed in 100 mM NaHCO3 buffer at pH of 8.3 at room temperature for one hour 
with continuous mixing in the dark. Excess dye was removed from labeled protein using 
an AKTA Pure 25 (GE Healthcare) in combination with a Superdex 75 increase size 
exclusion column (GE Healthcare) using PBS as the running buffer, at 4ºC. Labeled 
lysostaphin was incorporated in the hydrogel conditions tested: 4.0% w/v 20 kDa PEG-
4MAL, 1 mM RGD, VPM; and 8.0% w/v 10 kDa PEG-4MAL, 1mM RGD, VPM. For the 
diffusion release study, hydrogels were polymerized, swollen in PBS, and incubated 
statically at 37ºC and 5.0% CO2. For the protease-triggered release studies, 4.0% w/v 20 
kDa PEG-4MAL, 1 mM RGD, VPM hydrogels were swollen in PBS supplemented with 2 
U/mL, 10 U/mL, or 50 U/mL collagenase type 1 (Worthington) and incubated shaking at 
200 rpm, 37ºC, and 5.0% CO2. At each time point, the supernatant was sampled and read 
(488/530 excitation/emission) on a Synergy H4 (BioTek) plate reader. The measured 
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fluorescence values were normalized to the fluorescence of PEG-4MAL/lysostaphin 
mixtures of the respective hydrogel condition. 
Measurement of hydrogel mechanical properties 
Hydrogels with (424 U/mL) and without (0 U/mL) lysostaphin (4.0% w/v 20 kDa PEG-
4MAL, 1 mM RGD, VPM) were synthesized in circular 4.5 mm diameter silicone isolators 
and swollen overnight in PBS at 4ºC. The loss and storage moduli were measured using a 
MCR 302 stress-controlled rheometer (Anton Paar) in combination with a 9 mm diameter, 
2º measuring cone. The hydrogels were placed between the cone and plate and the cone 
was lowered to 39 µm. A strain amplitude sweep was performed at a constant frequency 
of 10 rad/s to identify the linear viscoelastic range. Oscillatory frequency sweeps were then 
performed (ω=0.5-30 rad/s) at a constant strain of 2%. 
Human mesenchymal stem cell differentiation potential and calcium deposition 
Bone marrow-derived human mesenchymal stem cells (Texas A&M) were cultured in 
growth media: αMEM (ThemoFisher) with 16.5% fetal bovine serum, 2-4 mM L-
glutamine (ThermoFisher), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37ºC, 5% 
CO2. Media was changed every 2-3 days. Cells were seeded at 10,000 cells/cm
2 and 
differentiated using growth media supplemented with 10 nM dexamethasone, 20 mM β-
glycerolphosphate, and 50 µM L-ascorbic acid supplemented with the indicated 
concentration of lysostaphin. After nine days of differentiation, alkaline phosphatase 
(ALP) activity was assessed. Cells were lysed and ALP activity was measured using 4-
methylumbelliferyl phosphate disodium salt (MUP) substrate (181). Fluorescence was read 
at 360nm/465nm excitation/emission using a Synergy H4 plate reader (BioTek). Activity 
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was standardized with purified calf intestinal ALP at known dilutions, and normalized to 
total protein content determined using the bicinchoninic acid assay (Pierce BCA Protein 
Assay Kit, ThermoFisher) per the manufacturer’s instructions. After 21 days of 
differentiation, cultures were fixed in 10% formalin, stained with alizarin red, and imaged 
at 4x with an EVOS Cell Imaging System (ThermoFisher). Alizarin red was then extracted 
and absorption was measured at 405 nm using a Synergy H4 plate reader (BioTek). 
In vitro antimicrobial assessment of lysostaphin gels 
The indicated bacterial strain was grown overnight on TSA at 37ºC. Bacterial cells were 
suspended in sterile PBS to an optical density to 0.20 measured at 600 nm (Microscan 
Turbidity Meter, Siemens). This suspension was then diluted 100 x in 100 mM MES buffer 
and used as the inoculum. Hydrogels were synthesized (4.0% w/v 20kDa PEG-MAL, 1mM 
RGD, VPM, 424U/mL lysostaphin), inoculated with the diluted bacterial culture, and 
incubated overnight in 25% trypic soy broth (TSB) at 37ºC statically. Viable bacteria were 
enumerated by washing the hydrogels three times in PBS and degrading them in 365 U/mL 
collagenase Type 1 (Worthington) for 1 hour. The degraded gels were serially diluted in 
PBS and 10 µL of each dilution was plated on TSA and grown overnight at 37ºC. Colony 
forming units (CFU) were then enumerated. 
Anti-biofilm activity of lysostaphin hydrogels 
Biofilms were grown by inoculating 500 µL of BHI supplemented with 1% glucose (182) 
in a 48-well tissue culture plate with 20 µL of UAMS-1 cells picked from a TSA plate and 
suspended in PBS to an optical density to 0.20 measured at 600 nm. The biofilm was 
cultured 24 hours at 37ºC statically. Biofilms were washed with PBS and 75 µL hydrogels 
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(4.0% w/v 20 kDa PEG-MAL, 1mM RGD, VPM, 0 U/mL, 424 U/mL, or 4240 U/mL 
lysostaphin) were polymerized on top of the biofilm or hydrogel buffer with a matching 
amount of lysostaphin added to the well, and incubated for 15 minutes at 37ºC, 5.0% CO2 
to allow for hydrogel polymerization. BHI media with 1% glucose was then added and 
biofilms were grown overnight, at 37ºC. Biofilms were washed, fixed with 4.0% 
paraformaldehyde, and stained using LIVE/DEAD BacLight Bacterial Viability Kit 
(ThermoFisher) per manufacturer’s instructions (183). A Nikon-C2 laser scanning 
confocal microscope using a 4X objective to acquire four images per well that were 
subsequently stitched together was used to image the biofilms. Live bacteria stained with 
SYTO9 were imaged using a 488 nm excitation laser in combination with a 525/50nm 
filter. Live bacteria were quantified by measuring the average pixel intensity of a 
2656.37µm x 2657.37µm selection of the image centered over the center of the well. 
Murine femur fracture model 
All animal procedures were performed in accordance with Institutional Care and Use 
Committee-approved protocols at the Georgia Institute of Technology. Male C57/B6 mice 
10-12 weeks old were housed with 12 hour light/dark cycles and freely provided food and 
water. Mice were anesthetized under isofluorane and administered slow-release 
buprenorphine (1 mg/kg) to control pain post operatively. Fur on the right hind-leg was 
removed by shaving followed by the application of depilatory cream. Animals receiving 
antibiotic injections were administered oxacillin (100 mg/kg) intraperitoneally. The skin 
was disinfected by swabbing with alcohol followed by chlorohexidine. A lateral incision 
was made over the femur and the muscle was blunt dissected to expose the femur. The 
patella was then dislocated and a sterile 25-guage needle was inserted into the femur shaft 
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and retracted. The femur was fractured at the mid-diaphysis with a custom-made three-
point bender. Following fracture, the needle was positioned through the femur to stabilize 
the fracture and cut to an appropriate length. For animals receiving a hydrogel, 5 µL of the 
hydrogel was pipetted over the fracture site and allowed to polymerize. The average 
inoculum of UAMS-1 used in all studies was 1.55 +/- 0.51 x 108 CFU/mL, which correlated 
to approximately 1500 CFU/mouse. The inoculum for the USA300 study was 3.43 x 108 
CFU/mL, correlating to approximately 3400 CFU/mouse. For animals receiving soluble 
lysostaphin, 5 µL of lysostaphin at a concentration equal to that of the hydrogel was 
pipetted over the fracture after the infection was initiated with a hydrogel containing 
bacteria. The muscle and patella were then sutured back into place and the wound was 
closed using wound clips. An X-ray image (MX-20 Radiolography System – Faxitron 
Imaging, 23kV, 15 second scan time) was taken to confirm proper insertion of the needle 
and stabilization of the femur. Mice were allowed to recover under a warming lamp until 
ambulatory. 
Recovery of bacteria from tissue samples 
Mice were euthanized by CO2 inhalation 7 days after surgery. Wound clips were removed 
and the skin on the right hind-leg was sterilized with alcohol. A lateral incision was made 
over the femur and the needle was removed from the femoral shaft and placed in PBS. The 
femur and surrounding tissue were separated, weighed and placed in PBS. All samples 
were kept on ice following dissection and removal. The tissue and femur samples were 
then homogenized via bead beating (Femur: MP Biomedicals lysing matrix A, 2x40sec @ 
6 m/s; Tissue: OPS Diagnostics 1.4 mm zirconium beads, 5x40sec @ 6 m/s) using the 
FastPrep-24 (MP Biomedical). Following homogenization, single cell bacterial 
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suspensions were achieved by a series of water bath sonication (42 kHz, Model 2510, 
Branson Co., Danbury, CT) sonicating and vortexing steps (sonicate 10min, vortex 30sec, 
sonicate 5min, vortex 30sec, sonicate 30sec, vortex 30sec) (93). Homogenates were serially 
diluted, plated on TSA, and incubated overnight at 37˚C. Colonies were enumerated, 
normalized to sample weight, and transformed using the formula CFU=log10(1+X) to avoid 
negative values. The detection limit was set to be 10 colonies in the undiluted sample to 
avoid false positive results.  
Microcomputed tomography and mechanical testing of femurs 
Five weeks post-operatively, mice were euthanized by CO2 inhalation. The femur was 
dissected and the needle was removed. The femur was placed in gauze soaked in 0.9% w/v 
saline and frozen at -20ºC until further analysis. Samples were thawed under running 
deionized water and imaged using the µCT50 (Scanco Medical) at 55 kVp and 145 µA 
with a 0.5 mm filter and 300 ms integration time to achieve a 10 µm voxel size. 3D 
reconstructions were generated by segmenting the fracture callus from cortical bone and 
applying a Gaussian filter (sigma = 0.8, support =1) and threshold value equivalent to 50% 
of intact cortical bone (173). Immediately after imaging, samples were mounted in potting 
blocks filled with Wood’s metal and torsion to failure was assessed with a MRTP-0.2NM 
force transducer (Interface) interfaced with an ELF 3200 (Bose) mechanical testing system 
running WinTest7. A continuous ramp function of 3 degrees/s was applied and the highest 
recorded torque value was reported. Femurs not able to be tested due to a lack of 
mechanical integrity were assigned a value of 0. 
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Dot blot for anti-lysostaphin antibody generation 
Upon euthanization by CO2 inhalation five weeks after fracture, blood was collected via 
cardiac puncture and serum was separated, frozen, and stored at -80ºC until analysis. A 
nitrocellulose membrane was hydrated in tris buffered saline (TBS) and lysostaphin (100 
µg/mL) was bound to the membrane using a vacuum driven Manifold I Spot Blot System 
(Schleicher & Schuell). Samples were then blocked with TBS supplemented with 0.05% 
Tween-20 (TBS-T) and 1% bovine serum albumin (BSA). The spot blots were then washed 
in TBS-T. Serum sample were diluted 10,000 times in blocking buffer and flowed over the 
membrane. A polyclonal mouse anti-lysostaphin IgG (Antibody Research Corporation) 
was used as a positive control. Following washing with TSB-T, anti-lysostaphin antibodies 
were detected using an AlexaFluor-488 labeled polyclonal goat anti-mouse IgG antibody 
(Abcam) diluted 1,000 times in blocking buffer. The blot was then imaged using a Typhoon 
FLA 9500 gel imager (GE Healthcare). Blot intensity was then quantified using 
ImageQuant (GE Healthcare). Positive blots were determined to be twice the average 
intensity of serum samples from animals not exposed to lysostaphin. 
Histology of femur samples 
At the designated time point, mice were euthanized by CO2 inhalation. The skin was 
removed and the needle was carefully extracted from the femoral canal. The entire femur 
and intact surrounding tissue was removed and fixed in 10% neutral buffered formalin. The 
samples were then decalcified in formic acid, paraffin embedded, and 5 µm sections were 
prepared. Samples were deparaffinized, rehydrated, and stained using H&E, Saf-O/FG, or 
Gram stain. Color images were acquired with a Nikon Eclipse E600 microscope using a 
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Plan Fluor 20x objective (Nikon), Micropublisher 5.0 RTV (Q imaging) color camera and 
Q-Capture software (Q imaging). 
In vivo cytokine analysis 
One week post-operatively, mice were euthanized via CO2 inhalation. The femur was 
dissected and the fracture site with surrounding tissue was removed and placed in RIPA 
buffer. Samples were minced and placed on ice. Samples were sonicated for 10 s and debris 
was pelleted by centrifugation. The supernatant was passed through a 0.45 µm filter, snap 
frozen in liquid nitrogen, and stored at -80ºC until analysis. A MilliPlex 25-plex mouse 
cytokine kit (Millipore Sigma) was used per the manufactures instructions to assay for 
tissue concentrations of G-CSF, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-
7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IP-10, KC, MCP-1, MIP-1α, MIP-
1β, MIP-2, RANTES, and TNF-α. Samples with measurements below the detection limit 
of the assay were reported as the detection threshold. Similarly, samples with values greater 
than the standard cure were reported as the maximum. All cytokines were normalized to 
the total protein content of the individual sample, which was determined using a 
bicinchoninic acid (BCA) assay kit (Pierce by ThermoFisher) per manufacturer’s 
instructions.  
Statistics 
Individual data points are plotted with a line representing the mean and error bars indicating 
the standard deviation of the mean. Statistical significance (P < 0.05) was determined using 
the student t test to evaluate two groups, ANOVA for multivariate groups with a Tukey 
post hoc test, or a Kruskal-Wallis test with Dunn’s post hoc test for nonparametric data. 
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One-phase association curves were fit to the release data and an extra sum of squares F test 
as used to compare that K values were different. All calculations were performed using 
Prism (GraphPad). The multivariate analysis of multiplex cytokine data was performed 
using JMP Pro 13. Multivariate ANOVA with a sum combination was used to compare 
across cytokines. A two-way ANOVA with a Bonferroni correction was used to make 





LYSOSTAPHIN AND BMP-2 CO-DELIVERY REDUCES S. AUREUS 
INFECTION AND REGENERATES CRITICAL-SIZED 
SEGMENTAL BONE DEFECTS 
4.1 Abstract 
In the US, nearly 112,000 orthopedic device infections occur annually, with 
Staphylococcus aureus being the most common pathogen. These infections lead to implant 
failure and subsequent removal, motiving the development of bifunctional materials that 
both promote repair and prevent failure due to infection. Lysostaphin is an anti-
staphylococcal enzyme that functions as a glycine-glycine endopeptidase cleaving the 
penta-glycine linkages in the peptidoglycan cell wall of Staphylococcal species leading to 
lysis and biofilm reduction. Lysostaphin use is limited by a lack of effective delivery 
methods to provide sustained, high doses of enzyme to infection sites. We engineered a 
BMP-2 loaded lysostaphin-delivering hydrogel that simultaneously prevents S. aureus 
infection and repairs segmental bone defects. Lysostaphin-delivering hydrogels eradicated 
S. aureus infection one week after implantation. At 8 weeks, BMP-2 loaded lysostaphin 
hydrogels significantly regenerated bone within the defect compared to untreated controls, 
which resulted in mechanically functional bone as assessed by torsion to failure testing. 
Lysostaphin-delivering hydrogels exhibit no hepatotoxicity and restore the local 
inflammatory environment to that of a sterile injury after one week, as assessed by cytokine 
and immune cell profiling. These data support that BMP-2 loaded lysostaphin-delivering 
hydrogel therapy effectively eliminates S. aureus infection while simultaneously 
regenerating functional bone resulting in segmental defect healing.  
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4.2 Introduction 
Effective treatment of infected segmental bone defects remains a significant clinical 
challenge in the field of orthopaedics (184). Nonunion bone defects are a common clinical 
scenario accounting for over 600,000 hospital cases per year totaling over 5 billion dollars 
in costs (185, 186). The current standard of care includes surgical placement of bone auto- 
and allografts to facilitate healing (30, 187). However, these grafting procedures have 
failure rates reported as high as 13% (188) and donor site morbidity occurs in 20-30% of 
cases (189).  Furthermore, bacterial infection of bone grafts significantly increases implant 
failure rates, often leading to corrective surgery, including debridement of infected tissue, 
and significant morbidity to the patient (31-33, 187, 190, 191). Up to 30% of nonunion 
injuries produce positive bacterial cultures, with staphylococcal species being the most 
common pathogen (137-139). This motivates the development of materials that both 
promote bone regeneration and prevent failure due to infection. 
 Lysostaphin is a metalloendopeptidase produced by Staphylococcus simulans (4). 
This antimicrobial enzyme is specific to staphylococcal species. Its specificity is provided 
by a domain that binds the S. aureus cell wall (3, 192), and the antimicrobial activity is 
attributed to a catalytic domain that functions by cleaving the second and third glycine 
residues making up the pentaglycine peptidoglycan cross bridges responsible for bacterial 
cell wall integrity (5), leading to cell lysis. The catalytic nature of lysostaphin make its 
antimicrobial activity independent of the bacterial metabolic state, providing activity 
against sessile biofilm bacteria (6). This in in contrast to most small molecule antibiotics 
that require metabolically active bacteria to be effective (72). Lysostaphin therapy prevents 
or reduces infection in several small animal models, including systemic infection (10, 193, 
 80 
194), wound infection (193), endocarditis (7, 9), nasal colonization (151, 195), keratitis 
(149), catheter colonization (11, 13), ocular infection (176), and neonatal infections (12). 
A clinical case report of systemic lysostaphin therapy in an unresponsive leukemia patient 
with MRSA pneumonia, multiple abscesses, and cellulitis has been reported after failure 
of aggressive antibiotic therapy (152). The patient received intravenous infusion of 500 mg 
of lysostaphin. The reported side-effects included flushing, mild hypotension, and 
tachycardia, which were effectively controlled. Blood, sputum, and abscess cultures were 
negative following lysostaphin administration until the patient’s death three days later, 
which was unrelated to the infection. Biomaterial carriers have been explored to increase 
lysostaphin stability and retention times at the site of administration, but retention times 
are still limited to a few hours (196-199). Biosynexus Corp. moved to commercialize 
lysostaphin cream to reduce intranasal S. aureus colonization. The phase I/II clinical trials 
demonstrated safety and efficacy; but upon completion, the current clinical standard, 
mupirocin, came off patent protection, making the further development of lysostaphin 
cream for intranasal infections economically insolvent (200). Taken together, it is evident 
that there is significant potential for the use of lysostaphin to treat staphylococcal 
infections. 
Due to the high failure rates of bone grafting to treat segmental defects, 
recombinant bone morphogenetic proteins (BMPs), such as BMP-2 (201), BMP-7 (202), 
and BMP-14 (203) have been under development for use in humans. BMP-2 has been FDA 
approved to facilitate bone formation in anterior lumbar interbody fusion procedures (204). 
However, for effective induction of bone formation, superphysological doses are delivered, 
which can result in several unintended side effects, such as ectopic bone formation, nerve 
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damage, and significant inflammation (205). This motivates the development of delivery 
carriers for controlled BMP-2 release to improve bone healing and reduce unintended side 
effects. 
 Hydrogels are a class of materials that can be engineered to deliver a wide array of 
protein therapeutics. Hydrogels are water-swollen cross-linked polymer networks with 
characteristics that are highly desirable for protein delivery scaffolds. Our lab has 
engineered 4-arm poly(ethylene glycol)-maleimide (PEG-4MAL) hydrogels for the 
delivery of both protein and cell based therapeutics (160-165). This synthetic delivery 
platform provides a well-defined hydrogel mesh structure, mild reaction conditions that are 
minimally toxic to cells, precise stoichiometric incorporation of biomolecules and cell 
adhesive ligands, control over the polymerization kinetics for injectable or pre-cast gel 
delivery, and small degradation products that have low toxicity and are excreted through 
the urine. We have previously engineered PEG-4MAL hydrogels functionalized with the 
collagen-mimetic cell adhesive peptide GFOGER and loaded with BMP-2 to treat critical-
sized mouse radial segmental bone defects (164). These BMP-2 loaded hydrogels 
regenerated bone of superior quality compared to the clinical standard of a BMP-2 loaded 
collagen sponge. 
We hypothesized that BMP-2 and lysostaphin co-delivery would eradicate S. 
aureus infection, allowing for bone regeneration and functional healing. Therefore, we 
synthesized protease degradable PEG-4MAL hydrogels functionalized with GFOGER and 
loaded with BMP-2 and lysostaphin, and delivered them to mouse radial segmental defects 
to treat S. aureus infection. We then evaluated their efficacy through a combination of 
bacterial viability counts, µCT imaging, histology, and mechanical testing. We also 
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assessed the safety profile of these materials by performing liver function testing, testing 
for anti-lysostaphin antibody generation, and characterizing the local inflammatory 
environment with cytokine array profiling and cell recruitment analysis. 
4.3 Results 
4.3.1 Lysostaphin-delivering hydrogels eliminate S. aureus infection in a mouse radial 
segmental defect 
 Injuries resulting in a critical-sized segmental bone defects often require reparative 
surgery and the utilization of bone grafting or growth factor delivery to repair the injury. 
However, these strategies come with high rates of graft failure (30) and bacterial infection 
rates as high as 30% (22). Therefore, it is desirable to engineer bi-functional materials 
capable of eliminating infection while simultaneously repairing the bone. Our lab has 
previously reported that BMP-2 delivery using a PEG hydrogel functionalized with the 
collagen-mimetic peptide GFOGER to a mouse radial segmental defect outperforms the 
conventional BMP-2 loaded collagen sponge as measured by increased bone volume and 
superior functional healing. We set out to engineer a bone reparative hydrogel that 
eliminates S. aureus infection through the delivery of lysostaphin. To test our materials, a 
2.5 mm non-healing segmental bone defect was removed from a mouse radius (Figure 16). 
The hydrogel is pre-cast inside of a 4.0 mm polyimide sleeve and placed over each end of 
the radius within the defect. Bone regeneration is then assessed over time with µCT. We 
synthesized lysostaphin- and BMP-2-delivering hydrogels  with a one-pot reaction by 
mixing the protease-degradable cross-linking peptide VPM and the cell adhesive peptide 
GFOGER, which was covalently incorporated into the network via a peptide terminal 
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cysteine residue, with a 4-arm maleimide terminated PEG (PEG-4MAL) macromer (Figure 
16). Both lysostaphin and BMP-2 were physically entrapped within the hydrogel mesh 
structure, as neither protein has free thiols available for covalent tethering into the matrix. 
This allows for lysostaphin to diffuse throughout the gel and kill bacteria. The hydrogel 
was then injected into a 4.0 mm polyimide sleeve for subsequent implantation to treat the 
radial segmental bone defect. To induce an infection component to the model, S. aureus, 
was added to the hydrogel. Consistency between experiments was assessed by assaying 





Figure 16: Lysostaphin and BMP-2 co-delivery to a critical-size segmental bone 
defect. A 2.5 mm segment of the radius is removed to create a critical-sized bone defect 
that does not spontaneously heal. A PEG-4MAL hydrogel functionalized with the 
adhesive ligand GFOGER and loaded with lysostaphin and BMP-2 is synthesized with S. 
aureus. Lysostaphin enzymatically creates holes in the bacterial cell wall leading to lysis. 
These infected hydrogel scaffolds are loaded into a 4 mm polyimide sleeve and placed 
over the ends of the defect. Co-delivery of BMP-2 and lysostaphin results in infection 
clearance followed by subsequent defect regeneration.  
First, we tested the ability of lysostaphin-delivering hydrogels to eliminate S. 
aureus infection using the described mouse segmental defect infection model. S. aureus 
Xen29, a luminescent strain derived from an abdominal wound infection (ATCC 12600) 
that has kanamycin resistance allowing for selective growth, was chosen for the initial 
studies. The antimicrobial activity of the lysostaphin-delivering hydrogels was assessed by 
implanting hydrogels and then performing a microbiologic and histologic analysis at 7 days 
post-implantation (Figure 17A). The experimental groups included Xen29-containing 
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hydrogels with and without lysostaphin, and sterile hydrogels that were either empty, or 
loaded with lysostaphin. Bacteria recovered from the tissue samples were grown on both 
antibiotic-free agar and agar supplemented with kanamycin to selectively culture Xen29. 
The results showed that antibiotic selection of Xen29 did not affect bacterial viability 
(Figure 17B), and that there was a very strong correlation (R2 = 0.96) between each culture 
media used (Figure 17C). With this result in mind, we used kanamycin selection for all 
Xen29 studies to reduce the chances of contamination in the necropsy procedure. The 
detection limit of this assay was set to be 100 CFU per sample (or 10 bacterial colonies in 
an undiluted sample). Microbiologic analysis showed significant reduction and complete 
eradication of S. aureus in the infection group treated with lysostaphin (Figure 17D). This 
demonstrates that lysostaphin-delivering hydrogels successfully prevent infection in radial 
segmental defects. Histologic analysis via hematoxylin and eosin staining (H&E) revealed 
significant leukocytic infiltrate in the untreated infection group, which we attribute to a 
robust inflammatory response to the pathogen (Figure 17E). In contrast, infections treated 
with lysostaphin-delivering hydrogels did not display this strong inflammatory response 
and had tissue morphology similar to both sterile control groups; this result suggests that 
the infection was cleared by the lysostaphin-containing hydrogel. Similar histologic results 
were observed using safranin-O/fast green (Saf-O/FG) staining. The Gram stain revealed 
the presence of Gram positive bacteria in the Xen29 group. No bacteria was detected using 
Gram staining in the lysostaphin-delivering hydrogel group, further supporting that the 
infection was eliminated. 
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Figure 17: Lysostaphin-delivering hydrogels eliminate infection at 1 week. (A) 
Lysostaphin-delivering hydrogels infected with S. aureus Xen29 were implanted into 
mouse radial segmental defects. Viable bacteria were recovered and histologic analysis 
was performed one week later. (B) Viable bacteria recovered from defect sites culture on 
antibiotic free (TSA) and kanamycin supplemented (LB/Km) media. (C) Correlation of 
recovered bacteria samples from each culture media used in (C). (D) Viable bacteria 
recovered from the implant and surrounding tissue one week after implantation. (E) 
Histologic images of tissue sections stained with H&E, Saf-O/FG, and Gram stain. 
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Kruskal-Wallis with Dunn’s post-hoc test. Means ± SD. N=5-11 per group combined 
from two independent experiments. ***P < 0.001, ****P < 0.0001. 
4.3.2 BMP-2 loaded lysostaphin-delivering hydrogels eliminate infection and promote 
bone repair in a critical-sized segmental bone defect 
 Next, we tested the ability of BMP-2 loaded lysostaphin-delivering hydrogels to 
simultaneously kill bacteria and promote new bone formation. Radial defects were created 
and both sterile and infected (S. aureus Xen29) hydrogels, with and without lysostaphin, 
were assessed. All implants contained 50 ng of BMP-2. Live animal X-ray imaging and 
µCT analysis was performed at 0, 4, and 8 weeks and terminal microbiologic and histologic 
analysis was completed at 8 weeks (Figure 18). The experimental groups included 
hydrogels with and without lysostaphin that were synthesized sterilely or with S. aureus 
Xen29. X-ray imaging shows that infected mice, not receiving lysostaphin treatment, 
exhibit significant osteolysis and reactive bone formation at 4 and 8 weeks post-
implantation (Figure 19). In contrast, infections treated with hydrogels containing 
lysostaphin have significant new bone formation, similar to defects treated with sterile 
hydrogels with and without lysostaphin (Figure 19). Analysis of the defect with µCT 
imaging corroborates these findings. Representative µCT reconstructions reveal no new 
bone formation in the defect site for the infection only control group, whereas infected 
mice treated with lysostaphin undergo progressive bone regeneration throughout the 8 
week observation period (Figure 20A, C, E). At the time of surgery, all of the defects had 
equal amounts of bone present (Figure 20B). Subsequent longitudinal quantification of 
bone volume at the defect site reveals a significant increase in new bone formation for 
infections treated with lysostaphin-containing hydrogels and the sterile controls compared 
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to the infection only group at 4 weeks (Figure 20D). At 8 weeks bone volume is 
significantly increased in both of the sterile groups, with no differences between the 
infection and lysostaphin hydrogel-treated infection groups (Figure 20E).  
 
Figure 18: Experimental outline of the Xen29 bone repair study. Bone formation was 
assessed longitudinally with a combination of in vivo X-ray and µCT imaging at 0, 4, and 
8 weeks after defect creation and implant placement. At 8 weeks, end point histologic and 
microbiologic analysis was performed. 
 
 
Figure 19: Longitudinal X-ray imaging of lysostaphin-delivering hydrogels to treat 
infection and repair bone. Representative radiographic images of the mouse radii at the 





Figure 20: BMP-2 loaded lysostaphin-delivering hydrogels improve bone repair. 
Representative µCT reconstructions (A) and bone volume quantification (B) at the time 
of surgery. Ordinary one-way ANOVA with Tukey’s post-hoc test. Representative µCT 
reconstructions (C) and bone volume quantification (D) 4 weeks post-operatively. 
Ordinary one-way ANOVA with Tukey’s post-hoc test. Representative µCT 
reconstructions (E) and bone volume quantification (F) 8 weeks after implantation. 
Kruskal-Wallis with Dunn’s multiple comparisons test. Means ± SD. N=7 per group. *P 
< 0.05, ***P < 0.001, ****P < 0.0001.  
To confirm that lysostaphin-delivering hydrogel therapy eliminated the bacterial 
infections, the implants and surrounding tissue were processed and assayed for viable 
bacteria. The microbiologic analysis showed a significant reduction of viable bacteria for 
the lysostaphin-delivering hydrogel treatment group compared to the infection-only control 
(Figure 21A) demonstrating lysostaphin-delivering hydrogels eliminated the infection. 
Notably, high variability exists in the infection-only group, with some samples showing 
infection and others not. We tested for the presence of bacteria by culturing the remaining 
tissue sample in liquid culture media containing kanamycin, to selectively grow Xen29, 
overnight. All samples in the infection group were positive for Xen29, even though 
colonies were not detected using the quantitative assay. Importantly, the infections are 
localized to the radius, as no viable bacteria were recovered from the liver in any of the 
samples tested (Figure 21B). We also assessed if bone volume was correlated with the 
number of recovered CFU’s in the infection only control (Figure 22). No linear correlation 
(R2 = 0.073) was observed as determined by regression analysis. Pearson’s correlation test 




Figure 21: Lysostaphin-delivering hydrogels eliminate bacteria at 8 weeks. (A) 
Viable bacteria recovered from the defect and surrounding tissue after 8 weeks in vivo. 
(B) Viable bacteria recovered from the liver 8 weeks after implantation. Kruskal-Wallis 
with Dunn’s multiple comparisons test. Means ± SD. N=3-6 per group. *P < 0.05.  
 
Figure 22: Bone volume and colony forming unit correlation at 8 weeks. Bone 
volume vs. CFU/mg was plotted for each sample from the Xen29 group. Linear 
regression analysis and Pearson’s Correlation analysis was performed. 
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Finally, one sample per experimental group underwent histologic analysis (Figure 
23). We sectioned and stained the radius with H&E to observe general tissue morphology, 
Saf-O/FG for collagen deposition, and Grams stain for the presence of bacteria. H&E 
staining reveals significant leukocytic infiltrate for the untreated Xen29 sample with no 
bone formation and the presence of Gram positive bacteria in the Gram stain. New bone is 
located within the defect for the Xen29 sample treated with the lysostaphin-containing 
hydrogel on H&E and Saf-O/FG staining. No bacteria are present on the gram stain, 
confirming the infection was eliminated. Both sterile groups show bone formation within 
the implant and a well-defined bone marrow cavity. 
 
Figure 23: Histologic sections of tissue samples 8 weeks post-implantation. Mouse 
radii were sectioned and stained with H&E, Saf-O/FG, and Gram stain. One sample was 
randomly selected and prepared per experimental group. Representative images are 
displayed. 
 93 
4.3.3 Lysostaphin-delivering hydrogels regenerate bone in a radial defect infected with 
a clinical isolate of S. aureus 
 The development of a bacterial biofilm can significantly complicate the treatment 
of segmental bone defects, resulting in multiple surgeries. The first to eliminate the 
infection, and then subsequent surgeries for repairing the bone defect. To test that the BMP-
2 loaded lysostaphin-delivering hydrogels can prevent biofilm infection and regenerate 
bone, we utilized the S. aureus strain UAMS-1. UAMS-1 is a clinical isolate from a 
pediatric case of osteomyelitis and a prolific biofilm-former (172). We performed a 
bacterial inoculum dosing study to identify the minimum dose of UAMS-1 required to 
initiate a persistent infection. Hydrogels infected with UAMS-1 at varying concentrations 
spanning three orders of magnitude were synthesized and implanted in mouse radial 
segmental defects. The bacterial inoculum was confirmed by assaying the implants for 
viable UAMS-1 after surgery and plotting these values against the number of bacteria we 
expected to recover (Figure 24A). The results showed that the bacterial dose implanted was 
highly correlated (R2=0.97) with the expected dose. One week later, mice were euthanized 
and bacteria were recovered from the defects and surrounding tissue (Figure 24B). All 
doses except for the lowest dose tested were above the detection limit of the assay. 
Therefore we selected the bacterial dose of roughly 1,000 CFU/implant UAMS-1 for all 
the subsequent studies. 
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Figure 24: Identification of the minimum dose to initiate UAMS-1 infections in a 
radial segmental defect. (A) Three doses of UAMS-1 spanning three orders of 
magnitude were implanted into mouse radial segmental defects. (B) Bacterial counts at 
one week post implantation for the 1,000 CFU/implant group. Linear regression analysis 
with Goodness of Fit test. Means ± SD. N=7 per group. 
 Following the identification of an appropriate UAMS-1 dose, we tested the efficacy 
of BMP-2 loaded lysostaphin-delivering hydrogels to prevent infection and regenerate 
bone. We hypothesized that increasing the BMP-2 dose from 50 ng, used in the Xen29 
study, to 100 ng would improve bone regeneration in the infected implants treated with 
lysostaphin. Segmental defects were created and hydrogel scaffolds were deployed (Figure 
25). Longitudinal bone formation was monitored using µCT imaging at 4 and 8 weeks. At 
the end of the 8 week study, mechanical testing and histologic analysis was performed on 
the mouse forelimbs. The experimental groups included UAMS-1 infected hydrogels with 
and without lysostaphin, and sterile hydrogels without lysostaphin. We also included a 
group of UAMS-1 infected hydrogels that were dipped in gentamicin (10 mg/mL (206, 
207)) to simulate the current therapeutic standard of antibiotic doped implants. 
Representative µCT reconstructions 4 weeks following implantation showed no new bone 
formation in the untreated, infected control group (Figure 26A). Both the lysostaphin-
delivering and sterile hydrogel groups exhibited new bone formation inside the defect. 
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Hydrogels that were treated with gentamicin also had bone formation. However, some 
samples were completely devoid of new bone, suggesting not all of the infections were 
cleared. At 8 weeks, representative µCT images showed similar trends to the 4 week time 
point, but with improved bone formation in the sterile and lysostaphin-delivering hydrogel 
treated groups (Figure 26C). Quantification of the bone volume within the defect site at 4 
weeks shows that there was significantly more bone in the sterile and lysostaphin-
delivering hydrogel treated groups compared to the untreated infected control (Figure 
26B). The gentamicin-treated hydrogel group was no different than the untreated infected 
control. Similarly, at 8 weeks, the lysostaphin-delivering hydrogel group and the sterile 
control had significantly more bone within the defect site than the untreated control (Figure 
26D). Again, the gentamicin-treated hydrogel group was no different than the untreated 
control. We also quantified the extent of bridging by scoring the 8 week µCT 
reconstructions: 0 = no bone formation, 1 = less than half of the defect, 2 = greater than 
half of the defect, 3 = defect bridged. The results indicated that the sterile and lysostaphin-
delivering hydrogels had higher defect bridging scores compared to the untreated control 
(Figure 27A). Implants dipped in gentamicin were no different than the sterile implants. 
Taken together, these results show that BMP-2 loaded lysostaphin-delivering hydrogels 
significantly improve bone regeneration compared to untreated infections and regenerate 
an equal amount of bone as sterile implants. Torsion to failure testing was used to determine 
if the regenerated bone provided functional improvements. The bregenerated bone in the 
lysostaphin-delivering hydrogel group, the sterile control group, and the gentamicin-
treated group had significantly improved mechanical properties compared to that of the 
untreated infection control (Figure 27B). No differences were observed between the 
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samples tested in the lysostaphin-delivering hydrogel group and the antibiotic prophylaxis 
group. Notably, the bone regenerated in the sterile control group was of superior quality as 
assessed through torsion to failure testing to that of the lysostaphin-delivering hydrogel 
group, even though no differences were observed in the bridging score. Additionally, the 
sterile control groups average torsion to failure value was higher than that of normal intact 
bone (3.2 ± 0.3 mN·m, as reported in Shekaran et al.). The average torsion values measured 
for infections treated with lysostaphin-delivering hydrogels were slightly lower than naïve 
bone. Taken together, this suggests that the lysis of bacteria may have an effect on the 
quality of the regenerated bone, but not the total amount of bone formed. Histologic 
analysis revealed the presence of inflammatory cell infiltrate, no new bone formation, and 
the Gram positive bacteria within the defect for the untreated and gentamicin-treated 
infected samples, indicating a persistent infection (Figure 28). The infection treated with a 
lysostaphin-delivering hydrogel has similar findings to that of the sterile control. Bone was 
present within the defect site and a marrow cavity was formed. No bacteria are detected 
with Gram staining, suggesting the infection has been clearedThese data indicate that 
BMP-2 loaded lysostaphin-delivering hydrogels eliminate infection and drive defect repair, 
leading to functional bone regeneration. 
 
Figure 25: Experimental outline of the UAMS-1 bone repair study. Bone formation 
was assessed longitudinally with a combination of in vivo X-ray and µCT imaging at 0, 4, 
and 8 weeks after defect creation and implant placement. At 8 weeks, end point histologic 




Figure 26: UAMS-1 infect defects treated with BMP-2 loaded lysostaphin-delivering 
hydrogels significantly improve bone repair. Representative µCT reconstructions (A) 
and bone volume quantification (B) 4 weeks post operatively. Representative µCT 
reconstructions (C) and bone volume quantification (D) 8 weeks after implantation. 
Kruskal-Wallis with Dunn’s multiple comparisons test. Means ± SD. N=8-9 per group. 




Figure 27: BMP-2 loaded lysostaphin-delivering hydrogels functionally heal defects. 
(A) Defect bridging was assessed semi-quantitatively using the following scale: 0 = no 
bone formation, 1 = less than half of the defect, 2 = greater than half of the defect, 3 = 
defect bridged. Kruskal-Wallis with Dunn’s multiple comparisons test. N=3-6 per group. 
Whiskers represent minimum and maximum, box extends from 25th to 75th percentiles, line 
represents median. **P < 0.01. (B) Functional healing was assessed using torsion to 
failure testing. The average torsion to failure values for healthy mouse radii are plotted as 
horizontal red lines (0.0032 ± 0.0003 Nm) as reported in Shekaran et al. Means ± SD. 




Figure 28: Histologic sections of tissue samples 8 weeks post-implantation. Mouse 
radii were sectioned and stained with H&E, Saf-O/FG, and Gram stain. One sample was 
randomly selected and prepared per experimental group. Representative images are 
displayed. 
4.3.4 Lysostaphin-delivering hydrogels exhibit no hepatotoxicity and restore the native 
inflammatory environment 
 Lysostaphin is a protein that does not occur naturally in the human body, and could 
trigger an inflammatory reaction in response to administration, which could negatively 
impact bone formation. Furthermore, lysostaphin functions by directly lysing bacteria, 
which in itself could cause a significant inflammatory response. Therefore, we assessed the 
safety profile of lysostaphin-delivering hydrogel therapy with liver function tests, and 




...1 Lysostaphin-delivering hydrogels result in minimal systemic toxicity 
 We performed liver function testing at 1 week post-operation to test if BMP-2 
loaded lysostaphin-delivering hydrogel therapy resulted in liver toxicity. The experimental 
groups included lysostaphin-delivering hydrogels with and without UAMS-1 infection. 
Liver function was assessed by measuring total protein, albumin, aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase. 
Normal values obtained from the literature are plotted on the graphs for male C57B/6J mice 
90-135 days old with the black hashed line indicating the median values and the red lines 
indicated the 2.5 and 97.5 percentiles for healthy mice (208). Overall, no differences in 
total protein levels and the albumin fraction were seen between groups (Figure 29A). The 
albumin levels were on average higher than the reference values (Figure 29B). However, 
elevated albumin levels are not typically associated with liver toxicity (209). Acute liver 
toxicity is primarily identified by elevated serum AST and ALT. Upon liver injury, cells 
release AST and ALT into the blood stream. Our results showed that 1/5 and 2/6 animals 
in the infection and sterile groups had elevated AST levels (Figure 29C). ALT, a more 
specific indicator of acute liver toxicity, results were within normal limits (Figure 29D). 
Taken together, these data suggest that no acute liver injury is associated with lysostaphin-
delivering hydrogel therapy. The final blood chemistry test examined was alkaline 
phosphatase. Elevated levels can point to liver or bone disease, which were not observed, 
further supporting that our therapy is not systemically toxic (Figure 29E). Finally, we 
screened for anti-lysostaphin antibody generation using a dot blot assay. Anti-lysostaphin 
antibodies were present in 1/20 animals before surgery. Four weeks following 
implantation, 3/7 lysostaphin-delivering hydrogel treated animals converted to being 
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positive for anti-lysostaphin antibodies. 1/6 animals in the infection-only control group (no 
lysostaphin) also converted. These data indicate that lysostaphin-delivering hydrogels do 
not result in liver toxicity, but can elicit an antibody response. 
 
Figure 29: BMP-2 loaded lysostaphin-delivering hydrogels do not show signs of 
systemic toxicity. Segmental defects were created and lysostaphin-delivering hydrogels 
loaded were BMP-2 with and without infection were implanted. Systemic toxicity was 
assessed at 1 week with liver function testing. Serum samples were tested for total protein 
(A), albumin (B), aspartate aminotransferase (AST) (C), alanine aminotransferase (ALT) 
(D), and alkaline phosphatase (Alk phosphatase) (E) levels. Means ± SD. N=5-6 per 
group. One-way ANOVA with Tukey’s post-hoc test. No differences were detected 
between groups. 
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...2 Lysostaphin-delivering hydrogels restore the cytokine milieu to a pro-
regenerative state 
We characterized the local cytokine milieu generated in response to BMP-2 loaded 
lysostaphin-delivering hydrogel therapy. Hydrogels were placed, and 1 and 4 weeks post 
implantation, the implant tube and surrounding tissue was isolated and analyzed using a 
multiplexed cytokine array assay. The experimental groups included UAMS-1 containing 
hydrogels with and without lysostaphin and lysostaphin-free sterile controls. All implants 
contained 100 ng of BMP-2. At the one week time point, hierarchical cluster analysis 
reveals clear segregation of the untreated infection group from the sterile control and 
lysostaphin-delivering hydrogel group (Figure 30A). Notably, no obvious clustering of the 
sterile and lysostaphin hydrogel-treated group is apparent, suggesting the infection has 
been cleared and the local inflammatory environment has been restored to that of a sterile 
wound environment. Several individual cytokines were significantly elevated in the 
infection only control group, including G-CSF, IL-1β, KC, IL-6, MIP-1α, MIP-1β, MIP-2, 
and IP-10 (Figure 30B-I). These cytokines are primarily associated with the acute 
inflammatory response and are responsible for inflammatory cell recruitment. No 
significant differences were detected between infections treated with lysostaphin-
delivering hydrogels and the sterile controls. Principal component analysis was performed, 
which confirmed that the infection only group had a significantly cytokine milieu than the 
sterile and lysostaphin-delivering hydrogel treated mice (Figure 31). These same trends 
continued at the four week time point. Hierarchical cluster analysis delineates the infection 
group from both the sterile and lysostaphin-delivering hydrogel treated groups, which are 
indistinguishable from each other (Figure 32A). This is further illustrated through 
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individual cytokine analysis. Significantly elevated levels of G-CSF, KC, MIP-2, MIP-1 α, 
and MIP-1β in the UAMS-1 infection mice were detected (Figure 32B-F). Principal 
component analysis revealed similar global cytokine levels for the sterile and lysostaphin-
delivering hydrogel treated mice, which were significantly different that the infection only 
controls as captured by component 1 (Figure 33). Again, these cytokines are primarily 
associated with inflammatory cell recruitment, showing a continued immune response to 
the infection. Fewer differences in individual cytokine expression levels were detected at 
the 4 week time point, which may be attributed to the local inflammatory profile changing 
from an acute to a chronic state (210). Again, no differences were detected between the 
sterile and lysostaphin-delivering hydrogel treated mice. 
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Figure 30: BMP-2 loaded lysostaphin-delivering hydrogels restore the local 
inflammatory environment to a regenerative state one week after implantation. 
Segmental defects were created and hydrogel scaffolds infected with UAMS-1 with or 
without lysostaphin as well as sterile gels were implanted and the inflammatory response 
was assessed using a multiplexed cytokine array assay 1 week later. (A) Hierarchical 
cluster analysis of cytokine profiles using the Ward Method. (B-I) Cytokines with 
statistically different tissue levels as determined using two-way ANOVA with a 
Bonferonni Correction for multiple comparisons. Means ± SD. N=6-7 per group. *P < 
0.05, ***P < 0.001, ****P < 0.0001, ns is not significant. 
 




Figure 32: Cytokine profile of BMP-2 loaded lysostaphin-delivering hydrogels 4 
weeks post-operatively. Segmental defects were created and hydrogel scaffolds infected 
with UAMS-1 with or without lysostaphin as well as sterile gels were implanted and the 
inflammatory response was assessed using a multiplexed cytokine array assay 4 week 
later. (A) Hierarchical cluster analysis of cytokine profiles using the Ward Method. (B-F) 
Cytokines with statistically different tissue levels as determined using two-way ANOVA 
with a Bonferonni Correction for multiple comparisons. Means ± SD. N=6-7 per group. 
*P < 0.05, ***P < 0.001, ****P < 0.0001, ns is not significant. 
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Figure 33: Principal component analysis of the local cytokine levels four weeks post-
implantation. 
...3 Lysostaphin-delivering hydrogel therapy does not alter the native inflammatory 
cell profile 
To further characterize the host response to BMP-2-loaded lysostaphin-delivering 
hydrogel therapy to treat S. aureus infection, we profiled the inflammatory cell makeup at 
the defect site via flow cytometry one week after surgery. Segmental defects were made 
and lysostaphin-delivering hydrogels loaded with 100 ng of BMP-2 were implanted. The 
experimental groups included hydrogels with and without lysostaphin that were implanted 
with and without UAMS-1. One week following implantation, mice were euthanized, 
tissue was isolated, and single cell suspensions were stained for inflammatory cell markers. 
The gating strategy used to identify the individual cells types is outlined in Figure 34. All 
analysis was performed on live cells. T cells were identified as being low side scatter CD3 
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positive events and where then separated into CD4 positive helper T cells and CD8 positive 
cytotoxic T cell subsets (211). Low side scatter CD19 positive events made up the B cell 
population (212, 213). Myeloid cells were identified as being CD11b positive and were 
sorted using F4/80 staining to separate macrophages (F4/80 positive) from monocytes and 
neutrophils (F4/80 negative). Macrophages were split into the classically activated CD86 
positive M1 macrophage and alternatively activated CD206 positive M2 macrophage 
subsets (214). Similarly, monocytes were split into inflammatory Ly6CHi monocyte (IM) 
and anti-inflammatory Ly6CLo monocyte (AM) subsets (215, 216). Neutrophils were 
classified as the Ly6G positive myeloid cells (217). Sorted cells were then analyzed as both 
the total number of cells per tissue weight and the percent of the parent cell population. 
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Figure 34: Gating strategy for inflammatory cell profiling analysis. Single cell 
suspension of tissue samples were created and stained for subsequent flow cytometry 
analysis. Single cells were identified and live cells were selected. T cells were identified 
by selecting as low side scatter CD3 positive events and then sorted into CD8 positive 
cytotoxic T cells and CD4 positive helper T cells. B cells were low side scatter CD19 
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positive events. Myeloid cells were identified as being CD11b positive. Macrophages 
were identified as CD11b and F4/80 positive events then split into CD86 positive M1 and 
CD206 positive M2 subsets. Neutrophils are identified as Ly6G positive myeloid cells. 
Monocytes are classified as Ly6G negative myeloid cells and split into Ly6CHi IM 
monocytes and Ly6CLo AM monocytes. 
 Analysis of the total number of cells at the defect site revealed a significantly higher 
number of total cells (Figure 35A), T cells (Figure 35B), helper T cells (Figure 35C), 
cytotoxic T cells (Figure 35D), myeloid cells (Figure 35I), neutrophils (Figure 35J), and 
IM monocytes (Figure 35L) for the infection-only group compared to the lysostaphin-
delivering hydrogel-treated infections and both sterile control groups. Significantly higher 
levels of AM monocytes were observed in the lysostaphin-delivering hydrogel-treated 
infections and the sterile lysostaphin hydrogel group compared to the infection-only control 
(Figure 35K). Overall, the higher numbers of inflammatory cells observed in the infection 
control group is not surprising as all animals analyzed had visible tissue abscesses present 
at necropsy. This is also the most likely explanation for the significantly elevated levels of 
myeloid cells, but more specifically neutrophils in the group, as abscesses are primarily 
composed of neutrophilic infiltrate. Remarkably, for all cell types identified, no differences 
were observed between the lysostaphin-delivering hydrogel-treated infections and both 
sterile control groups (Figure 35A-L), showing that lysostaphin-delivering hydrogels do 
not alter the inflammatory cell populations at the defect site both with and without 
infection. No differences in the number of B cells (Figure 35E), total macrophages (Figure 
35F), M1 macrophages (Figure 35G), or M2 macrophages (Figure 35H) among any of the 
groups were detected, even though the total number of cells present was elevated in the 
infection-only groups. For this reason, we posit that these cell populations are tissue 
resident cells. It may also be that the elevated levels of monocytes observed in the infection-
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only group have been recruited at higher number due to the infection, but have not yet 
become fully differentiated macrophages. In an attempt to remove the confounder of 
increased total cells being present in the infection control group, we also analyzed the data 
as percent of parent cell. The infection-only group had significantly higher proportions of 
helper T cells (Figure 36A) and neutrophils (Figure 36F) and a significantly lower 
proportion of macrophages (Figure 36C), IM monocytes (Figure 36G) and AM monocytes 
(Figure 36H) compared to all other experimental groups. No differences were observed 
between the lysostaphin-delivering hydrogel groups with and without infection or the 
empty sterile group, providing more evidence that lysostaphin-delivering hydrogel therapy 
does not affect the inflammatory cell profile compared to empty uninfected controls. The 
percent of cytotoxic T cells (Figure 36B) and M1 (Figure 36D) and M2 (Figure 36E) 
macrophages were equivalent among all groups. Taken together, these data indicate that 
infections treated with BMP-2 loaded lysostaphin-delivering hydrogels return the 
inflammatory cell profile to that of empty BMP-2 hydrogel controls, which subsequently 
allows for bone regeneration within the defect site. 
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Figure 35: Total number of inflammatory cells 1 week post implantation of BMP-2 
loaded lysostaphin-delivering hydrogels. One week following segmental defect 
creation and implant placement, mice were euthanized and the implant and surrounding 
tissue were recovered and flow cytometry was performed to enumerate the total number 
of inflammatory cells present. (A) Total cells, (B) CD3+ T cells, (C) CD3+CD4+ helper 
T cells, (D) CD3+CD8+ cytotoxic T cells, (E) CD19+ B cells, (F) F4/80+ macrophages, 
(G) CD86+ M1 macrophages, (H) CD206+ M2 macrophages, (I) CD11b+ myeloid cells, 
(J) Ly6G+ neutrophils, (K) Ly6Clow AM monocytes, and (L) Ly6C
high IM monocytes 
were enumerated. Data were log transformed and ordinary one-way ANOVA with a 
Tukey post hoc test was used. Means ± SD. N=6-7 per group. *P < 0.05, **P < 0.01, 




Figure 36: Percent of parent inflammatory cells 1 week post implantation of BMP-2 
loaded lysostaphin-delivering hydrogels. One week following segmental defect 
creation and implant placement, mice were euthanized and the implant and surrounding 
tissue were recovered and flow cytometry was performed to enumerate the total number 
of inflammatory cells present. (A) CD4+ helper T cells as a percent of CD3+ cells, (B) 
CD8+ cytotoxic T cells as a percent of CD3+ cells, (C) F480+ macrophages as a percent 
of CD11b+ cells, (D) CD86+ M1 macrophages as a percent of F480+ cells, (E) CD206+ 
M2 macrophages as a percent of F4/80+ cells, (F) Ly6G+ neutrophils as a percent of 
CD11b+ cells, (G) Ly6CLo AM monocytes as a percent of CD11b+ cells, and (H) Ly6CHi 
IM monocytes as a percent of CD11b+ cells were analyzed. Ordinary one-way ANOVA 
with a Tukey post hoc test, or Kurskall-Wallis with Dunn’s test for non-parametric data 






 Non-healing segmental bone defects often require the placement of a bone auto- or 
allograft, or the use of BMP-2 to induce osteogensis and cause defect healing. However, 
these injuries carry rates of infection reported as high as 30%, making it critically important 
that infection is prevented, in order to facilitate healing (138, 139). We engineered an 
injectable PEG hydrogel that both induces bone regeneration and fights infection through 
the delivery of BMP-2 and lysostaphin respectively. We showed that BMP-2 loaded 
lysostaphin-delivering hydrogels eradicate infection and regenerate bone. Liver function 
testing revealed no signs of toxicity even though anti-lysostaphin antibodies were 
generated. Locally, lysostaphin-delivering hydrogels returned the inflammatory 
environment to that of an uninfected defect as measured by both cytokine secretion and 
immune cell profiling. These results support the development of BMP-2 loaded 
lysostaphin-delivering hydrogels to prevent S. aureus infection and promote segmental 
bone defect regeneration. 
 Infection prevention is critical to the success of segmental bone defect repair (218, 
219). Injuries resulting in segmental bone defects carry a disproportionately high infection 
rate compared to other orthopaedic injuries, often due to the complexity of the injury, such 
as exposed bone fragments (22). Treatment requires extensive surgical debridement to 
remove necrotic bone and tissue, followed by the placement of an antibiotic impregnated 
spacer. A second procedure is performed at a later time, once the infection has cleared, to 
remove the spacer and place the bone graft (220). Even with proper surgical intervention, 
infection remains one of the primary causes of non-union (139). Interventions that fight 
infection while also being osteoinductive have the potential to significantly reduce the 
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incidence of non-union, leading to improved patient outcomes. Current strategies have 
centered on adding broad spectrum antimicrobial therapy to an already osteoinductive 
scaffold (221). Alternatives to broad spectrum antimicrobials, such as silver (43) and D-
amino acids (129, 222), have also been shown to be effective at reducing infection and 
promoting bone repair.  
Antimicrobial prophylaxis is a critical component to treating segmental bone 
defects (138, 139). Lysostaphin provides potent bacteriospecific antimicrobial activity. 
This targeted approach ensures that only the pathogen of interest is eliminated, but may not 
be an ideal approach to prevent infection, when the target is often unknown and broad 
spectrum agents are desirable (179). Further, it is possible that prevention of a single 
pathogen may allow other opportunistic pathogens to colonize the injury site, such as with 
a less common gram negative pathogen like Pseudomonas aeruginosa. In orthopaedics, 
roughly two thirds of all infections are staphylococcal in nature (2), providing lysostaphin 
therapy significant prophylactic coverage using an extremely targeted approach. Our 
strategy could be expanded to include other species specific antimicrobial agents, such as 
bacteriophage lysins (71) or antimicrobial peptides (223), thereby enhancing its 
translational potential as a prophylactic agent (179).  
Infections treated with BMP-2 loaded lysostaphin-delivering hydrogels induced 
bone volume equal to sterile hydrogels. However, the mechanical strength of the 
regenerated bone was reduced. This may be due to the bacterial by-products released by 
lysostaphin during bacterial lysis. The bacterial debris may negatively affect the repair 
process, leading to lower quality bone. Bacterial debris may acutely activate local immune 
cells, causing changes to the local wound environment that affect bone regeneration, but 
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are resolved within the first week, since we observed no differences in either the cytokine 
or cell profile at that time compared to uninfected controls. Increased immune cell 
activation at very early time points may cause a more rapid release of BMP-2, which could 
also be responsible for the reduced bone quality. Modification of the release rate of BMP-
2 though changes to hydrogel mesh structure may improve bone formation through 
optimized BMP-2 presentation. Studies investigating lysostaphin-delivering hydrogel 
BMP-2 release and hydrogel degradation in vivo in combination with further cytokine and 
cellular analysis at earlier time points may be required to more fully understand how to 
improve the functionality of regenerated bone. 
The synthetic nature of our PEG-4MAL hydrogels functionalized with the 
GFOGER peptide and loaded with recombinant BMP-2 protein has several advantages 
over traditional bone grafting procedures. Synthetic scaffolds do not require graft 
procurement, which will eliminate donor site morbidity. Removing this aspect of the 
procedure could reduce the opportunity for intraoperative infection by shortening the 
procedure times (224, 225). Additionally, the “off the shelf” nature of this synthetic 
delivery vehicle is scalable to any defect size. Lysostaphin-delivering hydrogels are 
inherently adhesive and can be delivered via injection, allowing for the material to coat and 
fill any gaps within the injury for easy administration to orthopaedic injuries that may be 
very anatomically complex and heterogeneous. However, further studies will need to be 
performed in larger animal models to confirm that larger BMP-2 loaded lysostaphin-
delivering hydrogels can regenerate bone in larger defects.  
In these studies, the scaffold and the bacteria are delivered together, effectively 
modeling infection prevention. Clinically, injuries occur and then intervention follows 
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some time later, allowing for bacteria to begin colonizing the injury before treatment. This 
motivates further development of a delayed treatment model (115). To more accurately 
simulate infection prevention, defects could be created and inoculated with bacteria and 
then several hours/days later lysostaphin-delivering hydrogels would be administered.  
Bacterial infection triggers a robust inflammatory response in an effort to clear the 
pathogen from the body. Our histologic analysis supported that S. aureus infection resulted 
in the development of significant leukocytic infiltrate. Importantly, both the cytokine and 
immune cell profiling supported this data. One week post infection, several cytokines 
responsible for immune cell recruitment were significantly upregulated, including G-CSF, 
MIP-1a, MIP-1b, MIP-2, KC, IP-10, IL-6, and IL-1b. G-CSF, MIP-2, and KC contribute 
to neutrophil recruitment (226, 227), which was directly supported by the flow cytometry 
results, showing significant increases in both the total number and percent of myeloid cells 
at the implant site in the infection-only group compared to the sterile control. This result 
clearly supports a robust innate immune response to the infection, and that lysostaphin-
delivering hydrogels are able to either prevent this response to infection from occurring or 
restore the inflammatory environment to normal levels through the elimination of bacteria. 
Notably, no differences in the cellular response to the material were observed between 
sterile empty hydrogels and sterile lysostaphin-delivering hydrogels, supporting that 
lysostaphin delivery does not, in itself, trigger a significant inflammatory response. In 
terms of the adaptive immune response, we observed significantly elevated levels of T cells 
including both helper and cytotoxic T cells in the untreated infection animals. Interestingly, 
the percentage of cytotoxic T cells remained constant in the infection-only group compared 
to both sterile controls, but both the number and proportion of helper T cells was 
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significantly elevated. Helper T cells are required for B cell antibody affinity maturation 
and class switching (228). They are also involved in the recruitment of neutrophils and 
macrophages from the bone marrow, thereby promoting phagocytosis (229), supporting 
that this increase is evidence of a typical adaptive immune response to infection. Other 
groups have characterized the inflammatory cells at present in bone infection sites for a 
limited number of cell types, such as myeloid derived suppressor cells (MDSCs) (230-232) 
and B cells (233) as well as T cell subsets located at the draining lymph node and in spleen 
(234). Vidlak and Kielian have also reported MDSC, monocyte, macrophage, and CD3+ T 
cell compositions (235) in the context of prosthetic joint infections. To our knowledge, this 
is the most comprehensive report of immune cell subtypes for bone-associated S. aureus 
infections. 
 In conclusion, we have engineered a lysostaphin- and BMP-2-delivering hydrogel 
that simultaneously eradicates S. aureus infection and repairs critical-sized mouse radial 
segmental bone defects. This bacteriospecific strategy is limited in that it is only effective 
against Staphylococcus species. However, future studies could investigate the 
incorporation of antimicrobial agents that could expand the activity spectrum. These 
hydrogels show no signs of systemic or local toxicity, supporting further investigation 
using higher order animal models.  
4.5 Materials and Methods 
Bacterial strains and culture 
S. aureus strains UAMS-1 (ATCC 49230) and Xen29 (Perkin-Elmer) were grown at 37ºC 
on TSA or Luria-Burtani (LB) agar supplemented with 50 µg/mL kanamycin respectively. 
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Lysostaphin and BMP-2 co-delivering hydrogel synthesis 
Hydrogels were synthesized using 20 kDa PEG-MAL (Lysan Bio) functionalized with the 
collagen-mimetic peptide GFOGER (New England Peptide), lysostaphin (AMBI), S. 
aureus UAMS-1 or Xen29, and then cross-linked using the cysteine-flanked protease 
degradable peptide VPM. All components were suspended in 100 mM MES buffered PBS 
at a pH of 5.5 – 6.0. Single colonies of UAMS-1 or Xen29 were picked from agar plates 
and suspended in PBS to an optical density of 0.20 measured at 600 nm using a benchtop 
spectrophotometer (Microscan Turbidity Meter, Siemens). The bacteria suspension was 
diluted 100 fold for UAMS-1 studies and 10 fold for Xen29 studies. BMP-2 (R&D 
Systems) was prepared at 333 ng/mL in 4 mM HCl. For hydrogels with lysostaphin, the 
enzyme was added to PEG-MAL. Hydrogels were synthesized by mixing 4:2:2:1:1 parts 
PEG-MAL, 1.0 mM GFOGER, VPM, BMP-2, and bacteria, followed by injection into a 
polyimide tube with 300 µm laser machined holes (Microlumen). The final hydrogel 
composition was 4.0% w/v 20 kDa PEG-MAL, 1 mM GFOGER, (412 ± 85) UAMS-1, 100 
ng BMP-2, with or without 1 U lysostaphin. Hydrogels were polymerized at 37ºC and 5% 
CO2 for 15 minutes and then swollen in PBS cut into 4 mm segments, and kept in PBS 
until implantation. 
Murine radial segmental defect infection model 
All live animal experiments were performed in accordance with the Institutional Animal 
Care and Use Committee at Georgia Institute of Technology under veterinary supervision. 
Male C57/B6 mice (Jackson Laboratories) 10-12 weeks old were anesthetized via 
isoflurane inhalation. Depilatory cream was used to remove fur from the right forelimb. 
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The limb was surface disinfected by applying 70% isopropyl alcohol followed by 
chlorohexidine solution. 1 mg/kg slow release buprenorphine was injected 
intraperitoneally before surgery as an analgesic. A 1 cm incision was made on the right 
forelimb over the radius, followed by blunt dissection of the radius. A 2.5 mm section of 
the radius was then excised using a custom made double-bladed bone cutting device. A 4 
mm polyimide implant tube containing the hydrogel was then fitted over each end of the 
radius. For mice receiving local gentamicin therapy, infected UAMS-1 containing implants 
were dipped in 10 mg/mL gentamicin (206, 207) followed by dipping in 0.9% w/v sodium 
chloride prior to implantation. The wound was sutured closed and a X-ray image (MX-20 
Radiography System, Faxitron) was taken of the radius to confirm a successful surgery.  
Mice placed under and warming lamp and monitored until ambulatory.  
Recovery of bacteria from tissue samples 
Mice were euthanized via CO2 inhalation and the right forelimb was sterilized with 70% 
isopropyl alcohol and the skin was removed. The implant tube and surrounding tissue and 
bone were removed, weighed, and kept on ice. Tissue samples from the mouse forelimb 
were homogenized using bead beating tubes (1.4 mm zirconium beads, OPS Diagnostics) 
in combination with the FastPrep 24 (MP Biomedicals) set to 6 m/s for a total of 5 
successive runs, 40 s in duration. Liver samples were homogenized for 10 sec using a Lab 
Gen 7 (Cole Plamer) tissue homogenizer. Single cell bacterial suspensions were then 
prepared by a series of sonication and vortexing steps (10 min sonication, 30 sec vortex, 5 
min sonication, 30 sec vortex, 30 sec sonication, 30 sec vortex). These single cell 
suspensions were then serially diluted in PBS, plated on agar plates, incubated overnight 
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at 37ºC, and enumerated. Bacterial counts were normalized to tissue weight and reported 
as CFU/mg or CFU/implant if tissue weights were not recorded.  
Microcomputed tomography and bone volume quantification 
Microcomputed tomography of mouse radii was performed as previously described with 
modifications (164, 236). Animals were anesthetized via isoflurane inhalation and a 3.2 
mm length sectioned centered over the radial defect was imaged using a VivaCT system 
(Scano Medical) with the following imaging parameters: 145 μA intensity, 55 kVp energy, 
200 ms integration time, and 15 μm resolution. Contours of the radius within the implant 
tube were drawn on each 2D section and a Gaussian filter was applied (sigma = 1, support 
= 1, threshold = 540 mg HA/ccm) to quantify bone volume.  
Mechanical testing of radii 
Mechanical testing was performed as described in Shekaran et. al. Briefly, mice were 
euthanized via CO2 inhalation and the right forelimb was dissected, wrapped in saline 
soaked gauze, and frozen at -20ºC until the time of analysis. Samples were thawed under 
running deionized water and the radius and surrounding tissue was removed from the radius 
and ulna. The ulna was then cut at its midpoint using a scalpel blade to ensure the 
mechanical integrity of the radius was evaluated. Samples were potted in woods metal 
containing blocks. Torsion to failure testing was performed using a Bose Electroforce ELF 
3200 system in conjunction with a 0.07 Nm torque sensor (Transducer Techniques) by 
applying a constant rotation of 3 degree per second. The maximum recorded torque value 
was reported. 
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Dot blot for anti-lysostaphin antibody generation 
Pre-exposure blood samples were collected at the time of surgery via cheek bleed. Post-
exposure blood samples were collected 4 weeks after surgery by cardiac puncture after CO2 
euthanasia. Blood samples were clotted, centrifuged, and serum was collected and stored 
at -80ºC until analysis. The dot blot assay was performed using a vacuum driven Manifold 
I Spot Blot System (Schleicher & Schuell). The nitrocellulose membrane was coated with 
lysostaphin (AMBI, 100 µg/mL), blocked, washed, and then 10,000 fold diluted serum 
samples were exposed to the membrane. A mouse anti-lysostaphin polyclonal IgG 
(Antibody Research Corporation) was used as a positive control. Anti-lysostaphin 
antibodies were detected using an AlexaFluor 488 conjugated polyclonal goat anti-mouse 
IgG antibody (Abcam). A Typhoon FLA 9500 gel imager (GE Healthcare) was used to 
image the membrane. ImageQuant (GE Healthcare) was used to quantify blot intensity. 
Positive results were determined to be five times the average intensity of serum samples 
from animals that were not exposed to lysostaphin. 
Liver function analysis 
Mice were euthanized by CO2 inhalation and blood was taken via cardiac puncture. Serum 
was separated and samples were sent for blood chemistry testing at Antech Diagnostics. 
Histology of tissue samples 
Mice were euthanized via CO2 asphyxiation and the right forelimb was dissected, fixed in 
10% neutral buffered formalin, and decalcified in formic acid. Sampled were then 
processed and embedding in paraffin. 5 µm sections of the radius and implant tube were 
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cut, and stained with either hematoxylin and eosin, safranin-O and fast green, or gram stain 
using standard methods. Color images of the tissue sections were taken with a Nikon 
Eclipse E600 microscope using a Plan Fluor 20x objective (Nikon), Micropublisher 5.0 
RTV (Q imaging) color camera, and Q-Capture software (Q imaging).  
In vivo flow cytometry analysis 
Flow cytometry analysis of tissue samples was performed as previously described (237). 
Briefly, mice were euthanized via CO2 asphyxiation and the right forelimb was dissected. 
The implant tube and surrounding tissue were removed, weighed, and digested in 
collagenase type 1-A (1 mg/mL, Sigma) at 37ºC for 45 min. Following digestion, samples 
were separated using a cell strainer to form a single cell suspension. The single cell 
suspensions were stained for flow cytometry using standard methods. The samples were 
analyzed on a FACS-Aria IIIu flow cytometer (BD Biosciences). The antibodies used for 
cell staining were: AlexaFluor 488 conjugated anti-CD206 (BioLegend), BV421 
conjugated anti-CD19 (BioLegend), BV605 conjugated anti-CD4 (BioLegend), BV785 
anti-CD8a (BioLegend), PE/Cy7 conjugated anti-CD3ε (BioLegend), BV510 conjugated 
anti-Ly-6C (BioLegend), APC conjugated anti-F4/80 (BioLegend), APC/Cy7 conjugated 
anti-Ly-6G (BioLegend), and PE conjugated anti-CD86 (BioLegend). Live/dead staining 
was performed using the Zombie Red fixable viability kit per manufacturer’s instructions 
(BioLegend). Precision Counting Beads (BioLegend) were used to report cell numbers. 
In vivo cytokine array analysis 
Following euthanasia via CO2 inhalation, the right forelimb was dissected and the implant 
tube and surrounding tissue was removed for processing. The samples were placed in RIPA 
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buffer, minced, and sonicated. The homogenate was centrifuged at 10,000 g for 5 minutes 
and the supernatant was filtered using a 0.45 µm spin filter, snap frozen in liquid nitrogen, 
and stored at -80ºC until the time of analysis. A MilliPlex 25-plex mouse cytokine array 
kit (Millipore Sigma) was used to quantify tissue concentrations of G-CSF, GM-CSF, IFN-
γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-
15, IL-17, IP-10, KC, MCP-1, MIP-1α, MIP-1β, MIP-2, RANTES, and TNF-α per the 
manufacturer’s instructions. Results were read using a Luminex system (Luminex 
Corporation) and normalized to total protein content of the sample measured with a 
bicinchoninic acid (BCA) assay kit (Pierce by ThermoFisher). Samples below or above the 
detection limit of the assay were reported as the minimum or maximum value respectively. 
Statistics 
All data is plotted as individual data points with a line indicating the mean and the error 
bars representing the standard deviation of the mean. A P value less than 0.05 was deemed 
statistically significant. Statistical comparisons between two groups were made with the 
Student’s t Test. Multivariate parametric data was analyzed using ANOVA with Tukey’s 
post-hoc test and non-parametric data was analyzed using the Kruskall-Wallis test with 
Dunn’s multiple comparison test. A two-way ANOVA with a Bonferroni correction was 
used to identify statistically significant cytokines. All calculations were performed using 
Prism (GraphPad). Hierarchal cluster analysis was performed on the cytokine data using 
JMP Pro 13. 
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LYSOSTPAHIN-DELIVERING HYDROGELS TO TREAT 
ESTABLISHED INFECTIONS 
5.1  Abstract 
Traumatic injuries resulting in complex open fractures are associated with high 
infection rates, with reports of up to 30%. These infections are treated with a combination 
of systemic antibiotic therapy, extensive surgical debridement, followed by a second 
surgery to repair the bone, resulting in significant patient morbidity. Lysostaphin is a 
bacteriolytic enzyme that specifically kills S. aureus, but translation has been impeded by 
the lack of an effective delivery vehicle.  We engineered an injectable lysostaphin-
delivering hydrogel capable of conforming and adhering to the infected injury. We 
investigated the ability of lysostaphin-delivering hydrogels to treat established segmental 
bone defect infections. Lysostaphin-delivering hydrogels alone modestly reduced bacterial 
counts at one week post implantation. Long term, lysostaphin laden hydrogels preserved 
bone volume compared to untreated controls. Importantly, the combination of lysostaphin-
delivering hydrogel treatment and systemic antibiotic therapy to established bone 
infections resulted in an enhanced antibacterial effect, resulting in a nearly two log 
reduction in bacteria numbers. Taken together, lysostaphin-delivering hydrogels have the 




 Traumatic injuries resulting in complex open fractures are associated with the 
highest infection rates, with reports of up to 30% (137-139, 238). Additionally, orthopaedic 
injuries account for 65% of all military combat casualties, and carry infection rates as high 
as 50% (218). Staphylococcal species are the most common pathogens, responsible for 
over two thirds of cases (2). Successful clinical management of these complex injuries is 
focused on preventing infections through a combination of extensive and early surgical 
debridement of the affected bone, fracture stabilization, and aggressive antibiotic therapy 
(218). Even with the employment of optimal care, infection rates remain high. The 
placement of biomaterials, such as fixation hardware, reduces the number of bacteria 
required to initiate an infection by up to 10,000 fold or more (239). Colonization of 
orthopaedic hardware leads to bacterial biofilm formation and the subsequent development 
of osteomyelitis (inflammation of the bone), characterized by osteolysis and reactive bone 
formation (17, 18).  
Bacterial biofilms play a significant role in the pathogenesis of orthopaedic 
infections and subsequent progression to osteomyelitis. Biofilms are communities of 
bacteria encased within a secreted matrix composed of DNA, protein, and polysaccharides 
(143). They form in a stepwise manner: the implant is coated with host proteins, bacteria 
then adhere to these proteins and subsequently begin to grow, leading to colonization, and 
finally biofilm formation (239). The biofilm matrix then acts as a defense mechanism 
against the host immune response to infection, and a diffusion barrier to antibiotics (144, 
240).  
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Clinical management of hardware-associated biofilm infections is limited to 
surgical debridement, antibiotic therapy, and implant removal and replacement. Recently, 
employment of the Masquelet technique, a two stage reconstruction protocol for segmental 
bone defects, has become popular in treating these infections (220). The first stage consists 
of extensive tissue debridement, limb stabilization followed by the placement of an 
antibiotic eluting space maintainer, and ensuring soft tissue coverage and wound healing. 
The second stage of the procedure commences once the infection has been eradicated, often 
4-8 weeks later. In this surgery, the cement spacer is removed, permanent fixation hardware 
is placed, and an autogenous bone graft is harvested and deployed (241). The development 
of treatment protocols that simultaneously eradicate the bacterial infection and promote 
bone healing would effectively eliminate a surgery, having the potential to reduce patient 
morbidity and healthcare costs. The elimination of a surgical procedure will significantly 
reduce the recovery time for patients, which may result in reduced complications and 
improved outcomes. However, preclinical studies have focused primarily on evaluating 
prophylactic therapies and do not address these established infection scenarios.  
Lysostaphin is an endopeptidase produced by Staphylococcus simulans as a defense 
mechanism against Staphylococcus aureus (4). It is specific to, and highly active against, 
staphylococcal species (4, 103). Lysostaphin is composed of a SH3B targeting domain, 
providing its specificity, and a catalytic domain that cleaves the glycine-glycine 
peptidoglycan linkages present in the cell wall (3, 242). Bacterial lysis is achieved by rapid 
catalytic degradation of the cell wall. The catalytic nature of lysostaphin allows for it to 
have activity against biofilm infections in vivo, in models of endocarditis (7, 9, 103), 
jugular vein catheterization (11), and nasal colonization (151, 195).  
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Further development of lysostaphin as a therapeutic to treat biofilm infections has 
been severely limited by a lack of effective delivery vehicles. Biomaterial-based strategies 
for lysostaphin delivery have been primarily centered around preventing infections (150, 
154-156) as opposed to treating established infections. Local delivery of antibacterials 
provides high, sustained, local doses, to infection sites (157, 158). We have previously 
engineered PEG hydrogels for the delivery of cell and protein based therapeutics to treat a 
variety of disease pathologies (160-165). This hydrogel system consists of a 4-arm PEG 
macromer with maleimide functionalized end groups that react specifically with thiols, 
allowing for covalent incorporation of cell adhesive peptides, and cross-linking with 
protease degradable cysteine-terminated peptides. 
In this study, we engineered an injectable PEG hydrogel for local lysostaphin 
delivery to treat established bone infections. We extended the mouse radial segmental 
defect infection model to assess treatments for established infections, by first initiating an 
infection, and then in a second procedure, providing therapy to the infection site. We 
showed that lysostaphin-delivering hydrogels alone reduce bacteria counts at one week 
after treatment, and that this infection reduction translated to a preservation of bone 
volume. Next, we investigated the effect of administering systemic antibiotic therapy in 
conjunction with lysostaphin-delivering hydrogels and showed that there was a combined 
effect provided by combination therapy. These proof-of-concept studies provide a platform 
for further optimization of lysostaphin-delivering hydrogels and simultaneous antibiotic 




5.3.1 Lysostaphin-delivering hydrogels reduce bacteria in an established biofilm 
infection model 
 Few mouse models exist to study the treatment of established biofilm infections. 
Therefore, we first set out to develop and validate an established biofilm infection model 
by adapting the murine radial segmental defect infection model. We first initiate an 
infection, allowing for implant colonization, and then treat the established infection at a 
later time, in a two-stage surgical model (Figure 37). The infection is initiated by 
implanting hydrogels containing S. aureus UAMS-1 into a radial segmental defect. The 
infection is allowed to become established over the course of 7 days. Then, a second 
revision surgery is performed to remove the contaminated implant, debride surrounding 
dead tissue, and place a sterile implant with additional gel polymerized in situ to provide 
extra lysostaphin therapy. This model mimics current therapeutic strategies where infected 
hardware is removed and the wound bed is cleaned and treated locally.  
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Figure 37: In vivo established S. aureus biofilm infection model. In vivo biofilms were 
established by implanting hydrogel scaffolds containing S. aureus UAMS-1. A 2.5 mm 
segment of the radius was removed and a 4.0 mm perforated polyimide tube filled with a 
hydrogel is fitted over the ends of the radius, filling the defect. Seven days following 
infection initiation, revision surgery was performed to remove the infected implant and 
surrounding dead tissue, irrigate the wound, place a sterile scaffold, and an additional 
wound filling gel, polymerized in situ, to deliver additional lysostaphin. Seven days 
following revision surgery, mice were assayed for viable bacteria within the defect site. 
 To establish a working model, we tested two different doses of S. aureus UAMS-1 
(low dose = 55 ± 24 CFU/implant; high dose = 613 ± 117 CFU/implant) to identify the 
lowest bacterial dose that reliably initiates the infection (Figure 38A). At the time of 
revision surgery, sterile implants were placed and an additional 10 µL of gel was 
polymerized in situ in the wound bed over the implant. Both empty and lysostaphin-
containing hydrogels were evaluated for each bacterial dose. Seven days following revision 
surgery, mice were euthanized and assayed for viable bacteria at the infection site. There 
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was a statistically significant reduction in recovered bacteria in the lysostaphin-delivering 
hydrogel-treated group compared to the untreated control for the low dose of UAMS-1 of 
roughly 50% (Figure 38B). This shows that lysostaphin-delivering hydrogels are modestly 
effective against bacteria growing in an established infection. No differences were detected 
in the high dose group between the treated and untreated groups (P < 0.053). Notably, there 
were no differences in the number of bacteria recovered from untreated mice in the low 
and high bacterial inoculum groups (Figure 38C). For this reason, we selected the lower 
dose to initiate infections for all the following studies.  
 
 
Figure 38: Lysostaphin-delivering hydrogels reduce in vivo biofilm. (A) Biofilms 
were initiated and 7 days later revision surgery was performed. 7 days following revision 
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surgery bacteria from the implant and surrounding tissue was quantified. (B) Bacterial 
counts 7 days after revision surgery recovered from mice receiving the low initial dose of 
S. aureus UAMS-1. (C) Bacterial counts 7 days after revision surgery recovered from 
mice receiving the high initial dose of S. aureus UAMS-1. Means ± SD. N=4-6 per 
group. *P < 0.05, Student’s t test. 
To determine if this reduction of bacteria translated to differences in bone within 
the defect, we assessed bone volume at 4 and 8 weeks following revision surgery via µCT 
imaging (Figure 39A). Representative µCT reconstructions of radii scanned at 4 weeks 
post-revision surgery show no gross morphological differences between groups (Figure 
39B). However, at 8 weeks, no bone is present in the untreated infection control group, 
with minimal bone loss observed in the lysostaphin-delivering hydrogel group. 
Quantification of the µCT imaging at 5 weeks revealed no differences in bone volume 
between empty and lysostaphin-delivering hydrogel treated mice (Figure 39C). However, 
at 9 weeks, significantly more bone was present within the defect for mice treated with 
lysostaphin-delivering hydrogels compared to the untreated control group (Figure 39D). 
This result suggests that treatment with lysostaphin-delivering hydrogels reduces bone 
resorption in our mouse model, since no apparent new bone formation was present in the 




Figure 39: Lysostaphin-delivering hydrogels preserve bone volume. (A) S. aureus 
infections were initiated for one week and then treated with lysostaphin-delivering 
hydrogels. Bone formation was assessed using µCT imaging at 5 and 9 weeks. 
Representative µCT reconstructions at 5 weeks (B) and 9 weeks (C) post infection 
initiation. Bone volume within the implant site quantified at 5 weeks (C) and 9 weeks (D) 
post-revision surgery. Means ± SD. N=3-5 per group. *P < 0.05. Student’s t test.  
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5.3.2 Lysostaphin-delivering hydrogels act in combination with systemic antibiotic 
therapy to reduce infection 
 The previous studies demonstrated that lysostaphin-delivering hydrogels modestly 
reduce bacteria compared to untreated controls at one week following revision surgery, and 
that there is less apparent bone loss 8 weeks after revision surgery. These reductions were 
promising, but may not be clinically relevant, since the infections are not close to being 
eliminated. With this observation in mind, we hypothesized that optimization of bacterial 
clearance will be critical to developing a wound environment that can support new bone 
formation. We set out to further reduce the viable bacteria recovered at 7 days post-revision 
surgery by testing the effect of systemic antibiotic therapy in combination with lysostaphin-
delivering hydrogels. We initiated biofilm growth and then, at revision surgery, treated 
mice with lysostaphin-delivering hydrogels or lysostaphin-delivering hydrogels paired 
with twice daily injections of tobramycin for 4 days, totaling 8 injections (Figure 40A). 
The control groups included mice treated with empty hydrogels, with and without 
tobramycin therapy. Mice were then assessed for viable bacteria one week following 
revision surgery. The microbiologic assessment of the implants and surrounding tissue 
showed a significant reduction in bacteria for the lysostaphin-delivering hydrogel with 
tobramycin group compared to the untreated infection control (Figure 40B). No effect was 
observed in mice treated with systemic tobramycin alone compared to control. Notably, 
2/5 mice treated with lysostaphin-delivering hydrogels in combination with systemic 
antibiotics responded robustly to the therapy with bacterial reductions of 2 and 5 orders of 
magnitude compared to untreated controls. This result shows that the addition of 
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tobramycin to lysostaphin-delivering hydrogel therapy provides a combined effect, 
potentiating the antimicrobial capacity of the material.  
 
Figure 40: Systemic tobramycin administration provides a combined antimicrobial 
effect. (A) In vivo biofilms were established for seven days. At the time of revision 
surgery, tobramycin was administered twice daily for 4 days. 7 days following revision 
surgery, mice were assayed for bacteria. (B) Viable bacteria recovered from mouse radii 
7 days following revision surgery. Means ± SD. N=3-5 per group. *P < 0.05.  Kruskall-
Wallis with Dunn’s post hoc test for. 
  It has been reported that lysostaphin acts synergistically with oxacillin in vitro (5, 
103). Therefore, we hypothesized that systemic oxacillin therapy would potentiate the 
antimicrobial activity of lysostaphin-delivering hydrogels. Infections of UAMS-1 were 
initiated in the defect site. Twice daily oxacillin injections (100 mg/kg) began at day 6, 1 
day prior to revision surgery, and continued until microbiologic assessment at day 14 for 
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animals receiving antibiotics (Figure 41A). At day 7, revision surgery was performed and 
mice were treated with empty hydrogels or lysostaphin-delivering hydrogels. At day 14, 
mice were euthanized and both the implant and surrounded tissue were separately assayed 
for viable bacteria. A significant reduction in bacteria recovered from the surrounding 
tissue was observed in the lysostaphin-delivering hydrogel with oxacillin group compared 
to both the infection-only control and the systemic oxacillin-treated group (Figure 41B). 
Bacteria counts of the implant tube revealed significantly more bacteria in the lysostaphin-
delivering hydrogel group compared to the untreated control (Figure 41C). However, 
lysostaphin-delivering hydrogels combined with antibiotic therapy significantly reduced 
bacteria compared to the untreated infection control and the hydrogel only group (Figure 
41D). Analysis of the total bacteria recovered from both the tissue and implant tube showed 
that combing lysostaphin-delivering hydrogels with oxacillin therapy was superior in 
reducing bacterial counts compared to the untreated control and lysostaphin-delivering 
hydrogels alone. Taken together, the efficacy of lysostaphin-delivering hydrogels is 
potentiated when paired with systemic oxacillin therapy, suggesting that to effectively 





Figure 41: Systemic oxacillin administration enhances lysostaphin-delivering 
hydrogel efficacy. (A) S. aureus infections were initiated and after seven days, revision 
surgery was performed to remove the implant and place lysostaphin-delivering hydrogels. 
Animals undergoing systemic oxacillin therapy received twice daily injections beginning 
one day before revision surgery and continued until necropsy. At 7 days post-revision 
surgery, the (B) tissue surrounding the implant and the (C) implant were assayed for viable 
bacteria. (D) indicates the sum of all bacteria recovered. Means ± SD. N=5-10 per group 
combined from two independent experiments. *P < 0.05, ***P < 0.001, ****P < 0.0001, 






 In this study, we developed a novel mouse model to study orthopaedic hardware-
associated established infections in the context of segmental bone defects, and then used 
this model to test the efficacy of lysostaphin-delivering hydrogels. We identified the 
minimal bacterial dose required to reliably establish an infection in a mouse radial 
segmental defect. After 7 days of infection, we performed a second revision surgery to 
clean the wound bed, remove infected hardware, replace the hardware, and apply the 
specified hydrogel treatment. Our results showed that lysostaphin-delivering hydrogels by 
themselves reduce infection compared to the untreated controls and that this effect reduces 
infection-associated bone loss. Importantly, we showed that lysostaphin-delivering 
hydrogel therapy in combination with either systemic tobramycin or oxacillin further 
potentiates the antimicrobial effect.  
 Treating orthopaedic hardware-associated established infections remains a very 
complicated and challenging clinical scenario (158). Successful therapy typically requires 
extended antibiotic regimens, multiple surgeries, and significant patient morbidity. 
Progress remains slow in the development of experimental therapies that address these 
infections. Several animal models exist to study established orthopaedic infections. 
However, until recently, these have been limited to rats and larger animals, which are 
expensive to work with and require significant ethical justification, limiting their use. 
These issues motivate the development of murine established infection models for rapid 
screening of experimental therapies.  One murine established infection mouse model first 
initiates a tibial infection by injection of bacteria into the medullary canal, and then 2 weeks 
later, necrotic bone is debrided from the tibial canal using a needle (243). This model has 
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been used to compare systemic antibiotic therapy to tissue debridement as well as 
characterize the inflammatory response of tissue debridement in osteomyelitis (244). 
However, this approach is limited in that there is no bone fracture or hardware placement, 
two critical components to treating most orthopaedic injuries. To date, only a single murine 
model has been published involving established orthopaedic hardware infections (53). In 
this femoral fracture model, the authors first initiate an infection and then perform a 
revision surgery seven days later, where necrotic tissue and bone are debrided and an 
antibiotic spacer is placed in the expanded osteotomy site. Our approach differs in that we 
are investigating segmental bone defect infections and our procedure does not require a 
fixation device, as the radius is self-stabilized by the ulna. This is advantageous in that the 
model is simplified by not including fixation hardware, which eliminates the possibility of 
hardware failure. Furthermore, the use of a segmental defect will enable the evaluation of 
bifunctional therapies that simultaneously eradicate infection and repair bone. However, 
further characterization of the model should be performed, including analyzing if biofilm 
and osteomyelitis are present at 1 week, both in the debrided tissue and at the defect site. 
The amount of bacteria present at the time of revision should also be quantified, along with 
the amount of bacteria removed during the debridement procedure. This analysis will 
provide better characterization of the contribution of tissue debridement and how the 
hydrogel treatment potentiates the affect. 
 Our results clearly demonstrate that systemic antibiotics potentiate the efficacy of 
lysostaphin-delivering hydrogel therapy. However, even with combination therapy, we do 
not consistently eradicate the infection. This could be due to a variety of factors including, 
improper lysostaphin release kinetics, ineffective intracellular killing of S. aureus, or poor 
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penetration into the biofilm. Bacterial regrowth after the cessation of systemic antibiotic 
therapy cannot be ruled out, and furthermore, the surviving bacteria could be resistant to 
both the given antibiotic and lysostaphin. Bacterial infection causes a significant 
upregulation in inflammatory cytokines, that recruit inflammatory cells and trigger 
protease production (169). The lysostaphin-delivering hydrogel responds to this by 
degrading, and more rapidly releasing lysostaphin. Modification of the hydrogel structure 
by reducing the mesh size or utilizing a cross-linking peptide that is less responsive to 
proteases should extend the release of lysostaphin, increasing the time that bactericidal 
concentrations of lysostaphin are present at the infection. The elimination of intracellular 
bacteria is a significant challenge when treating bone infections (245). Although S. aureus 
was primarily thought of as an extracellular pathogen, this is no longer the case (246). S. 
aureus invades both phagocytic and non-phagocytic cells, which can persist and eventually 
lead to the generation of small colony variants exhibiting high levels of antibiotic resistance 
(246). Lysostaphin exhibits variable activity against intracellular bacteria, limiting its 
efficacy treating these infections (247). Additionally, both oxacillin and tobramycin have 
very poor intracellular antimicrobial activity (248). Other antibiotics may also be 
considered, such as macrolides, vancomycin, or fluoroquinolones, to see if they further 
potentiate the effect of lysostaphin-delivering hydrogels. However, reports of the 
effectiveness of monotherapy in the context of osteomyelitis are variable (249). With some 
classes, such as macrolides, being recommended against due to low bioavailability in bone 
(249). Although we observed significant reductions in bacteria, it may be possible to further 
reduce bacterial numbers through the addition of antibiotics with high activity against 
intracellular pathogens. Checkerboard assays could be performed to identify antibiotics 
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that act synergistically with lysostaphin-delivering hydrogels. Rifampin is a critical 
therapeutic component when treating orthopaedic infections where the hardware is 
retained. Moreover, it has relatively high activity against bacteria growing in biofilm and 
is highly effective against intracellular bacteria. However, rifampin must be given in 
combination with another antibiotic to avoid the rapid development of resistance against it 
(250, 251). For these reasons, the addition of systemic rifampin therapy to our antibiotic 
regimen and lysostaphin-delivering hydrogel may be a way to further reduce the infection. 
Another option could be to expand the defect to simulate more extensive debridement. This 
modification may improve therapeutic efficacy, as extensive debridement is a more 
effective treatment than antibiotics alone (243). 
Eradication of the biofilm will be critical to successfully engineering an implant 
that is also capable of regenerating bone to repair a segmental defect. Our results indicate 
that lysostaphin-delivering hydrogels alone do not promote new bone formation, but do 
preserve some bone mass compared to untreated controls. Multiple groups have shown that 
increasing the BMP-2 dose, even with infection still present, increases new bone formation 
within the defect (40, 115). Further optimization of the hydrogel formulation, including 
BMP-2 dosing, will be required to simultaneously eliminate the infection and regenerate 
bone. This dual function strategy may allow for the elimination of a revision surgery to 
repair the fracture after mitigation of the infection, thereby reducing patient morbidity and 
associated health care costs, having the potential to significantly transform how these 
complex clinical scenarios are managed. 
 Lysostaphin therapy provides bacteriospecific targeting of staphylococcal species. 
This is particularly advantageous when treating established bacterial infections, where the 
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pathogen can be identified prior to administering therapy. A targeted approach will ensure 
patients have the best chance of recovery, while also reducing unwanted side effects 
associated with broad spectrum strategies aimed at eliminated all bacteria. The 
incorporation of other bacteriospecific antimicrobial strategies, such as phage lysins, 
bacteriophage, or antimicrobial peptides, will provide personalized treatment approaches 
for successfully treating infections. Furthermore, the development of targeted 
bacteriospecfic approaches as either primary or adjuvant therapies will help to reduce the 
spread of antibiotic resistance associated with long term systemic antibiotic therapy. 
5.5 Materials and Methods 
Bacterial strains and culture 
S. aureus UAMS-1 (ATCC 49230) was grown on trypic soy agar (TSA) plates at 37ºC. 
Lysostaphin-delivering hydrogel synthesis 
Hydrogels were synthesized by reacting a20 kDa 4-arm PEG macromer with end 
functional maleimide units (PEG-4MAL) (Lysan Bio) with the collagen mimetic GFOGER 
peptide (GGYGGP(GPP)5GFOGER(GPP)5GPC; New England Peptide) and the cysteine-
flanked protease degradable cross-linking peptide VPM (GCRDVPMSMRGGDRCG; 
Genscript). The individual hydrogel components, lysostpahin (AMBI Products LLC), and 
S. aureus UAMS-1 were suspended in 100 mM MES in PBS and pH adjusted to a final pH 
of 5.5-6.0 and the VPM cross-linker in 100 mM MES in PBS at a pH of 5.5-6.0.  
For hydrogels used to initiate the bacterial infection, single colonies of S. aureus 
UAMS-1 were picked from a TSA plate and suspended in PBS to an optical density of 0.20 
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at 600 nm measured using a spectrophotometer (MicroScan Turbidity Meter, Siemens), 
and then diluted 1,000 fold in PBS. Hydrogels were synthesized by mixing PEG-4MAL, 
VPM, and the bacterial suspension at a volume ratio of 2:2:1. Following mixing, hydrogels 
wereinjected into a polyimide tube with 300 µm laser machined holes (Microlumen). The 
final hydrogel composition was 4.0% w/v 20 kDa PEG-4MAL and containing 55 ± 24 CFU 
of S. aureus UAMS-1. The hydrogel was allowed to fully polymerize in a humidified 
incubator at 37ºC at 5% CO2 for 15 minutes before being swollen in PBS. Individual 
implants were created by cutting the hydrogel containing implant to into 4 mm long 
segments. The implants were kept in PBS until implantation.  
The hydrogels placed at the revision surgery were synthesized in a similar fashion 
with slight modifications. Individual hydrogel components were suspended in 100 mM 
MES in PBS and pH adjusted to 5.5-60. Hydrogels components, 20 kDa PEG-4MAL, 
GFOGER, lysostaphin, and VPM, were then mixed at volume ratios of 2:1:1:1 to produce 
hydrogels with a final compositions of 4.0% w/v 20 kDa PEG-4MAL, 1.0 mM GFOGER, 
with or without 25 U of lysostaphin. These hydrogels were injected into polyimide tubes, 
allowed to polymerize for 15 min at 5.0% CO2 in a humidified incubator, cut into 4 mm 
segments, and swollen in PBS until implantation. After placement of this sterile implant at 
revision surgery, a second hydrogel was polymerized in situ over the implant tube. This 
hydrogel was the same composition as the hydrogel in the implant tube. It was prepared by 
mixing a 3:2 volume ratio of 2:1 20 kDa PEG-4MAL:lysostaphin (42400 U/mL) solution 
with a 1:1 GFOGER:VPM solution and then pipetting this hydrogel over the wound bed 
for a final hydrogel composition of  4.0% w/v 20 kDa PEG-4MAL, 1.0 mM GFOGER, 
with or without 85 U of lysostaphin polymerizing in the wound bed. 
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Murine radial segmental defect established biofilm infection model 
All live animal experiments were performed under protocols approved by the 
Institutional Animal Care and Use Committee at Georgia Institute of Technology with 
veterinary supervision. Male C57/B6 mice 10-12 weeks old (Jackson Laboratories) were 
anesthetized via isoflurane inhalation. Slow release buprenorphine was administered (1 
mg/kg) intraperitoneally as an analgesic. Right forepaw fur war removed with depilatory 
cream and the area was sterilized with 70% isopropyl alcohol and the subsequent 
application of cholorhexidine. A 1.5mm incision was made on the right forepaw and the 
radius was blunt dissected. A 2.5 mm segment of the radius was then removed using custom 
made bone cutters. A 3 µL hydrogel (4.0% w/v 20 kDa PEG, VPM) containing S. aureus 
UAMS-1 loaded inside of a 4 mm polyimide tube was then slipped over the ends of the 
radial defect. The wound was sutured closed and an X-ray image was taken to confirm 
proper defect formation and implant placement using the MX-20 Radiography System 
(Faxitron) (164). Mice were then monitored under a warming lamp until ambulatory. 7 
days following infection initiation surgery, mice were anesthetized under isoflurane, slow 
release buprenorphine was injected (1 mg/kg) intraperitoneally, fur was removed from the 
right forepaw with depilatory cream, and the skin was sterilized with 70% isopropyl 
alcohol followed by chlorohexidine. The incision site was reopened, and the wound was 
debrided by removing the original implant and surrounding dead tissue. The wound was 
irrigated with 0.9% w/v saline. A 4 mm perforated polyimide tube containing a 3 µL 
hydrogel scaffold (4.0% w/v 20 kDa PEG, 1 mM GFOGER, VPM) with or without 
lysostaphin was placed over the ends of the radial defect. A 10 µL (4.0% w/v 20 kDa PEG, 
1 mM GFOGER, VPM) hydrogel with or without lysostaphin was polymerized in situ over 
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the implant tube. The incision was sutured closed and mice were monitored under a 
warming lamp until ambulatory.  
µCT imaging and analysis 
µCT imaging was performed as previously described with slight modification (164, 
236). Animals were anesthetized under isoflurane and 3.2 mm of the radius was scanned 
using the VivaCT system (Scanco Medical, 145 mA intensity, 55 kVp energy, 200 ms 
integration time, and 15 µm resolution). Bone volume was determined by contouring 2D 
slices of the radius and implant tube at the defect area for a total of 3.2 mm radial length. 
A Gaussian filter was applied and bone volume was quantified. 
Recovery of bacteria from tissue samples 
At the designated experimental end point, mice were euthanized via CO2 inhalation. 
The right forepaw was sterilized with 70% ethanol and the radius was dissected. The 
polyimide tube containing the hydrogel and other surrounding tissue was removed, placed 
in a bead beating tube containing 1.4 mm zirconium beads (OPS Diagnostic), weighed, and 
stored in PBS on ice. Tissue samples were homogenized with 5 successive runs at 6 m/s 
for 40 s using a FastPrep 24 (MP Biomedicals). Samples then underwent a series of 
sonication followed by vortexing (10 min sonication, 30 sec vortex, 5 min sonication, 30 
sec vortex, 30 sec sonication, 30 sec vortex) to disperse the biofilm and create a single cell 
bacterial suspension. Bacteria were enumerated by serially diluting the samples and 
culturing the dilutions on TSA plates overnight at 37ºC. Bacterial colony forming units 
(CFU) were enumerated, normalized to tissue weight, and reported as CFU/mg. 
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Statistics 
Individual data points are plotted with bars representing the mean ± standard deviation. 
A student t test was used to compare two individual groups. Multiple groups were 
compared with ANOVA in combination with a Tukey post-hoc test. Non-parametric data 




 The overarching objective of this thesis was to engineer a synthetic hydrogel 
serving as a controlled delivery vehicle for lysostaphin to treat orthopaedic S. aureus 
infections and promote bone repair. We have demonstrated that lysostaphin-delivering 
hydrogels prevent infection while simultaneous supporting fracture healing and segmental 
bone defect regeneration. Additionally, lysostaphin-delivering hydrogels reduce in vivo 
established orthopaedic infections, and this effect is potentiated by the additional of 
systemic antibiotic therapy. 
 In Aim 1, we engineered injectable lysostaphin-delivering hydrogels for controlled 
release of lysostaphin to eradicate S. aureus femur fracture infections. We showed that 
hydrogel encapsulation of lysostaphin retains the enzyme activity, stability, and that 
modulation of the material parameters directly modulates the enzyme release rate. 
Lysostaphin-delivering hydrogels were effective against several strains of bacteria, 
including bacteria growing in biofilm. In vivo, lysostaphin-delivering hydrogels eliminate 
bacteria and support bone repair, outperforming both soluble enzyme delivery and systemic 
antibiotic prophylaxis. Cytokine analysis showed that the inflammatory environment of 
lysostaphin treated infections is no different than untreated controls. 
 In Aim 2, we demonstrated that the addition of BMP-2 to lysostaphin-delivering 
hydrogels supports bone regeneration in a S. aureus infected mouse radial segmental defect 
model. Lysostaphin-delivering hydrogels were used to treat both Xen29 and UAMS-1 
infections. Bacteria was eliminated 1 week after implantation, and at 8 weeks, significantly 
more bone was regenerated within the defect. Radii treated with lysostaphin-delivering 
hydrogels demonstrated improved mechanical properties compared to untreated controls. 
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Safety profiling revealed no systemic toxicity and that infections treated with lysostaphin-
delivering hydrogels had no effect on the local cytokine and inflammatory cell milieu. 
 In Aim 3, we created a model of established biofilm infection by initiating 
infections in a mouse radial defect and then performing a second operation to remove 
necrotic tissue and deliver lysostaphin-delivering hydrogel therapy. Established infections 
treated with lysostaphin-delivering hydrogels had significantly reduced bacteria and 
retained significantly more bone that untreated controls. The addition of systemic 
antibiotics potentiated the antimicrobial effect of lysostaphin-delivering hydrogels. 
 Translation of this technology to the human scale will require significantly more 
validation. This will include evaluation of the antimicrobial efficacy in larger animal 
models of orthopaedic implant infection. Additionally, significantly more material safety 
analysis will have to be performed. The synthetic, well defined composition of the material 
may increase the probability of successful scaling. Each component can be synthesized in 
scalable amounts at very high purity, which allows for consistent and repeatable material 
synthesis. However, a major limitation to human translation will be navigation through the 
FDA regulations regarding combination products. Since the hydrogel is composed of 
several different biologically active components, safety will need to be demonstrated for 
each one in order to reach market approval. 
 Future studies as a follow up to this work should include further developing 
strategies to treat established biofilm infections. Successful eradication of bacteria growing 
in an established biofilm may require further controlling the lysostaphin release rate 
through modification of the hydrogel material properties. It is likely that lysostaphin-
delivering hydrogels degrade faster when implanted to established infection sites due to 
the body’s response to bacteria recruiting inflammatory cells, leading to higher protease 
levels and faster hydrogel degradation (169). Synthesizing hydrogels with a higher cross-
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link density, or utilizing cross-linking peptides that are less sensitive to proteolytic cleavage 
would be one way to extend lysostaphin release. This could also be accomplished by 
engineering a free cysteine residue into lysostaphin, allowing for covalent incorporation 
into the hydrogel. We have shown that encapsulation of lysostaphin within the hydrogel 
improves enzyme stability. A combination of stable lysostaphin and a slower release rate 
may further increase the time bactericidal concentrations of lysostaphin are in contact with 
the biofilm. 
 Optimization of the antibiotic regimen may also be critical to eliminating 
established infections. Lysostaphin and oxacillin cannot cross mammalian cell membranes 
and are therefore not effective at killing intracellular bacteria. The addition of antibiotic 
adjuvants such as rifampin, which is highly active against both intracellular bacteria and 
bacteria growing in biofilm, may be critical to achieve total infection clearance (250, 251). 
 The extension of the femur fracture model to include an established biofilm 
infection will also be important to more fully evaluate the translational potential of 
lysostaphin-delivering hydrogel therapy. Currently, only one mouse model of an 
established femur infection has been published (53). The authors stabilize the femur using 
a fixation plate and then perform a small osteotomy to create a defect. Upon revision, the 
osteotomy is expanded allowing for necrotic bone to be removed. A similar approach may 
be ideal to further test lysostaphin-delivering hydrogels, since the infection would be more 
localized to the injury site and in direct contact with an in situ polymerized hydrogel. A 
similar approach could be used for either the radial segmental defect model or the femur 
fracture model.  
 Recently, there has been increasing interest in the immune response to infection 
(252). Using the mouse radial segmental defect infection model, we characterized the 
immune cells involved in the local inflammatory response to infection. Extending our 
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immune cell analysis to established infections treated with lysostaphin-delivering 
hydrogels may offer insight into how the host response to infection affects bacterial 
clearance, as our current results have shown significant variability in the animal’s ability 
to clear bacteria. Chronic S. aureus infection can lead to a suppressed immune response to 
the infection (252, 253). It would be interesting to test if similar immunomodulatory effects 
are occurring, and if lysostaphin-delivering hydrogel therapy alters the immune response 
in an established infection setting. 
 This work was focused on treating S. aureus infections. However, S. epidermidis 
plays an equally important role in orthopaedic infections (2). We have shown that 
lysostaphin-delivering hydrogels are effective at killing S. epidermidis in vitro, but did not 
validate these results in vivo. The models developed and described herein should be 
extended to S. epidermidis strains. S. epidermidis orthopaedic hardware infections typically 
include a biofilm component, as biofilm formation is the primary virulence factor (254). 
We have shown lysostaphin-delivering hydrogels are efficacious in reducing in vivo 
established S. aureus biofilm infections. This strategy should be testes using established S. 
epidermidis biofilms as well.  
 Staphylococcal species account for roughly two thirds of all orthopaedic infections 
(35). Therefore, lysostaphin-delivering hydrogels will need to be expanded to target other 
organisms. Bacteriophage lysins are another type of bacteriolytic enzyme currently under 
development (71). Lysins that specifically target non-staphylococcal bacteria have been 
identified, which may make them good candidates to expand the target range of 
lysostaphin-delivering hydrogels, making them a more effective prophylactic therapy. 
 Overall, these studies begin to address the major unmet clinical need of preventing 
and treating S. aureus orthopaedic hardware associated infections, which will only worsen 
with the continued emergence of antibiotic-resistant bacteria. Lysostaphin kills bacteria 
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using mechanisms separate to those of small molecule antibiotics, making it effective 
against antibiotic-resistant strains. These data show our simple, injectable, biomaterial 
based delivery carrier outperforms systemic antibiotic therapy and restores a local pro-
healing inflammatory environment. Overall, we have engineered and characterized 
lysostaphin-delivering hydrogels to treat S. aureus infections while simultaneously 
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